Network meta-analysis
Diarrhea
Type 2 diabetes (adults)
longest follow-upRecorded harmsDoses of a drug pooledHazard ratio (from event counts)
180
Randomized trials
57
Treatments
98,260
Participants
10,423
Events
In plain language
Across 180 trials with 98,260 participants, 6 of 56 treatments had a clearly better result than placebo on diarrhea, 22 a clearly worse one, and for 28 the evidence could not tell them apart from placebo. The most favorable estimate was for Liraglutide after insulin degludec injection: hazard ratio (from event counts) 0.25 (95% credible interval 0.00 to 7.52).
Lower values favor the treatment. "Clearly" means the 95% credible interval excludes no difference. These are averages across trials; they do not say how any one person will respond. Not medical advice.
Network of trials
Each circle is a treatment; each line joins treatments that were randomized against each other in at least one trial.
Effects compared with Placebo
Hazard ratio (from event counts). Lower values favor the treatment.
| Treatment | Bayesian HR (95% CrI) | 95% prediction interval | Frequentist HR (95% CI) | Verdict |
|---|---|---|---|---|
| Liraglutide after insulin degludec injection LIRAGL_SC | 0.25 (0.00 to 7.52) | 0.00 to 7.59 | Unclear | |
| Sulfonylurea OTHER_ACTIVE_sulfonylurea | 0.28 (0.10 to 0.69) | 0.09 to 0.75 | Better | |
| GLP-1 receptor agonist (liraglutide, exenatide, exenatide ER, albiglutide or dulaglutide) injection GLP1RE_SC | 0.45 (0.14 to 1.27) | 0.13 to 1.40 | Unclear | |
| Premixed insulin INS_PREMIX | 0.49 (0.26 to 0.90) | 0.22 to 1.04 | Better | |
| Insulin glargine INS_GLARGINE | 0.51 (0.41 to 0.64) | 0.31 to 0.85 | Better | |
| Insulin degludec INS_DEGLUDEC | 0.54 (0.34 to 0.83) | 0.28 to 0.98 | Better | |
| Insulin lispro (prandial) INS_LISPRO | 0.54 (0.34 to 0.87) | 0.29 to 1.03 | Better | |
| Pioglitazone PIOGLITAZONE | 0.58 (0.33 to 1.01) | 0.29 to 1.18 | Unclear | |
| Glimepiride GLIMEPIRIDE | 0.63 (0.41 to 0.95) | 0.34 to 1.16 | Better | |
| Liraglutide and metformin injection LIRAMETF_SC | 0.68 (0.06 to 3.92) | 0.05 to 4.07 | Unclear | |
| Basal bolus insulin OTHER_ACTIVE_basal_bolus_insulin | 0.71 (0.27 to 1.83) | 0.25 to 2.02 | Unclear | |
| Insulin aspart (prandial) INS_ASPART | 0.73 (0.37 to 1.41) | 0.33 to 1.63 | Unclear | |
| Rosiglitazone ROSIGLITAZONE | 0.77 (0.12 to 4.16) | 0.11 to 4.44 | Unclear | |
| Sitagliptin SITAGLIPTIN | 0.78 (0.60 to 1.01) | 0.47 to 1.31 | Unclear | |
| Insulin detemir INS_DETEMIR | 0.79 (0.32 to 1.89) | 0.29 to 2.12 | Unclear | |
| Insulin icodec INS_ICODEC | 0.80 (0.35 to 1.87) | 0.31 to 2.06 | Unclear | |
| Ecc500 po ECC500_PO | 0.82 (0.23 to 3.75) | 0.20 to 4.01 | Unclear | |
| Polyethylene glycol loxenatide injection PEGLOX_SC | 0.94 (0.28 to 3.30) | 0.26 to 3.50 | Unclear | |
| Additional oad OTHER_ACTIVE_additional_OAD | 1.02 (0.40 to 2.30) | 0.36 to 2.57 | Unclear | |
| Albiglutide injection ALBI_SC | 1.03 (0.71 to 1.52) | 0.58 to 1.85 | Unclear | |
| Standard care or no added treatment STANDARD_CARE | 1.04 (0.32 to 3.08) | 0.30 to 3.33 | Unclear | |
| Insulin glargine with lixisenatide injection IGLARLIXI_SC | 1.06 (0.73 to 1.53) | 0.60 to 1.89 | Unclear | |
| Dapagliflozin DAPAGLIFLOZIN | 1.07 (0.54 to 2.14) | 0.48 to 2.42 | Unclear | |
| Bofanglutide (GZR18) injection BOFANG_SC | 1.08 (0.14 to 13.20) | 0.14 to 13.61 | Unclear | |
| Exenatide extended release and dapagliflozin injection DAPAEXEN_SC | 1.14 (0.49 to 2.66) | 0.43 to 2.98 | Unclear | |
| Glibenclamide GLIBENCLAMIDE | 1.19 (0.47 to 2.82) | 0.43 to 3.15 | Unclear | |
| Lixisenatide injection LIXI_SC | 1.19 (0.97 to 1.47) | 0.73 to 1.97 | Unclear | |
| Insulin degludec with liraglutide injection IDEGLIRA_SC | 1.25 (0.87 to 1.84) | 0.71 to 2.28 | Unclear | |
| Canagliflozin CANAGLIFLOZIN | 1.27 (0.68 to 2.43) | 0.59 to 2.80 | Unclear | |
| Exenatide injection EXEN_SC | 1.30 (1.03 to 1.66) | 0.79 to 2.18 | Worse | |
| Exenatide extended release injection EXENER_SC | 1.43 (1.09 to 1.87) | 0.85 to 2.44 | Worse | |
| Dulaglutide injection DULA_SC | 1.72 (1.43 to 2.11) | 1.07 to 2.85 | Worse | |
| Semaglutide tablet SEMA_PO | 1.73 (1.36 to 2.25) | 1.06 to 2.88 | Worse | |
| Taspoglutide injection TASP_SC | 1.81 (1.25 to 2.71) | 1.01 to 3.31 | Worse | |
| Liraglutide injection LIRA_SC | 1.87 (1.56 to 2.24) | 1.15 to 3.00 | Worse | |
| Insulin icodec with semaglutide injection ICOSEMA_SC | 1.87 (0.99 to 3.59) | 0.87 to 4.18 | Unclear | |
| Metformin METFORMIN | 1.98 (1.28 to 3.03) | 1.07 to 3.63 | Worse | |
| Visepegenatide injection VISEPE_SC | 2.13 (1.09 to 4.19) | 0.96 to 4.73 | Worse | |
| Semaglutide injection SEMA_SC | 2.13 (1.73 to 2.65) | 1.31 to 3.49 | Worse | |
| Efpe sc EFPE_SC | 2.13 (1.13 to 4.25) | 1.00 to 4.90 | Worse | |
| Orforglipron tablet ORFO_PO | 2.23 (1.71 to 3.02) | 1.34 to 3.81 | Worse | |
| Loti po LOTI_PO | 2.27 (1.25 to 4.32) | 1.08 to 5.01 | Worse | |
| Exenimp implant EXENIMP_IMPLANT | 2.28 (0.64 to 9.84) | 0.59 to 10.63 | Unclear | |
| Dulaglutide with macupatide injection DULAMACU_SC | 2.42 (0.71 to 8.37) | 0.65 to 8.97 | Unclear | |
| Macupatide OTHER_ACTIVE_macupatide | 2.45 (0.56 to 9.27) | 0.52 to 10.08 | Unclear | |
| Vildagliptin VILDAGLIPTIN | 2.71 (0.29 to 28.84) | 0.27 to 29.46 | Unclear | |
| Tirzepatide injection TIRZ_SC | 2.82 (2.14 to 3.70) | 1.70 to 4.77 | Worse | |
| HRS-7535 tablet HRS7535_PO | 3.40 (1.06 to 13.71) | 0.99 to 15.12 | Worse | |
| Danuglipron tablet DANU_PO | 3.79 (1.18 to 18.10) | 1.11 to 18.93 | Worse | |
| Cotadutide injection COTA_SC | 3.80 (2.06 to 7.32) | 1.78 to 8.27 | Worse | |
| Safiglipron (HRS-7535) tablet SAFIGL_PO | 4.28 (2.13 to 9.15) | 1.88 to 10.27 | Worse | |
| Exenatide and rosiglitazone injection EXENROSI_SC | 4.29 (1.28 to 17.60) | 1.18 to 18.21 | Worse | |
| Mazdutide injection MAZD_SC | 4.41 (2.30 to 8.80) | 2.02 to 10.05 | Worse | |
| Ecnoglutide injection ECNO_SC | 4.89 (1.06 to 43.58) | 1.01 to 44.70 | Worse | |
| Efsubaglutide alfa injection EFSUBA_SC | 6.68 (2.71 to 17.87) | 2.44 to 19.76 | Worse | |
| Bgm050 sc BGM050_SC | 21.49 (5.17 to 163) | 4.83 to 176 | Worse |
Ranking
How likely each treatment is to be among the best. Rankings ignore the size of differences and their certainty, so read them with the effects above.
League table
Every treatment against every other: hazard ratio (from event counts) of the row treatment versus the column treatment, posterior median and 95% credible interval. Green: row clearly better; red: row clearly worse.
| Row versus column | PLACEBO | LIRAGL_SC | OTHER_ACTIVE_sulfonylurea | GLP1RE_SC | INS_PREMIX | INS_GLARGINE | INS_DEGLUDEC | INS_LISPRO | PIOGLITAZONE | GLIMEPIRIDE | LIRAMETF_SC | OTHER_ACTIVE_basal_bolus_insulin | INS_ASPART | ROSIGLITAZONE | SITAGLIPTIN | INS_DETEMIR | INS_ICODEC | ECC500_PO | PEGLOX_SC | OTHER_ACTIVE_additional_OAD | ALBI_SC | STANDARD_CARE | IGLARLIXI_SC | DAPAGLIFLOZIN | BOFANG_SC | DAPAEXEN_SC | GLIBENCLAMIDE | LIXI_SC | IDEGLIRA_SC | CANAGLIFLOZIN | EXEN_SC | EXENER_SC | DULA_SC | SEMA_PO | TASP_SC | LIRA_SC | ICOSEMA_SC | METFORMIN | VISEPE_SC | SEMA_SC | EFPE_SC | ORFO_PO | LOTI_PO | EXENIMP_IMPLANT | DULAMACU_SC | OTHER_ACTIVE_macupatide | VILDAGLIPTIN | TIRZ_SC | HRS7535_PO | DANU_PO | COTA_SC | SAFIGL_PO | EXENROSI_SC | MAZD_SC | ECNO_SC | EFSUBA_SC | BGM050_SC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PLACEBO | PLACEBO | 4.02 0.13 to 245 | 3.63 1.45 to 10.37 | 2.25 0.78 to 7.13 | 2.04 1.11 to 3.90 | 1.95 1.56 to 2.45 | 1.87 1.21 to 2.98 | 1.84 1.15 to 2.90 | 1.72 0.99 to 3.00 | 1.59 1.05 to 2.43 | 1.47 0.25 to 17.47 | 1.40 0.55 to 3.67 | 1.38 0.71 to 2.73 | 1.30 0.24 to 8.53 | 1.28 0.99 to 1.65 | 1.27 0.53 to 3.14 | 1.26 0.54 to 2.88 | 1.22 0.27 to 4.44 | 1.07 0.30 to 3.63 | 0.98 0.43 to 2.48 | 0.97 0.66 to 1.40 | 0.96 0.32 to 3.10 | 0.95 0.65 to 1.38 | 0.93 0.47 to 1.86 | 0.92 0.08 to 6.92 | 0.88 0.38 to 2.04 | 0.84 0.35 to 2.11 | 0.84 0.68 to 1.04 | 0.80 0.54 to 1.15 | 0.79 0.41 to 1.47 | 0.77 0.60 to 0.97 | 0.70 0.53 to 0.91 | 0.58 0.47 to 0.70 | 0.58 0.44 to 0.73 | 0.55 0.37 to 0.80 | 0.54 0.45 to 0.64 | 0.54 0.28 to 1.01 | 0.51 0.33 to 0.78 | 0.47 0.24 to 0.92 | 0.47 0.38 to 0.58 | 0.47 0.24 to 0.88 | 0.45 0.33 to 0.58 | 0.44 0.23 to 0.80 | 0.44 0.10 to 1.55 | 0.41 0.12 to 1.40 | 0.41 0.11 to 1.77 | 0.37 0.03 to 3.42 | 0.35 0.27 to 0.47 | 0.29 0.07 to 0.95 | 0.26 0.06 to 0.85 | 0.26 0.14 to 0.49 | 0.23 0.11 to 0.47 | 0.23 0.06 to 0.78 | 0.23 0.11 to 0.43 | 0.20 0.02 to 0.95 | 0.15 0.06 to 0.37 | 0.05 0.01 to 0.19 |
| LIRAGL_SC | 0.25 0.00 to 7.52 | LIRAGL_SC | 0.91 0.01 to 31.25 | 0.57 0.01 to 18.56 | 0.51 0.01 to 15.89 | 0.49 0.01 to 14.58 | 0.47 0.01 to 14.53 | 0.44 0.01 to 13.31 | 0.42 0.01 to 13.13 | 0.40 0.01 to 12.25 | 0.38 0.00 to 23.22 | 0.35 0.01 to 11.84 | 0.34 0.01 to 10.60 | 0.33 0.00 to 16.21 | 0.32 0.01 to 9.70 | 0.31 0.00 to 10.40 | 0.30 0.00 to 9.80 | 0.29 0.00 to 11.07 | 0.26 0.00 to 9.64 | 0.25 0.00 to 8.81 | 0.24 0.00 to 7.29 | 0.24 0.00 to 8.51 | 0.23 0.00 to 7.05 | 0.23 0.00 to 7.44 | 0.21 0.00 to 11.14 | 0.21 0.00 to 6.93 | 0.21 0.00 to 6.80 | 0.21 0.00 to 6.36 | 0.20 0.00 to 6.02 | 0.19 0.00 to 6.25 | 0.19 0.00 to 5.77 | 0.18 0.00 to 5.30 | 0.14 0.00 to 4.46 | 0.14 0.00 to 4.33 | 0.14 0.00 to 4.30 | 0.13 0.00 to 3.96 | 0.13 0.00 to 4.15 | 0.12 0.00 to 3.84 | 0.12 0.00 to 3.78 | 0.12 0.00 to 3.49 | 0.12 0.00 to 3.77 | 0.11 0.00 to 3.38 | 0.11 0.00 to 3.37 | 0.10 0.00 to 3.86 | 0.10 0.00 to 3.59 | 0.10 0.00 to 4.18 | 0.09 0.00 to 5.17 | 0.09 0.00 to 2.74 | 0.07 0.00 to 2.46 | 0.06 0.00 to 2.37 | 0.06 0.00 to 2.05 | 0.06 0.00 to 1.76 | 0.06 0.00 to 2.17 | 0.06 0.00 to 1.87 | 0.05 0.00 to 1.99 | 0.04 0.00 to 1.15 | 0.01 0.00 to 0.46 |
| OTHER_ACTIVE_sulfonylurea | 0.28 0.10 to 0.69 | 1.10 0.03 to 75.59 | OTHER_ACTIVE_sulfonylurea | 0.61 0.14 to 2.71 | 0.56 0.17 to 1.70 | 0.54 0.19 to 1.37 | 0.52 0.17 to 1.43 | 0.51 0.16 to 1.38 | 0.47 0.15 to 1.38 | 0.44 0.14 to 1.18 | 0.40 0.05 to 5.59 | 0.38 0.10 to 1.46 | 0.37 0.11 to 1.19 | 0.36 0.05 to 3.04 | 0.35 0.12 to 0.89 | 0.35 0.09 to 1.27 | 0.34 0.09 to 1.18 | 0.33 0.05 to 1.69 | 0.29 0.06 to 1.38 | 0.27 0.07 to 0.99 | 0.27 0.09 to 0.71 | 0.26 0.06 to 1.18 | 0.26 0.09 to 0.71 | 0.25 0.07 to 0.79 | 0.25 0.02 to 2.37 | 0.24 0.06 to 0.84 | 0.23 0.06 to 0.82 | 0.23 0.08 to 0.58 | 0.22 0.07 to 0.59 | 0.21 0.06 to 0.66 | 0.21 0.07 to 0.54 | 0.19 0.07 to 0.49 | 0.16 0.06 to 0.40 | 0.16 0.05 to 0.40 | 0.15 0.05 to 0.40 | 0.15 0.05 to 0.36 | 0.15 0.04 to 0.45 | 0.14 0.05 to 0.38 | 0.13 0.04 to 0.40 | 0.13 0.04 to 0.32 | 0.13 0.04 to 0.40 | 0.12 0.04 to 0.32 | 0.12 0.04 to 0.36 | 0.12 0.02 to 0.61 | 0.11 0.02 to 0.52 | 0.11 0.02 to 0.62 | 0.10 0.01 to 1.07 | 0.10 0.03 to 0.25 | 0.08 0.01 to 0.35 | 0.07 0.01 to 0.32 | 0.07 0.02 to 0.21 | 0.06 0.02 to 0.20 | 0.06 0.01 to 0.29 | 0.06 0.02 to 0.19 | 0.05 0.01 to 0.34 | 0.04 0.01 to 0.15 | 0.01 0.00 to 0.07 |
| GLP1RE_SC | 0.45 0.14 to 1.27 | 1.77 0.05 to 125 | 1.64 0.37 to 7.00 | GLP1RE_SC | 0.91 0.24 to 3.08 | 0.87 0.27 to 2.46 | 0.83 0.25 to 2.57 | 0.81 0.24 to 2.49 | 0.76 0.22 to 2.44 | 0.71 0.21 to 2.16 | 0.66 0.07 to 9.97 | 0.62 0.14 to 2.56 | 0.62 0.16 to 2.16 | 0.58 0.07 to 5.04 | 0.57 0.17 to 1.67 | 0.57 0.13 to 2.24 | 0.55 0.13 to 2.09 | 0.53 0.08 to 3.01 | 0.47 0.09 to 2.26 | 0.44 0.10 to 1.81 | 0.43 0.13 to 1.29 | 0.43 0.09 to 1.98 | 0.42 0.14 to 1.11 | 0.42 0.11 to 1.43 | 0.40 0.03 to 3.87 | 0.39 0.09 to 1.50 | 0.38 0.09 to 1.48 | 0.38 0.12 to 1.06 | 0.35 0.11 to 1.06 | 0.35 0.09 to 1.22 | 0.34 0.11 to 1.00 | 0.31 0.10 to 0.91 | 0.26 0.08 to 0.74 | 0.26 0.08 to 0.74 | 0.25 0.07 to 0.74 | 0.24 0.07 to 0.68 | 0.24 0.06 to 0.81 | 0.23 0.07 to 0.69 | 0.21 0.05 to 0.73 | 0.21 0.06 to 0.61 | 0.20 0.05 to 0.72 | 0.20 0.06 to 0.59 | 0.19 0.05 to 0.67 | 0.19 0.03 to 1.01 | 0.18 0.03 to 0.92 | 0.18 0.03 to 1.11 | 0.16 0.01 to 1.83 | 0.16 0.05 to 0.46 | 0.13 0.02 to 0.62 | 0.11 0.02 to 0.57 | 0.12 0.03 to 0.40 | 0.10 0.03 to 0.37 | 0.10 0.02 to 0.51 | 0.10 0.03 to 0.34 | 0.09 0.01 to 0.59 | 0.07 0.01 to 0.27 | 0.02 0.00 to 0.13 |
| INS_PREMIX | 0.49 0.26 to 0.90 | 1.96 0.06 to 126 | 1.79 0.59 to 5.98 | 1.10 0.32 to 4.17 | INS_PREMIX | 0.96 0.49 to 1.78 | 0.92 0.43 to 1.95 | 0.90 0.42 to 1.90 | 0.84 0.37 to 1.90 | 0.78 0.37 to 1.57 | 0.72 0.12 to 9.51 | 0.68 0.22 to 2.16 | 0.67 0.27 to 1.67 | 0.64 0.11 to 4.60 | 0.63 0.32 to 1.19 | 0.62 0.22 to 1.78 | 0.61 0.21 to 1.73 | 0.59 0.11 to 2.54 | 0.52 0.13 to 2.02 | 0.48 0.17 to 1.45 | 0.47 0.23 to 0.94 | 0.47 0.14 to 1.74 | 0.46 0.22 to 0.93 | 0.45 0.19 to 1.18 | 0.45 0.03 to 3.70 | 0.42 0.15 to 1.21 | 0.41 0.14 to 1.22 | 0.41 0.21 to 0.77 | 0.39 0.19 to 0.79 | 0.38 0.16 to 0.90 | 0.38 0.20 to 0.66 | 0.34 0.18 to 0.65 | 0.28 0.15 to 0.53 | 0.28 0.14 to 0.55 | 0.27 0.13 to 0.54 | 0.26 0.14 to 0.49 | 0.26 0.10 to 0.63 | 0.25 0.12 to 0.52 | 0.23 0.09 to 0.57 | 0.23 0.12 to 0.43 | 0.23 0.09 to 0.55 | 0.22 0.11 to 0.42 | 0.21 0.08 to 0.51 | 0.21 0.05 to 0.85 | 0.20 0.05 to 0.77 | 0.20 0.05 to 0.95 | 0.18 0.02 to 1.76 | 0.17 0.09 to 0.34 | 0.14 0.03 to 0.56 | 0.13 0.02 to 0.48 | 0.13 0.05 to 0.30 | 0.11 0.04 to 0.29 | 0.11 0.02 to 0.43 | 0.11 0.04 to 0.27 | 0.10 0.01 to 0.53 | 0.07 0.02 to 0.22 | 0.02 0.00 to 0.11 |
| INS_GLARGINE | 0.51 0.41 to 0.64 | 2.06 0.07 to 124 | 1.85 0.73 to 5.26 | 1.15 0.41 to 3.64 | 1.04 0.56 to 2.03 | INS_GLARGINE | 0.96 0.61 to 1.53 | 0.94 0.59 to 1.51 | 0.88 0.50 to 1.56 | 0.81 0.52 to 1.27 | 0.75 0.13 to 9.05 | 0.72 0.28 to 1.89 | 0.71 0.36 to 1.43 | 0.67 0.12 to 4.49 | 0.65 0.48 to 0.89 | 0.65 0.27 to 1.63 | 0.64 0.27 to 1.51 | 0.62 0.13 to 2.30 | 0.55 0.15 to 1.89 | 0.51 0.22 to 1.30 | 0.50 0.33 to 0.72 | 0.49 0.17 to 1.59 | 0.48 0.34 to 0.70 | 0.48 0.23 to 0.97 | 0.47 0.04 to 3.67 | 0.45 0.19 to 1.05 | 0.43 0.18 to 1.11 | 0.43 0.33 to 0.56 | 0.41 0.28 to 0.60 | 0.40 0.21 to 0.76 | 0.39 0.30 to 0.53 | 0.36 0.26 to 0.48 | 0.30 0.23 to 0.37 | 0.30 0.21 to 0.41 | 0.28 0.18 to 0.44 | 0.27 0.21 to 0.35 | 0.27 0.14 to 0.53 | 0.26 0.16 to 0.41 | 0.24 0.12 to 0.49 | 0.24 0.18 to 0.31 | 0.24 0.12 to 0.48 | 0.23 0.16 to 0.32 | 0.23 0.11 to 0.44 | 0.22 0.05 to 0.81 | 0.21 0.06 to 0.72 | 0.21 0.05 to 0.94 | 0.19 0.02 to 1.76 | 0.18 0.14 to 0.24 | 0.15 0.04 to 0.50 | 0.13 0.03 to 0.45 | 0.13 0.07 to 0.26 | 0.12 0.06 to 0.25 | 0.12 0.03 to 0.41 | 0.12 0.06 to 0.23 | 0.10 0.01 to 0.49 | 0.08 0.03 to 0.19 | 0.02 0.00 to 0.10 |
| INS_DEGLUDEC | 0.54 0.34 to 0.83 | 2.12 0.07 to 131 | 1.94 0.70 to 5.93 | 1.20 0.39 to 4.04 | 1.09 0.51 to 2.34 | 1.04 0.65 to 1.64 | INS_DEGLUDEC | 0.98 0.52 to 1.78 | 0.92 0.46 to 1.87 | 0.85 0.47 to 1.52 | 0.78 0.13 to 9.32 | 0.75 0.29 to 1.97 | 0.74 0.33 to 1.64 | 0.71 0.12 to 4.71 | 0.69 0.41 to 1.11 | 0.67 0.26 to 1.84 | 0.67 0.25 to 1.69 | 0.65 0.13 to 2.53 | 0.57 0.15 to 2.09 | 0.53 0.21 to 1.44 | 0.52 0.29 to 0.90 | 0.51 0.16 to 1.79 | 0.50 0.29 to 0.88 | 0.50 0.22 to 1.13 | 0.49 0.04 to 3.82 | 0.47 0.18 to 1.21 | 0.45 0.17 to 1.21 | 0.45 0.27 to 0.71 | 0.43 0.28 to 0.64 | 0.42 0.19 to 0.90 | 0.41 0.25 to 0.66 | 0.38 0.23 to 0.60 | 0.31 0.19 to 0.49 | 0.31 0.18 to 0.51 | 0.30 0.16 to 0.52 | 0.29 0.18 to 0.44 | 0.29 0.13 to 0.62 | 0.27 0.15 to 0.49 | 0.25 0.11 to 0.56 | 0.25 0.15 to 0.40 | 0.25 0.11 to 0.54 | 0.24 0.14 to 0.40 | 0.24 0.11 to 0.50 | 0.23 0.05 to 0.90 | 0.22 0.06 to 0.79 | 0.22 0.05 to 1.03 | 0.20 0.02 to 1.84 | 0.19 0.12 to 0.29 | 0.16 0.04 to 0.54 | 0.14 0.03 to 0.50 | 0.14 0.06 to 0.30 | 0.13 0.05 to 0.29 | 0.12 0.03 to 0.46 | 0.12 0.05 to 0.27 | 0.11 0.01 to 0.53 | 0.08 0.03 to 0.22 | 0.02 0.00 to 0.11 |
| INS_LISPRO | 0.54 0.34 to 0.87 | 2.25 0.08 to 135 | 1.98 0.72 to 6.17 | 1.23 0.40 to 4.13 | 1.11 0.53 to 2.40 | 1.06 0.66 to 1.70 | 1.02 0.56 to 1.92 | INS_LISPRO | 0.94 0.46 to 1.90 | 0.87 0.48 to 1.57 | 0.80 0.13 to 9.63 | 0.76 0.28 to 2.19 | 0.75 0.35 to 1.67 | 0.72 0.12 to 4.94 | 0.70 0.42 to 1.17 | 0.69 0.26 to 1.88 | 0.68 0.26 to 1.75 | 0.66 0.14 to 2.65 | 0.58 0.15 to 2.12 | 0.54 0.21 to 1.51 | 0.53 0.32 to 0.85 | 0.52 0.17 to 1.80 | 0.51 0.29 to 0.91 | 0.51 0.23 to 1.14 | 0.50 0.04 to 4.07 | 0.47 0.18 to 1.25 | 0.45 0.17 to 1.28 | 0.46 0.28 to 0.74 | 0.43 0.24 to 0.76 | 0.43 0.19 to 0.92 | 0.42 0.26 to 0.67 | 0.38 0.23 to 0.64 | 0.32 0.20 to 0.51 | 0.31 0.19 to 0.53 | 0.30 0.17 to 0.53 | 0.29 0.18 to 0.47 | 0.29 0.13 to 0.64 | 0.28 0.15 to 0.50 | 0.26 0.11 to 0.59 | 0.26 0.16 to 0.41 | 0.25 0.11 to 0.56 | 0.24 0.14 to 0.41 | 0.24 0.11 to 0.51 | 0.24 0.05 to 0.92 | 0.22 0.06 to 0.81 | 0.22 0.05 to 1.02 | 0.20 0.02 to 1.90 | 0.19 0.12 to 0.31 | 0.16 0.04 to 0.57 | 0.14 0.03 to 0.51 | 0.14 0.06 to 0.31 | 0.13 0.05 to 0.29 | 0.13 0.03 to 0.46 | 0.12 0.05 to 0.28 | 0.11 0.01 to 0.55 | 0.08 0.03 to 0.22 | 0.03 0.00 to 0.11 |
| PIOGLITAZONE | 0.58 0.33 to 1.01 | 2.37 0.08 to 149 | 2.12 0.73 to 6.85 | 1.31 0.41 to 4.62 | 1.19 0.53 to 2.69 | 1.13 0.64 to 1.99 | 1.09 0.53 to 2.16 | 1.07 0.53 to 2.16 | PIOGLITAZONE | 0.92 0.47 to 1.79 | 0.85 0.14 to 11.40 | 0.81 0.28 to 2.47 | 0.80 0.34 to 1.89 | 0.77 0.13 to 5.35 | 0.75 0.42 to 1.27 | 0.74 0.27 to 2.00 | 0.73 0.26 to 1.95 | 0.71 0.14 to 2.91 | 0.62 0.16 to 2.34 | 0.58 0.21 to 1.63 | 0.56 0.29 to 1.09 | 0.57 0.17 to 1.98 | 0.55 0.29 to 1.05 | 0.54 0.23 to 1.27 | 0.53 0.04 to 4.38 | 0.51 0.19 to 1.35 | 0.49 0.18 to 1.43 | 0.49 0.28 to 0.86 | 0.47 0.24 to 0.89 | 0.46 0.19 to 1.03 | 0.45 0.25 to 0.78 | 0.41 0.23 to 0.69 | 0.34 0.19 to 0.59 | 0.33 0.18 to 0.60 | 0.32 0.16 to 0.60 | 0.31 0.18 to 0.54 | 0.31 0.13 to 0.71 | 0.29 0.15 to 0.54 | 0.27 0.11 to 0.66 | 0.27 0.15 to 0.48 | 0.27 0.11 to 0.64 | 0.26 0.14 to 0.48 | 0.26 0.11 to 0.58 | 0.26 0.05 to 0.99 | 0.24 0.06 to 0.90 | 0.24 0.06 to 1.12 | 0.21 0.02 to 2.10 | 0.21 0.11 to 0.37 | 0.17 0.04 to 0.63 | 0.15 0.03 to 0.56 | 0.15 0.07 to 0.34 | 0.14 0.05 to 0.33 | 0.14 0.03 to 0.51 | 0.13 0.05 to 0.30 | 0.12 0.01 to 0.61 | 0.09 0.03 to 0.24 | 0.03 0.00 to 0.12 |
| GLIMEPIRIDE | 0.63 0.41 to 0.95 | 2.52 0.08 to 159 | 2.29 0.85 to 6.99 | 1.41 0.46 to 4.87 | 1.29 0.64 to 2.70 | 1.23 0.79 to 1.93 | 1.18 0.66 to 2.14 | 1.15 0.64 to 2.09 | 1.08 0.56 to 2.14 | GLIMEPIRIDE | 0.92 0.15 to 11.17 | 0.88 0.32 to 2.55 | 0.87 0.40 to 1.91 | 0.83 0.15 to 5.61 | 0.81 0.51 to 1.27 | 0.79 0.31 to 2.08 | 0.79 0.31 to 1.98 | 0.76 0.16 to 3.00 | 0.67 0.18 to 2.48 | 0.62 0.25 to 1.70 | 0.61 0.36 to 1.04 | 0.61 0.19 to 2.09 | 0.59 0.34 to 1.03 | 0.58 0.27 to 1.27 | 0.58 0.05 to 4.57 | 0.55 0.22 to 1.40 | 0.53 0.21 to 1.43 | 0.53 0.34 to 0.82 | 0.50 0.29 to 0.86 | 0.50 0.23 to 1.03 | 0.48 0.32 to 0.73 | 0.44 0.28 to 0.70 | 0.37 0.24 to 0.56 | 0.36 0.23 to 0.58 | 0.35 0.20 to 0.59 | 0.34 0.22 to 0.51 | 0.34 0.16 to 0.71 | 0.32 0.18 to 0.56 | 0.30 0.13 to 0.65 | 0.30 0.19 to 0.46 | 0.29 0.13 to 0.64 | 0.28 0.17 to 0.46 | 0.28 0.13 to 0.59 | 0.28 0.06 to 1.02 | 0.26 0.07 to 0.94 | 0.26 0.06 to 1.19 | 0.23 0.02 to 2.23 | 0.22 0.14 to 0.36 | 0.18 0.04 to 0.63 | 0.17 0.03 to 0.57 | 0.16 0.08 to 0.35 | 0.15 0.06 to 0.33 | 0.15 0.03 to 0.53 | 0.14 0.07 to 0.30 | 0.13 0.01 to 0.62 | 0.09 0.03 to 0.26 | 0.03 0.00 to 0.13 |
| LIRAMETF_SC | 0.68 0.06 to 3.92 | 2.62 0.04 to 258 | 2.48 0.18 to 18.89 | 1.52 0.10 to 13.38 | 1.39 0.11 to 8.67 | 1.33 0.11 to 7.62 | 1.28 0.11 to 7.68 | 1.25 0.10 to 7.63 | 1.17 0.09 to 7.28 | 1.09 0.09 to 6.47 | LIRAMETF_SC | 0.95 0.07 to 7.19 | 0.94 0.08 to 6.18 | 0.86 0.05 to 12.40 | 0.87 0.07 to 5.09 | 0.87 0.06 to 6.02 | 0.84 0.06 to 6.10 | 0.79 0.04 to 7.18 | 0.70 0.04 to 6.35 | 0.67 0.05 to 4.92 | 0.65 0.06 to 3.89 | 0.65 0.04 to 5.55 | 0.64 0.05 to 3.85 | 0.64 0.05 to 4.22 | 0.59 0.02 to 9.54 | 0.59 0.04 to 4.27 | 0.57 0.04 to 4.03 | 0.57 0.05 to 3.28 | 0.54 0.04 to 3.25 | 0.53 0.04 to 3.35 | 0.52 0.04 to 2.97 | 0.48 0.04 to 2.77 | 0.39 0.03 to 2.25 | 0.39 0.03 to 2.27 | 0.38 0.03 to 2.22 | 0.37 0.03 to 2.06 | 0.36 0.03 to 2.38 | 0.35 0.03 to 2.02 | 0.32 0.02 to 2.11 | 0.32 0.03 to 1.84 | 0.32 0.02 to 2.06 | 0.31 0.03 to 1.77 | 0.30 0.02 to 1.94 | 0.29 0.02 to 2.72 | 0.27 0.02 to 2.26 | 0.27 0.02 to 2.77 | 0.23 0.01 to 4.38 | 0.24 0.02 to 1.41 | 0.19 0.01 to 1.66 | 0.17 0.01 to 1.51 | 0.18 0.01 to 1.14 | 0.16 0.01 to 1.07 | 0.15 0.01 to 1.40 | 0.15 0.01 to 1.01 | 0.13 0.01 to 1.46 | 0.10 0.01 to 0.77 | 0.03 0.00 to 0.32 |
| OTHER_ACTIVE_basal_bolus_insulin | 0.71 0.27 to 1.83 | 2.86 0.08 to 182 | 2.62 0.68 to 10.31 | 1.62 0.39 to 6.96 | 1.46 0.46 to 4.49 | 1.40 0.53 to 3.56 | 1.33 0.51 to 3.50 | 1.32 0.46 to 3.63 | 1.23 0.41 to 3.58 | 1.13 0.39 to 3.17 | 1.05 0.14 to 14.27 | OTHER_ACTIVE_basal_bolus_insulin | 0.98 0.31 to 3.08 | 0.95 0.14 to 7.44 | 0.92 0.33 to 2.38 | 0.91 0.25 to 3.26 | 0.89 0.24 to 3.11 | 0.86 0.15 to 4.31 | 0.76 0.16 to 3.58 | 0.71 0.20 to 2.58 | 0.69 0.25 to 1.84 | 0.69 0.16 to 3.03 | 0.67 0.24 to 1.82 | 0.67 0.20 to 2.09 | 0.65 0.05 to 6.10 | 0.63 0.17 to 2.18 | 0.60 0.17 to 2.16 | 0.60 0.22 to 1.54 | 0.57 0.23 to 1.33 | 0.56 0.18 to 1.72 | 0.55 0.21 to 1.42 | 0.50 0.18 to 1.29 | 0.41 0.16 to 1.05 | 0.41 0.15 to 1.07 | 0.39 0.14 to 1.07 | 0.38 0.14 to 0.97 | 0.38 0.12 to 1.16 | 0.36 0.13 to 0.97 | 0.34 0.10 to 1.06 | 0.34 0.13 to 0.85 | 0.33 0.10 to 1.04 | 0.32 0.12 to 0.84 | 0.32 0.10 to 0.94 | 0.31 0.05 to 1.54 | 0.30 0.06 to 1.36 | 0.29 0.06 to 1.69 | 0.26 0.02 to 2.82 | 0.25 0.09 to 0.66 | 0.21 0.04 to 0.92 | 0.18 0.03 to 0.84 | 0.19 0.06 to 0.57 | 0.17 0.05 to 0.54 | 0.16 0.03 to 0.75 | 0.16 0.05 to 0.49 | 0.14 0.01 to 0.85 | 0.11 0.03 to 0.40 | 0.03 0.00 to 0.19 |
| INS_ASPART | 0.73 0.37 to 1.41 | 2.91 0.09 to 191 | 2.67 0.84 to 9.03 | 1.62 0.46 to 6.20 | 1.48 0.60 to 3.72 | 1.42 0.70 to 2.82 | 1.36 0.61 to 3.04 | 1.33 0.60 to 2.88 | 1.25 0.53 to 2.96 | 1.16 0.52 to 2.49 | 1.07 0.16 to 13.16 | 1.02 0.32 to 3.20 | INS_ASPART | 0.95 0.15 to 7.08 | 0.92 0.45 to 1.87 | 0.92 0.31 to 2.85 | 0.91 0.32 to 2.51 | 0.88 0.17 to 3.77 | 0.77 0.19 to 3.02 | 0.72 0.26 to 2.20 | 0.71 0.32 to 1.49 | 0.70 0.20 to 2.70 | 0.69 0.32 to 1.43 | 0.68 0.26 to 1.72 | 0.67 0.05 to 5.55 | 0.63 0.22 to 1.82 | 0.61 0.20 to 1.88 | 0.61 0.30 to 1.21 | 0.58 0.27 to 1.26 | 0.57 0.24 to 1.37 | 0.56 0.27 to 1.13 | 0.51 0.25 to 1.02 | 0.42 0.21 to 0.83 | 0.42 0.20 to 0.86 | 0.40 0.18 to 0.87 | 0.39 0.19 to 0.77 | 0.39 0.16 to 0.94 | 0.37 0.17 to 0.81 | 0.34 0.13 to 0.89 | 0.34 0.18 to 0.65 | 0.34 0.13 to 0.87 | 0.32 0.16 to 0.66 | 0.32 0.13 to 0.79 | 0.32 0.06 to 1.35 | 0.30 0.07 to 1.19 | 0.29 0.06 to 1.51 | 0.26 0.02 to 2.60 | 0.26 0.13 to 0.52 | 0.21 0.04 to 0.84 | 0.19 0.03 to 0.74 | 0.19 0.08 to 0.47 | 0.17 0.06 to 0.45 | 0.17 0.04 to 0.66 | 0.16 0.06 to 0.41 | 0.15 0.02 to 0.80 | 0.11 0.03 to 0.33 | 0.03 0.00 to 0.16 |
| ROSIGLITAZONE | 0.77 0.12 to 4.16 | 3.08 0.06 to 252 | 2.81 0.33 to 19.60 | 1.71 0.20 to 14.13 | 1.56 0.22 to 9.19 | 1.49 0.22 to 8.18 | 1.41 0.21 to 8.30 | 1.38 0.20 to 8.17 | 1.29 0.19 to 7.67 | 1.20 0.18 to 6.78 | 1.17 0.08 to 21.84 | 1.05 0.13 to 7.10 | 1.05 0.14 to 6.63 | ROSIGLITAZONE | 0.97 0.14 to 5.42 | 0.97 0.12 to 6.54 | 0.96 0.12 to 6.12 | 0.89 0.08 to 8.16 | 0.81 0.08 to 6.57 | 0.77 0.10 to 5.12 | 0.74 0.11 to 4.15 | 0.74 0.08 to 5.73 | 0.72 0.11 to 4.09 | 0.70 0.10 to 4.46 | 0.68 0.03 to 10.12 | 0.66 0.09 to 4.34 | 0.64 0.08 to 4.40 | 0.64 0.10 to 3.52 | 0.60 0.09 to 3.51 | 0.59 0.08 to 3.65 | 0.59 0.09 to 3.21 | 0.53 0.08 to 2.95 | 0.44 0.07 to 2.39 | 0.44 0.06 to 2.45 | 0.42 0.06 to 2.39 | 0.41 0.06 to 2.24 | 0.40 0.05 to 2.46 | 0.38 0.06 to 2.23 | 0.36 0.05 to 2.25 | 0.36 0.05 to 1.94 | 0.35 0.05 to 2.17 | 0.34 0.05 to 1.93 | 0.34 0.04 to 2.00 | 0.32 0.03 to 2.84 | 0.31 0.03 to 2.53 | 0.31 0.03 to 2.87 | 0.28 0.01 to 4.73 | 0.27 0.04 to 1.50 | 0.22 0.02 to 1.73 | 0.19 0.02 to 1.55 | 0.20 0.03 to 1.19 | 0.17 0.02 to 1.11 | 0.18 0.03 to 0.71 | 0.17 0.02 to 1.02 | 0.15 0.01 to 1.58 | 0.11 0.01 to 0.78 | 0.03 0.00 to 0.33 |
| SITAGLIPTIN | 0.78 0.60 to 1.01 | 3.12 0.10 to 192 | 2.86 1.13 to 8.17 | 1.75 0.60 to 5.84 | 1.59 0.84 to 3.16 | 1.53 1.13 to 2.08 | 1.46 0.90 to 2.41 | 1.44 0.85 to 2.39 | 1.34 0.79 to 2.38 | 1.24 0.78 to 1.97 | 1.15 0.20 to 13.99 | 1.09 0.42 to 2.99 | 1.08 0.53 to 2.20 | 1.03 0.18 to 6.91 | SITAGLIPTIN | 0.99 0.42 to 2.47 | 0.98 0.41 to 2.30 | 0.95 0.20 to 3.57 | 0.84 0.23 to 2.93 | 0.77 0.33 to 2.01 | 0.76 0.49 to 1.17 | 0.75 0.25 to 2.42 | 0.74 0.48 to 1.14 | 0.73 0.36 to 1.47 | 0.72 0.06 to 5.51 | 0.68 0.29 to 1.65 | 0.66 0.27 to 1.69 | 0.66 0.49 to 0.90 | 0.62 0.40 to 0.96 | 0.61 0.31 to 1.19 | 0.60 0.43 to 0.83 | 0.55 0.40 to 0.74 | 0.45 0.34 to 0.61 | 0.45 0.33 to 0.60 | 0.43 0.28 to 0.65 | 0.42 0.32 to 0.54 | 0.42 0.21 to 0.81 | 0.40 0.25 to 0.62 | 0.37 0.18 to 0.75 | 0.37 0.27 to 0.48 | 0.37 0.17 to 0.73 | 0.35 0.24 to 0.50 | 0.34 0.18 to 0.65 | 0.34 0.08 to 1.23 | 0.32 0.09 to 1.12 | 0.31 0.08 to 1.40 | 0.29 0.03 to 2.70 | 0.28 0.20 to 0.39 | 0.23 0.05 to 0.75 | 0.21 0.04 to 0.68 | 0.21 0.10 to 0.39 | 0.18 0.08 to 0.38 | 0.18 0.04 to 0.63 | 0.18 0.09 to 0.35 | 0.16 0.02 to 0.76 | 0.12 0.04 to 0.30 | 0.04 0.00 to 0.15 |
| INS_DETEMIR | 0.79 0.32 to 1.89 | 3.19 0.10 to 215 | 2.87 0.79 to 10.92 | 1.76 0.45 to 7.75 | 1.61 0.56 to 4.62 | 1.54 0.61 to 3.69 | 1.48 0.54 to 3.87 | 1.45 0.53 to 3.80 | 1.35 0.50 to 3.67 | 1.26 0.48 to 3.21 | 1.14 0.17 to 15.97 | 1.09 0.31 to 3.97 | 1.09 0.35 to 3.24 | 1.03 0.15 to 8.28 | 1.01 0.40 to 2.39 | INS_DETEMIR | 0.99 0.29 to 3.20 | 0.95 0.16 to 4.65 | 0.85 0.18 to 3.83 | 0.79 0.23 to 2.62 | 0.77 0.28 to 1.92 | 0.76 0.19 to 3.20 | 0.75 0.29 to 1.87 | 0.74 0.24 to 2.19 | 0.72 0.05 to 6.68 | 0.69 0.21 to 2.25 | 0.67 0.19 to 2.32 | 0.67 0.27 to 1.58 | 0.63 0.24 to 1.62 | 0.62 0.20 to 1.79 | 0.61 0.24 to 1.46 | 0.56 0.23 to 1.25 | 0.46 0.19 to 1.08 | 0.45 0.18 to 1.11 | 0.43 0.17 to 1.10 | 0.42 0.17 to 0.99 | 0.42 0.14 to 1.23 | 0.40 0.15 to 1.01 | 0.37 0.12 to 1.10 | 0.37 0.15 to 0.88 | 0.37 0.12 to 1.08 | 0.36 0.14 to 0.87 | 0.35 0.11 to 1.00 | 0.35 0.06 to 1.57 | 0.32 0.07 to 1.40 | 0.32 0.06 to 1.76 | 0.29 0.02 to 3.02 | 0.28 0.11 to 0.68 | 0.23 0.04 to 0.97 | 0.20 0.03 to 0.93 | 0.21 0.07 to 0.58 | 0.18 0.06 to 0.55 | 0.18 0.04 to 0.85 | 0.18 0.06 to 0.53 | 0.16 0.02 to 0.94 | 0.12 0.03 to 0.41 | 0.04 0.00 to 0.20 |
| INS_ICODEC | 0.80 0.35 to 1.87 | 3.30 0.10 to 210 | 2.92 0.85 to 11.08 | 1.81 0.48 to 7.50 | 1.64 0.58 to 4.68 | 1.56 0.66 to 3.69 | 1.50 0.59 to 3.93 | 1.47 0.57 to 3.84 | 1.38 0.51 to 3.78 | 1.27 0.50 to 3.20 | 1.18 0.16 to 16.50 | 1.12 0.32 to 4.09 | 1.10 0.40 to 3.16 | 1.05 0.16 to 8.30 | 1.02 0.43 to 2.46 | 1.01 0.31 to 3.48 | INS_ICODEC | 0.97 0.17 to 4.59 | 0.85 0.19 to 3.70 | 0.80 0.25 to 2.69 | 0.77 0.31 to 1.96 | 0.78 0.20 to 3.27 | 0.76 0.31 to 1.89 | 0.74 0.26 to 2.17 | 0.75 0.05 to 6.50 | 0.70 0.22 to 2.35 | 0.67 0.20 to 2.39 | 0.67 0.29 to 1.61 | 0.64 0.25 to 1.61 | 0.62 0.23 to 1.74 | 0.61 0.25 to 1.47 | 0.56 0.23 to 1.34 | 0.46 0.20 to 1.10 | 0.46 0.19 to 1.11 | 0.44 0.17 to 1.12 | 0.43 0.18 to 1.02 | 0.43 0.24 to 0.74 | 0.40 0.16 to 1.04 | 0.37 0.13 to 1.15 | 0.38 0.17 to 0.86 | 0.37 0.13 to 1.09 | 0.36 0.15 to 0.88 | 0.35 0.12 to 1.02 | 0.35 0.06 to 1.73 | 0.33 0.08 to 1.45 | 0.33 0.07 to 1.75 | 0.29 0.02 to 3.20 | 0.28 0.12 to 0.69 | 0.23 0.05 to 0.97 | 0.21 0.04 to 0.91 | 0.21 0.07 to 0.61 | 0.19 0.06 to 0.56 | 0.19 0.04 to 0.86 | 0.18 0.06 to 0.54 | 0.16 0.02 to 0.97 | 0.12 0.03 to 0.42 | 0.04 0.00 to 0.19 |
| ECC500_PO | 0.82 0.23 to 3.75 | 3.46 0.09 to 269 | 3.06 0.59 to 18.89 | 1.90 0.33 to 12.65 | 1.70 0.39 to 8.94 | 1.61 0.44 to 7.45 | 1.55 0.40 to 7.61 | 1.52 0.38 to 7.39 | 1.41 0.34 to 7.07 | 1.31 0.33 to 6.19 | 1.27 0.14 to 22.29 | 1.16 0.23 to 6.79 | 1.13 0.27 to 5.96 | 1.13 0.12 to 12.40 | 1.05 0.28 to 4.91 | 1.06 0.22 to 6.24 | 1.03 0.22 to 5.79 | ECC500_PO | 0.88 0.15 to 6.37 | 0.83 0.17 to 4.69 | 0.79 0.20 to 3.94 | 0.81 0.14 to 5.45 | 0.78 0.20 to 3.75 | 0.77 0.18 to 4.19 | 0.77 0.05 to 10.11 | 0.73 0.15 to 4.07 | 0.70 0.15 to 4.02 | 0.69 0.19 to 3.19 | 0.66 0.17 to 3.18 | 0.64 0.15 to 3.36 | 0.63 0.17 to 2.93 | 0.57 0.15 to 2.65 | 0.48 0.13 to 2.22 | 0.47 0.13 to 2.25 | 0.45 0.12 to 2.16 | 0.44 0.12 to 2.04 | 0.44 0.10 to 2.26 | 0.42 0.11 to 1.99 | 0.39 0.09 to 2.13 | 0.39 0.10 to 1.78 | 0.39 0.09 to 1.99 | 0.37 0.10 to 1.72 | 0.36 0.09 to 1.94 | 0.36 0.05 to 2.60 | 0.34 0.06 to 2.43 | 0.34 0.05 to 2.78 | 0.31 0.02 to 4.72 | 0.29 0.08 to 1.36 | 0.24 0.04 to 1.76 | 0.21 0.03 to 1.53 | 0.22 0.05 to 1.13 | 0.19 0.04 to 1.04 | 0.19 0.03 to 1.37 | 0.19 0.04 to 0.96 | 0.16 0.01 to 1.47 | 0.12 0.02 to 0.74 | 0.04 0.00 to 0.31 |
| PEGLOX_SC | 0.94 0.28 to 3.30 | 3.78 0.10 to 304 | 3.43 0.73 to 16.53 | 2.12 0.44 to 11.26 | 1.91 0.49 to 7.81 | 1.82 0.53 to 6.52 | 1.76 0.48 to 6.67 | 1.73 0.47 to 6.60 | 1.61 0.43 to 6.30 | 1.49 0.40 to 5.57 | 1.42 0.16 to 22.36 | 1.31 0.28 to 6.19 | 1.29 0.33 to 5.21 | 1.23 0.15 to 12.00 | 1.20 0.34 to 4.29 | 1.18 0.26 to 5.54 | 1.17 0.27 to 5.33 | 1.13 0.16 to 6.84 | PEGLOX_SC | 0.93 0.21 to 4.52 | 0.91 0.26 to 3.34 | 0.91 0.18 to 4.92 | 0.88 0.25 to 3.14 | 0.88 0.23 to 3.49 | 0.86 0.05 to 9.26 | 0.82 0.19 to 3.64 | 0.79 0.18 to 3.83 | 0.79 0.23 to 2.77 | 0.75 0.20 to 2.73 | 0.74 0.18 to 2.98 | 0.72 0.21 to 2.55 | 0.66 0.19 to 2.37 | 0.54 0.16 to 1.91 | 0.54 0.16 to 1.93 | 0.52 0.14 to 1.93 | 0.50 0.14 to 1.80 | 0.50 0.13 to 2.11 | 0.48 0.14 to 1.67 | 0.44 0.11 to 1.84 | 0.44 0.13 to 1.57 | 0.44 0.11 to 1.80 | 0.42 0.12 to 1.52 | 0.41 0.10 to 1.71 | 0.41 0.06 to 2.58 | 0.39 0.07 to 2.22 | 0.38 0.06 to 2.56 | 0.34 0.02 to 4.45 | 0.33 0.10 to 1.20 | 0.27 0.04 to 1.56 | 0.24 0.04 to 1.42 | 0.25 0.06 to 1.00 | 0.22 0.06 to 0.89 | 0.22 0.03 to 1.36 | 0.21 0.05 to 0.89 | 0.19 0.02 to 1.38 | 0.14 0.03 to 0.64 | 0.04 0.00 to 0.29 |
| OTHER_ACTIVE_additional_OAD | 1.02 0.40 to 2.30 | 4.07 0.11 to 283 | 3.68 1.01 to 13.64 | 2.25 0.55 to 9.64 | 2.07 0.69 to 5.76 | 1.97 0.77 to 4.54 | 1.89 0.69 to 4.79 | 1.86 0.66 to 4.70 | 1.72 0.61 to 4.69 | 1.61 0.59 to 3.97 | 1.49 0.20 to 20.09 | 1.41 0.39 to 4.98 | 1.38 0.46 to 3.89 | 1.31 0.20 to 10.23 | 1.29 0.50 to 3.04 | 1.27 0.38 to 4.33 | 1.25 0.37 to 3.99 | 1.21 0.21 to 5.74 | 1.08 0.22 to 4.82 | OTHER_ACTIVE_additional_OAD | 0.98 0.37 to 2.41 | 0.96 0.24 to 4.17 | 0.95 0.37 to 2.29 | 0.94 0.29 to 2.75 | 0.90 0.06 to 8.35 | 0.88 0.25 to 2.95 | 0.85 0.24 to 3.00 | 0.85 0.33 to 1.97 | 0.81 0.30 to 1.97 | 0.79 0.27 to 2.18 | 0.78 0.30 to 1.80 | 0.71 0.27 to 1.64 | 0.59 0.23 to 1.35 | 0.58 0.23 to 1.35 | 0.56 0.20 to 1.36 | 0.55 0.21 to 1.23 | 0.53 0.18 to 1.51 | 0.51 0.19 to 1.27 | 0.47 0.15 to 1.39 | 0.47 0.19 to 1.05 | 0.47 0.15 to 1.35 | 0.45 0.17 to 1.08 | 0.45 0.14 to 1.25 | 0.43 0.08 to 2.04 | 0.41 0.09 to 1.75 | 0.41 0.08 to 2.18 | 0.37 0.03 to 3.85 | 0.36 0.14 to 0.83 | 0.29 0.06 to 1.28 | 0.26 0.04 to 1.12 | 0.26 0.09 to 0.73 | 0.24 0.07 to 0.71 | 0.23 0.04 to 1.01 | 0.23 0.07 to 0.66 | 0.20 0.02 to 1.19 | 0.15 0.04 to 0.52 | 0.05 0.01 to 0.25 |
| ALBI_SC | 1.03 0.71 to 1.52 | 4.13 0.14 to 258 | 3.75 1.41 to 11.33 | 2.32 0.77 to 7.82 | 2.11 1.06 to 4.40 | 2.01 1.38 to 3.00 | 1.93 1.11 to 3.45 | 1.89 1.18 to 3.10 | 1.77 0.91 to 3.46 | 1.64 0.96 to 2.81 | 1.53 0.26 to 18.12 | 1.44 0.54 to 4.06 | 1.41 0.67 to 3.09 | 1.35 0.24 to 9.47 | 1.32 0.86 to 2.05 | 1.30 0.52 to 3.52 | 1.29 0.51 to 3.23 | 1.26 0.25 to 4.95 | 1.10 0.30 to 3.89 | 1.02 0.42 to 2.73 | ALBI_SC | 0.99 0.32 to 3.39 | 0.97 0.59 to 1.64 | 0.96 0.44 to 2.07 | 0.96 0.08 to 7.47 | 0.90 0.36 to 2.30 | 0.87 0.35 to 2.32 | 0.87 0.57 to 1.32 | 0.82 0.50 to 1.37 | 0.81 0.40 to 1.67 | 0.79 0.53 to 1.20 | 0.72 0.47 to 1.12 | 0.60 0.40 to 0.89 | 0.59 0.38 to 0.93 | 0.57 0.34 to 0.95 | 0.55 0.37 to 0.83 | 0.55 0.26 to 1.14 | 0.52 0.30 to 0.92 | 0.48 0.23 to 1.05 | 0.48 0.32 to 0.74 | 0.48 0.22 to 1.02 | 0.46 0.29 to 0.73 | 0.46 0.22 to 0.93 | 0.45 0.10 to 1.69 | 0.43 0.12 to 1.50 | 0.43 0.10 to 1.86 | 0.38 0.04 to 3.51 | 0.37 0.24 to 0.56 | 0.30 0.07 to 1.04 | 0.27 0.05 to 0.93 | 0.27 0.13 to 0.55 | 0.24 0.10 to 0.53 | 0.24 0.06 to 0.83 | 0.23 0.11 to 0.49 | 0.21 0.02 to 1.03 | 0.15 0.05 to 0.42 | 0.05 0.01 to 0.21 |
| STANDARD_CARE | 1.04 0.32 to 3.08 | 4.19 0.12 to 291 | 3.83 0.84 to 16.54 | 2.33 0.50 to 11.10 | 2.15 0.57 to 7.32 | 2.04 0.63 to 6.06 | 1.96 0.56 to 6.18 | 1.91 0.55 to 6.06 | 1.77 0.51 to 5.99 | 1.65 0.48 to 5.15 | 1.55 0.18 to 22.83 | 1.45 0.33 to 6.07 | 1.43 0.37 to 4.95 | 1.35 0.17 to 12.39 | 1.34 0.41 to 4.02 | 1.32 0.31 to 5.34 | 1.29 0.31 to 5.04 | 1.24 0.18 to 7.00 | 1.10 0.20 to 5.70 | 1.04 0.24 to 4.21 | 1.01 0.30 to 3.12 | STANDARD_CARE | 0.98 0.29 to 3.01 | 0.97 0.25 to 3.44 | 0.93 0.06 to 9.46 | 0.91 0.21 to 3.58 | 0.87 0.21 to 3.48 | 0.87 0.27 to 2.61 | 0.83 0.25 to 2.58 | 0.81 0.22 to 2.82 | 0.80 0.24 to 2.41 | 0.73 0.22 to 2.18 | 0.61 0.18 to 1.81 | 0.60 0.18 to 1.82 | 0.57 0.17 to 1.78 | 0.56 0.17 to 1.63 | 0.56 0.15 to 1.92 | 0.52 0.15 to 1.67 | 0.49 0.12 to 1.75 | 0.49 0.15 to 1.48 | 0.48 0.13 to 1.68 | 0.47 0.14 to 1.42 | 0.46 0.12 to 1.55 | 0.45 0.07 to 2.54 | 0.43 0.08 to 2.19 | 0.42 0.07 to 2.65 | 0.38 0.03 to 4.34 | 0.37 0.11 to 1.12 | 0.30 0.05 to 1.53 | 0.27 0.04 to 1.32 | 0.27 0.07 to 0.92 | 0.24 0.06 to 0.90 | 0.24 0.04 to 1.21 | 0.23 0.06 to 0.82 | 0.21 0.02 to 1.39 | 0.16 0.03 to 0.62 | 0.05 0.01 to 0.30 |
| IGLARLIXI_SC | 1.06 0.73 to 1.53 | 4.27 0.14 to 256 | 3.83 1.41 to 11.38 | 2.37 0.90 to 7.18 | 2.16 1.08 to 4.54 | 2.07 1.44 to 2.96 | 1.99 1.13 to 3.47 | 1.95 1.10 to 3.44 | 1.82 0.96 to 3.47 | 1.68 0.97 to 2.92 | 1.57 0.26 to 19.56 | 1.49 0.55 to 4.15 | 1.45 0.70 to 3.09 | 1.39 0.24 to 9.39 | 1.35 0.88 to 2.09 | 1.34 0.54 to 3.45 | 1.32 0.53 to 3.26 | 1.29 0.27 to 4.98 | 1.14 0.32 to 4.04 | 1.05 0.44 to 2.72 | 1.03 0.61 to 1.69 | 1.02 0.33 to 3.43 | IGLARLIXI_SC | 0.98 0.45 to 2.12 | 0.98 0.08 to 7.61 | 0.93 0.37 to 2.32 | 0.89 0.35 to 2.41 | 0.89 0.62 to 1.28 | 0.84 0.51 to 1.37 | 0.83 0.40 to 1.68 | 0.81 0.53 to 1.22 | 0.74 0.48 to 1.13 | 0.61 0.41 to 0.91 | 0.61 0.39 to 0.95 | 0.58 0.34 to 0.99 | 0.57 0.38 to 0.84 | 0.57 0.27 to 1.15 | 0.54 0.31 to 0.93 | 0.50 0.23 to 1.08 | 0.50 0.33 to 0.75 | 0.49 0.23 to 1.04 | 0.47 0.30 to 0.75 | 0.47 0.22 to 0.96 | 0.46 0.10 to 1.72 | 0.44 0.12 to 1.56 | 0.43 0.10 to 1.99 | 0.39 0.04 to 3.67 | 0.38 0.24 to 0.58 | 0.31 0.07 to 1.06 | 0.28 0.06 to 0.96 | 0.28 0.13 to 0.57 | 0.25 0.11 to 0.56 | 0.25 0.06 to 0.86 | 0.24 0.11 to 0.50 | 0.22 0.02 to 1.05 | 0.16 0.05 to 0.42 | 0.05 0.01 to 0.21 |
| DAPAGLIFLOZIN | 1.07 0.54 to 2.14 | 4.39 0.13 to 278 | 3.93 1.27 to 13.72 | 2.41 0.70 to 9.29 | 2.22 0.85 to 5.40 | 2.09 1.03 to 4.30 | 2.01 0.89 to 4.51 | 1.97 0.88 to 4.40 | 1.84 0.78 to 4.38 | 1.71 0.79 to 3.72 | 1.57 0.24 to 20.30 | 1.49 0.48 to 4.89 | 1.47 0.58 to 3.80 | 1.42 0.22 to 10.38 | 1.37 0.68 to 2.79 | 1.36 0.46 to 4.11 | 1.35 0.46 to 3.90 | 1.29 0.24 to 5.66 | 1.13 0.29 to 4.36 | 1.06 0.36 to 3.41 | 1.04 0.48 to 2.27 | 1.03 0.29 to 4.06 | 1.02 0.47 to 2.23 | DAPAGLIFLOZIN | 0.98 0.07 to 8.25 | 0.93 0.41 to 2.24 | 0.90 0.31 to 2.72 | 0.90 0.44 to 1.82 | 0.86 0.39 to 1.84 | 0.83 0.34 to 2.15 | 0.83 0.40 to 1.66 | 0.75 0.38 to 1.46 | 0.62 0.31 to 1.25 | 0.62 0.30 to 1.27 | 0.59 0.27 to 1.29 | 0.57 0.29 to 1.15 | 0.58 0.22 to 1.42 | 0.54 0.25 to 1.17 | 0.50 0.20 to 1.32 | 0.50 0.25 to 1.03 | 0.50 0.19 to 1.30 | 0.48 0.23 to 1.01 | 0.47 0.18 to 1.20 | 0.47 0.09 to 2.02 | 0.44 0.11 to 1.77 | 0.44 0.10 to 2.20 | 0.39 0.03 to 4.02 | 0.38 0.18 to 0.79 | 0.31 0.07 to 1.23 | 0.28 0.05 to 1.11 | 0.28 0.11 to 0.70 | 0.25 0.13 to 0.47 | 0.25 0.05 to 1.00 | 0.24 0.09 to 0.63 | 0.22 0.02 to 1.16 | 0.16 0.05 to 0.52 | 0.05 0.01 to 0.24 |
| BOFANG_SC | 1.08 0.14 to 13.20 | 4.77 0.09 to 499 | 4.05 0.42 to 59.10 | 2.50 0.26 to 37.38 | 2.22 0.27 to 28.75 | 2.12 0.27 to 25.75 | 2.03 0.26 to 25.05 | 1.99 0.25 to 24.50 | 1.87 0.23 to 24.84 | 1.71 0.22 to 21.55 | 1.68 0.10 to 52.25 | 1.55 0.16 to 21.49 | 1.50 0.18 to 20.42 | 1.46 0.10 to 32.40 | 1.39 0.18 to 16.86 | 1.38 0.15 to 19.21 | 1.34 0.15 to 19.56 | 1.31 0.10 to 21.38 | 1.17 0.11 to 19.60 | 1.11 0.12 to 15.55 | 1.04 0.13 to 13.02 | 1.08 0.11 to 16.42 | 1.02 0.13 to 12.37 | 1.02 0.12 to 13.55 | BOFANG_SC | 0.95 0.11 to 13.03 | 0.93 0.10 to 13.23 | 0.91 0.12 to 11.09 | 0.87 0.11 to 10.58 | 0.85 0.10 to 11.06 | 0.83 0.11 to 10.18 | 0.76 0.10 to 9.36 | 0.62 0.08 to 7.82 | 0.62 0.08 to 7.65 | 0.59 0.08 to 7.70 | 0.58 0.08 to 7.10 | 0.58 0.07 to 7.50 | 0.55 0.07 to 7.07 | 0.52 0.06 to 6.46 | 0.50 0.07 to 6.17 | 0.51 0.06 to 6.71 | 0.48 0.07 to 6.10 | 0.48 0.06 to 6.45 | 0.48 0.04 to 7.57 | 0.46 0.04 to 7.01 | 0.46 0.04 to 8.23 | 0.40 0.02 to 11.09 | 0.39 0.05 to 4.81 | 0.32 0.03 to 4.73 | 0.28 0.02 to 4.38 | 0.28 0.03 to 3.75 | 0.25 0.03 to 3.46 | 0.26 0.02 to 4.31 | 0.25 0.03 to 3.12 | 0.22 0.01 to 3.97 | 0.16 0.02 to 2.41 | 0.05 0.00 to 0.86 |
| DAPAEXEN_SC | 1.14 0.49 to 2.66 | 4.68 0.14 to 300 | 4.18 1.19 to 15.61 | 2.57 0.67 to 10.56 | 2.36 0.83 to 6.59 | 2.24 0.95 to 5.30 | 2.14 0.83 to 5.49 | 2.11 0.80 to 5.46 | 1.96 0.74 to 5.20 | 1.82 0.72 to 4.58 | 1.70 0.23 to 22.34 | 1.59 0.46 to 5.80 | 1.58 0.55 to 4.49 | 1.52 0.23 to 11.70 | 1.46 0.60 to 3.49 | 1.45 0.44 to 4.88 | 1.43 0.43 to 4.60 | 1.38 0.25 to 6.51 | 1.22 0.27 to 5.22 | 1.13 0.34 to 4.04 | 1.11 0.43 to 2.76 | 1.10 0.28 to 4.69 | 1.08 0.43 to 2.70 | 1.08 0.45 to 2.46 | 1.05 0.08 to 9.49 | DAPAEXEN_SC | 0.95 0.29 to 3.27 | 0.96 0.40 to 2.29 | 0.91 0.36 to 2.26 | 0.89 0.31 to 2.52 | 0.88 0.37 to 2.09 | 0.80 0.35 to 1.79 | 0.66 0.28 to 1.54 | 0.66 0.27 to 1.55 | 0.63 0.25 to 1.57 | 0.61 0.26 to 1.41 | 0.61 0.21 to 1.74 | 0.58 0.23 to 1.43 | 0.54 0.18 to 1.57 | 0.54 0.22 to 1.26 | 0.53 0.18 to 1.56 | 0.51 0.21 to 1.24 | 0.50 0.17 to 1.43 | 0.50 0.09 to 2.37 | 0.47 0.11 to 1.99 | 0.47 0.10 to 2.47 | 0.41 0.04 to 4.48 | 0.41 0.17 to 0.97 | 0.33 0.07 to 1.43 | 0.29 0.05 to 1.28 | 0.30 0.10 to 0.83 | 0.27 0.10 to 0.71 | 0.26 0.05 to 1.14 | 0.26 0.09 to 0.73 | 0.23 0.02 to 1.36 | 0.17 0.05 to 0.60 | 0.05 0.01 to 0.28 |
| GLIBENCLAMIDE | 1.19 0.47 to 2.82 | 4.75 0.15 to 299 | 4.37 1.22 to 16.59 | 2.66 0.68 to 11.40 | 2.45 0.82 to 7.19 | 2.33 0.90 to 5.55 | 2.23 0.82 to 5.79 | 2.20 0.78 to 5.86 | 2.04 0.70 to 5.70 | 1.90 0.70 to 4.87 | 1.76 0.25 to 24.06 | 1.68 0.46 to 5.96 | 1.64 0.53 to 4.89 | 1.55 0.23 to 12.71 | 1.52 0.59 to 3.69 | 1.50 0.43 to 5.21 | 1.49 0.42 to 4.93 | 1.42 0.25 to 6.89 | 1.27 0.26 to 5.69 | 1.17 0.33 to 4.11 | 1.15 0.43 to 2.88 | 1.16 0.29 to 4.78 | 1.13 0.42 to 2.83 | 1.11 0.37 to 3.27 | 1.08 0.08 to 10.13 | 1.05 0.31 to 3.46 | GLIBENCLAMIDE | 1.00 0.39 to 2.41 | 0.95 0.36 to 2.33 | 0.93 0.30 to 2.69 | 0.91 0.36 to 2.20 | 0.84 0.32 to 2.04 | 0.69 0.27 to 1.64 | 0.69 0.27 to 1.66 | 0.66 0.24 to 1.69 | 0.64 0.26 to 1.47 | 0.63 0.21 to 1.84 | 0.60 0.22 to 1.56 | 0.56 0.18 to 1.65 | 0.56 0.22 to 1.34 | 0.55 0.17 to 1.61 | 0.53 0.21 to 1.32 | 0.52 0.17 to 1.49 | 0.52 0.09 to 2.32 | 0.49 0.11 to 2.25 | 0.49 0.09 to 2.63 | 0.43 0.04 to 4.60 | 0.42 0.16 to 1.03 | 0.34 0.07 to 1.51 | 0.31 0.05 to 1.39 | 0.31 0.10 to 0.89 | 0.27 0.09 to 0.86 | 0.27 0.05 to 1.24 | 0.27 0.09 to 0.78 | 0.24 0.02 to 1.44 | 0.18 0.05 to 0.61 | 0.05 0.01 to 0.30 |
| LIXI_SC | 1.19 0.97 to 1.47 | 4.82 0.16 to 295 | 4.34 1.71 to 12.57 | 2.66 0.94 to 8.64 | 2.42 1.30 to 4.76 | 2.33 1.78 to 3.03 | 2.22 1.40 to 3.64 | 2.19 1.34 to 3.53 | 2.05 1.16 to 3.63 | 1.89 1.21 to 2.96 | 1.76 0.30 to 20.54 | 1.67 0.65 to 4.44 | 1.64 0.83 to 3.31 | 1.57 0.28 to 10.50 | 1.53 1.12 to 2.06 | 1.50 0.63 to 3.75 | 1.49 0.62 to 3.51 | 1.45 0.31 to 5.36 | 1.27 0.36 to 4.39 | 1.17 0.51 to 3.01 | 1.15 0.76 to 1.74 | 1.14 0.38 to 3.76 | 1.12 0.78 to 1.62 | 1.11 0.55 to 2.25 | 1.10 0.09 to 8.40 | 1.04 0.44 to 2.49 | 1.00 0.41 to 2.54 | LIXI_SC | 0.95 0.62 to 1.42 | 0.93 0.48 to 1.81 | 0.91 0.69 to 1.20 | 0.83 0.60 to 1.14 | 0.69 0.53 to 0.89 | 0.69 0.50 to 0.93 | 0.66 0.42 to 0.99 | 0.64 0.49 to 0.82 | 0.64 0.32 to 1.23 | 0.60 0.38 to 0.95 | 0.56 0.28 to 1.14 | 0.56 0.42 to 0.74 | 0.56 0.27 to 1.08 | 0.53 0.37 to 0.74 | 0.52 0.27 to 1.00 | 0.52 0.12 to 1.87 | 0.49 0.14 to 1.69 | 0.48 0.12 to 2.13 | 0.44 0.04 to 4.21 | 0.42 0.31 to 0.59 | 0.35 0.08 to 1.17 | 0.32 0.06 to 1.04 | 0.31 0.16 to 0.59 | 0.28 0.13 to 0.59 | 0.28 0.07 to 0.92 | 0.27 0.13 to 0.53 | 0.24 0.03 to 1.14 | 0.18 0.06 to 0.44 | 0.06 0.01 to 0.23 |
| IDEGLIRA_SC | 1.25 0.87 to 1.84 | 4.99 0.17 to 302 | 4.57 1.70 to 13.64 | 2.82 0.94 to 9.42 | 2.55 1.27 to 5.38 | 2.45 1.67 to 3.60 | 2.35 1.57 to 3.61 | 2.30 1.31 to 4.09 | 2.15 1.13 to 4.19 | 1.98 1.16 to 3.43 | 1.84 0.31 to 22.84 | 1.75 0.75 to 4.28 | 1.72 0.79 to 3.75 | 1.67 0.28 to 10.92 | 1.60 1.04 to 2.49 | 1.59 0.62 to 4.25 | 1.57 0.62 to 3.98 | 1.53 0.31 to 5.86 | 1.34 0.37 to 4.96 | 1.24 0.51 to 3.30 | 1.22 0.73 to 2.01 | 1.20 0.39 to 4.08 | 1.18 0.73 to 1.96 | 1.17 0.54 to 2.55 | 1.15 0.09 to 9.10 | 1.10 0.44 to 2.75 | 1.05 0.43 to 2.76 | 1.05 0.70 to 1.60 | IDEGLIRA_SC | 0.98 0.48 to 1.99 | 0.96 0.63 to 1.48 | 0.88 0.57 to 1.35 | 0.73 0.49 to 1.07 | 0.72 0.46 to 1.12 | 0.69 0.40 to 1.18 | 0.67 0.46 to 0.97 | 0.67 0.32 to 1.40 | 0.63 0.37 to 1.09 | 0.59 0.27 to 1.29 | 0.59 0.39 to 0.89 | 0.58 0.27 to 1.23 | 0.56 0.35 to 0.89 | 0.55 0.26 to 1.14 | 0.56 0.12 to 2.09 | 0.52 0.14 to 1.83 | 0.51 0.13 to 2.25 | 0.46 0.04 to 4.32 | 0.44 0.29 to 0.68 | 0.37 0.09 to 1.25 | 0.33 0.07 to 1.13 | 0.33 0.15 to 0.67 | 0.29 0.13 to 0.66 | 0.29 0.07 to 1.05 | 0.28 0.13 to 0.60 | 0.26 0.03 to 1.25 | 0.19 0.06 to 0.50 | 0.06 0.01 to 0.25 |
| CANAGLIFLOZIN | 1.27 0.68 to 2.43 | 5.15 0.16 to 327 | 4.67 1.51 to 15.70 | 2.87 0.82 to 11.03 | 2.60 1.11 to 6.32 | 2.49 1.31 to 4.83 | 2.40 1.12 to 5.24 | 2.34 1.08 to 5.20 | 2.19 0.97 to 5.16 | 2.01 0.97 to 4.30 | 1.87 0.30 to 24.20 | 1.79 0.58 to 5.61 | 1.76 0.73 to 4.21 | 1.68 0.27 to 12.40 | 1.63 0.84 to 3.20 | 1.62 0.56 to 4.91 | 1.61 0.57 to 4.29 | 1.55 0.30 to 6.61 | 1.36 0.34 to 5.46 | 1.27 0.46 to 3.71 | 1.23 0.60 to 2.53 | 1.24 0.35 to 4.51 | 1.21 0.60 to 2.50 | 1.20 0.47 to 2.97 | 1.17 0.09 to 9.75 | 1.12 0.40 to 3.20 | 1.07 0.37 to 3.29 | 1.07 0.55 to 2.09 | 1.02 0.50 to 2.10 | CANAGLIFLOZIN | 0.98 0.51 to 1.95 | 0.90 0.46 to 1.73 | 0.74 0.39 to 1.42 | 0.74 0.37 to 1.44 | 0.70 0.34 to 1.47 | 0.68 0.36 to 1.32 | 0.69 0.29 to 1.57 | 0.64 0.30 to 1.37 | 0.60 0.24 to 1.50 | 0.60 0.33 to 1.09 | 0.60 0.23 to 1.47 | 0.57 0.29 to 1.14 | 0.56 0.23 to 1.38 | 0.56 0.11 to 2.37 | 0.53 0.13 to 2.06 | 0.52 0.12 to 2.54 | 0.47 0.04 to 4.92 | 0.46 0.23 to 0.90 | 0.37 0.08 to 1.46 | 0.33 0.06 to 1.28 | 0.34 0.13 to 0.82 | 0.30 0.11 to 0.78 | 0.30 0.06 to 1.18 | 0.29 0.11 to 0.71 | 0.26 0.03 to 1.41 | 0.19 0.06 to 0.58 | 0.06 0.01 to 0.28 |
| EXEN_SC | 1.30 1.03 to 1.66 | 5.29 0.17 to 312 | 4.75 1.87 to 13.43 | 2.92 1.00 to 9.42 | 2.65 1.51 to 4.97 | 2.54 1.90 to 3.39 | 2.44 1.52 to 4.04 | 2.39 1.50 to 3.81 | 2.24 1.29 to 3.99 | 2.07 1.36 to 3.17 | 1.92 0.34 to 23.55 | 1.82 0.70 to 4.86 | 1.80 0.88 to 3.67 | 1.70 0.31 to 10.97 | 1.66 1.21 to 2.30 | 1.65 0.69 to 4.11 | 1.63 0.68 to 3.93 | 1.58 0.34 to 6.02 | 1.39 0.39 to 4.77 | 1.29 0.56 to 3.33 | 1.26 0.83 to 1.90 | 1.25 0.42 to 4.13 | 1.23 0.82 to 1.87 | 1.21 0.60 to 2.48 | 1.20 0.10 to 9.24 | 1.13 0.48 to 2.72 | 1.09 0.45 to 2.81 | 1.09 0.83 to 1.45 | 1.04 0.68 to 1.58 | 1.02 0.51 to 1.98 | EXEN_SC | 0.91 0.67 to 1.23 | 0.75 0.58 to 0.98 | 0.75 0.53 to 1.04 | 0.72 0.48 to 1.06 | 0.70 0.53 to 0.92 | 0.69 0.35 to 1.37 | 0.66 0.41 to 1.05 | 0.61 0.30 to 1.27 | 0.61 0.45 to 0.82 | 0.61 0.29 to 1.21 | 0.58 0.40 to 0.83 | 0.58 0.29 to 1.11 | 0.57 0.13 to 1.97 | 0.54 0.15 to 1.84 | 0.53 0.14 to 2.32 | 0.48 0.04 to 4.52 | 0.46 0.33 to 0.64 | 0.38 0.09 to 1.26 | 0.34 0.07 to 1.13 | 0.34 0.17 to 0.66 | 0.30 0.14 to 0.64 | 0.31 0.07 to 1.02 | 0.29 0.14 to 0.59 | 0.27 0.03 to 1.26 | 0.19 0.07 to 0.50 | 0.06 0.01 to 0.25 |
| EXENER_SC | 1.43 1.09 to 1.87 | 5.70 0.19 to 347 | 5.20 2.03 to 15.09 | 3.19 1.10 to 10.47 | 2.92 1.54 to 5.70 | 2.79 2.07 to 3.78 | 2.66 1.66 to 4.41 | 2.62 1.57 to 4.40 | 2.45 1.46 to 4.28 | 2.27 1.42 to 3.63 | 2.10 0.36 to 25.29 | 1.99 0.78 to 5.47 | 1.97 0.98 to 4.04 | 1.89 0.34 to 12.57 | 1.83 1.35 to 2.50 | 1.80 0.80 to 4.30 | 1.79 0.75 to 4.28 | 1.74 0.38 to 6.55 | 1.52 0.42 to 5.24 | 1.41 0.61 to 3.64 | 1.39 0.89 to 2.12 | 1.37 0.46 to 4.47 | 1.35 0.88 to 2.09 | 1.33 0.68 to 2.62 | 1.32 0.11 to 9.96 | 1.25 0.56 to 2.85 | 1.19 0.49 to 3.10 | 1.20 0.88 to 1.65 | 1.14 0.74 to 1.76 | 1.12 0.58 to 2.19 | 1.10 0.82 to 1.50 | EXENER_SC | 0.83 0.62 to 1.11 | 0.82 0.58 to 1.16 | 0.79 0.50 to 1.22 | 0.76 0.58 to 1.01 | 0.76 0.39 to 1.49 | 0.72 0.47 to 1.12 | 0.67 0.33 to 1.38 | 0.67 0.50 to 0.90 | 0.67 0.32 to 1.34 | 0.64 0.43 to 0.93 | 0.63 0.32 to 1.21 | 0.62 0.14 to 2.27 | 0.59 0.17 to 2.00 | 0.58 0.15 to 2.55 | 0.52 0.05 to 5.00 | 0.51 0.36 to 0.73 | 0.42 0.10 to 1.38 | 0.38 0.08 to 1.25 | 0.38 0.19 to 0.73 | 0.33 0.16 to 0.69 | 0.33 0.08 to 1.15 | 0.32 0.16 to 0.65 | 0.29 0.03 to 1.38 | 0.22 0.08 to 0.54 | 0.07 0.01 to 0.28 |
| DULA_SC | 1.72 1.43 to 2.11 | 6.92 0.22 to 407 | 6.26 2.51 to 18.13 | 3.88 1.36 to 12.38 | 3.52 1.88 to 6.84 | 3.37 2.67 to 4.28 | 3.22 2.03 to 5.20 | 3.17 1.98 to 5.10 | 2.96 1.71 to 5.30 | 2.74 1.80 to 4.22 | 2.55 0.44 to 30.37 | 2.41 0.95 to 6.36 | 2.37 1.21 to 4.80 | 2.26 0.42 to 14.81 | 2.20 1.65 to 2.97 | 2.19 0.92 to 5.33 | 2.16 0.91 to 5.08 | 2.10 0.45 to 7.77 | 1.84 0.52 to 6.31 | 1.71 0.74 to 4.38 | 1.68 1.12 to 2.47 | 1.65 0.55 to 5.42 | 1.63 1.10 to 2.43 | 1.61 0.80 to 3.26 | 1.60 0.13 to 12.04 | 1.51 0.65 to 3.56 | 1.45 0.61 to 3.70 | 1.45 1.12 to 1.89 | 1.37 0.93 to 2.04 | 1.35 0.70 to 2.55 | 1.32 1.02 to 1.73 | 1.21 0.90 to 1.62 | DULA_SC | 1.00 0.74 to 1.33 | 0.95 0.62 to 1.44 | 0.92 0.74 to 1.16 | 0.92 0.47 to 1.76 | 0.87 0.57 to 1.33 | 0.81 0.40 to 1.62 | 0.81 0.63 to 1.03 | 0.81 0.39 to 1.59 | 0.77 0.55 to 1.07 | 0.76 0.39 to 1.45 | 0.76 0.17 to 2.67 | 0.71 0.21 to 2.39 | 0.71 0.19 to 3.08 | 0.63 0.06 to 5.90 | 0.61 0.46 to 0.81 | 0.51 0.12 to 1.65 | 0.45 0.10 to 1.47 | 0.45 0.23 to 0.86 | 0.40 0.19 to 0.83 | 0.40 0.10 to 1.37 | 0.39 0.20 to 0.75 | 0.35 0.04 to 1.66 | 0.26 0.09 to 0.64 | 0.08 0.01 to 0.34 |
| SEMA_PO | 1.73 1.36 to 2.25 | 7.00 0.23 to 421 | 6.33 2.48 to 18.49 | 3.90 1.36 to 13.03 | 3.54 1.82 to 7.11 | 3.39 2.45 to 4.69 | 3.24 1.98 to 5.48 | 3.19 1.89 to 5.38 | 2.99 1.67 to 5.43 | 2.76 1.71 to 4.44 | 2.55 0.44 to 30.33 | 2.42 0.93 to 6.70 | 2.39 1.17 to 4.97 | 2.28 0.41 to 15.46 | 2.22 1.66 to 3.00 | 2.20 0.90 to 5.59 | 2.17 0.90 to 5.19 | 2.12 0.45 to 7.86 | 1.86 0.52 to 6.44 | 1.72 0.74 to 4.40 | 1.68 1.07 to 2.65 | 1.66 0.55 to 5.59 | 1.64 1.06 to 2.56 | 1.61 0.79 to 3.33 | 1.62 0.13 to 12.34 | 1.51 0.64 to 3.71 | 1.46 0.60 to 3.75 | 1.46 1.07 to 2.02 | 1.38 0.89 to 2.15 | 1.35 0.69 to 2.69 | 1.33 0.96 to 1.87 | 1.22 0.87 to 1.71 | 1.00 0.75 to 1.35 | SEMA_PO | 0.96 0.61 to 1.49 | 0.93 0.70 to 1.24 | 0.93 0.47 to 1.82 | 0.88 0.55 to 1.44 | 0.82 0.40 to 1.68 | 0.82 0.59 to 1.12 | 0.81 0.38 to 1.66 | 0.78 0.56 to 1.07 | 0.77 0.41 to 1.41 | 0.76 0.17 to 2.74 | 0.72 0.20 to 2.47 | 0.71 0.18 to 3.14 | 0.63 0.06 to 5.92 | 0.62 0.43 to 0.89 | 0.51 0.12 to 1.65 | 0.46 0.09 to 1.54 | 0.46 0.23 to 0.89 | 0.41 0.19 to 0.86 | 0.40 0.10 to 1.43 | 0.39 0.19 to 0.79 | 0.36 0.04 to 1.67 | 0.26 0.09 to 0.67 | 0.08 0.01 to 0.34 |
| TASP_SC | 1.81 1.25 to 2.71 | 7.25 0.23 to 462 | 6.58 2.49 to 20.11 | 4.04 1.35 to 13.85 | 3.71 1.86 to 7.65 | 3.54 2.30 to 5.48 | 3.38 1.93 to 6.19 | 3.32 1.88 to 5.93 | 3.10 1.66 to 6.12 | 2.88 1.69 to 5.01 | 2.65 0.45 to 34.10 | 2.53 0.93 to 7.08 | 2.50 1.15 to 5.43 | 2.41 0.42 to 15.99 | 2.31 1.53 to 3.58 | 2.30 0.91 to 5.96 | 2.26 0.89 to 5.83 | 2.22 0.46 to 8.46 | 1.94 0.52 to 7.17 | 1.79 0.73 to 4.88 | 1.75 1.05 to 2.98 | 1.74 0.56 to 6.05 | 1.71 1.01 to 2.90 | 1.69 0.78 to 3.69 | 1.69 0.13 to 13.04 | 1.58 0.64 to 4.00 | 1.52 0.59 to 4.10 | 1.52 1.01 to 2.36 | 1.44 0.85 to 2.48 | 1.42 0.68 to 2.94 | 1.39 0.95 to 2.07 | 1.27 0.82 to 1.99 | 1.05 0.70 to 1.61 | 1.04 0.67 to 1.64 | TASP_SC | 0.97 0.64 to 1.49 | 0.97 0.46 to 2.07 | 0.92 0.53 to 1.62 | 0.85 0.39 to 1.83 | 0.85 0.55 to 1.31 | 0.84 0.38 to 1.84 | 0.81 0.51 to 1.31 | 0.80 0.38 to 1.65 | 0.79 0.18 to 2.98 | 0.75 0.21 to 2.64 | 0.74 0.18 to 3.34 | 0.67 0.06 to 6.18 | 0.64 0.41 to 1.03 | 0.53 0.12 to 1.79 | 0.48 0.10 to 1.65 | 0.47 0.22 to 1.00 | 0.42 0.18 to 0.95 | 0.42 0.10 to 1.49 | 0.41 0.19 to 0.89 | 0.37 0.04 to 1.78 | 0.27 0.09 to 0.73 | 0.08 0.01 to 0.37 |
| LIRA_SC | 1.87 1.56 to 2.24 | 7.46 0.25 to 462 | 6.79 2.79 to 18.95 | 4.19 1.47 to 13.51 | 3.82 2.03 to 7.39 | 3.64 2.83 to 4.72 | 3.49 2.26 to 5.60 | 3.44 2.12 to 5.54 | 3.21 1.85 to 5.69 | 2.96 1.96 to 4.52 | 2.73 0.48 to 32.85 | 2.61 1.03 to 6.97 | 2.58 1.31 to 5.23 | 2.46 0.45 to 16.31 | 2.39 1.86 to 3.08 | 2.38 1.01 to 5.83 | 2.35 0.98 to 5.43 | 2.27 0.49 to 8.47 | 2.00 0.56 to 6.92 | 1.83 0.81 to 4.65 | 1.82 1.21 to 2.68 | 1.79 0.61 to 5.72 | 1.77 1.19 to 2.62 | 1.75 0.87 to 3.50 | 1.74 0.14 to 13.04 | 1.64 0.71 to 3.82 | 1.56 0.68 to 3.89 | 1.57 1.22 to 2.03 | 1.49 1.03 to 2.15 | 1.46 0.76 to 2.78 | 1.44 1.08 to 1.89 | 1.31 0.99 to 1.73 | 1.09 0.86 to 1.35 | 1.08 0.81 to 1.42 | 1.03 0.67 to 1.55 | LIRA_SC | 1.00 0.51 to 1.93 | 0.95 0.61 to 1.48 | 0.88 0.43 to 1.77 | 0.88 0.68 to 1.12 | 0.87 0.43 to 1.71 | 0.84 0.60 to 1.15 | 0.83 0.42 to 1.54 | 0.82 0.19 to 2.91 | 0.77 0.22 to 2.64 | 0.76 0.19 to 3.35 | 0.69 0.07 to 6.37 | 0.66 0.49 to 0.90 | 0.55 0.13 to 1.80 | 0.50 0.10 to 1.60 | 0.49 0.25 to 0.90 | 0.43 0.20 to 0.90 | 0.44 0.11 to 1.48 | 0.42 0.21 to 0.83 | 0.38 0.04 to 1.82 | 0.28 0.10 to 0.70 | 0.09 0.01 to 0.36 |
| ICOSEMA_SC | 1.87 0.99 to 3.59 | 7.71 0.24 to 483 | 6.85 2.23 to 23.09 | 4.23 1.23 to 16.09 | 3.87 1.58 to 9.60 | 3.64 1.89 to 7.11 | 3.51 1.61 to 7.65 | 3.44 1.57 to 7.64 | 3.23 1.40 to 7.43 | 2.98 1.41 to 6.41 | 2.77 0.42 to 36.06 | 2.62 0.86 to 8.49 | 2.58 1.06 to 6.41 | 2.47 0.41 to 18.40 | 2.39 1.23 to 4.74 | 2.37 0.81 to 7.16 | 2.33 1.35 to 4.11 | 2.26 0.44 to 9.64 | 2.00 0.47 to 7.86 | 1.88 0.66 to 5.42 | 1.81 0.88 to 3.82 | 1.79 0.52 to 6.80 | 1.77 0.87 to 3.73 | 1.74 0.70 to 4.52 | 1.74 0.13 to 14.49 | 1.63 0.57 to 4.81 | 1.58 0.54 to 4.83 | 1.57 0.82 to 3.11 | 1.49 0.72 to 3.16 | 1.46 0.64 to 3.48 | 1.44 0.73 to 2.86 | 1.31 0.67 to 2.58 | 1.09 0.57 to 2.11 | 1.08 0.55 to 2.15 | 1.03 0.48 to 2.20 | 1.00 0.52 to 1.94 | ICOSEMA_SC | 0.95 0.44 to 2.04 | 0.89 0.35 to 2.27 | 0.88 0.47 to 1.61 | 0.87 0.34 to 2.23 | 0.84 0.42 to 1.71 | 0.83 0.33 to 2.01 | 0.82 0.16 to 3.47 | 0.77 0.19 to 3.04 | 0.76 0.18 to 3.73 | 0.68 0.06 to 7.09 | 0.67 0.33 to 1.32 | 0.55 0.12 to 2.13 | 0.49 0.09 to 1.89 | 0.49 0.20 to 1.22 | 0.43 0.17 to 1.14 | 0.44 0.09 to 1.74 | 0.42 0.16 to 1.08 | 0.38 0.04 to 2.02 | 0.28 0.09 to 0.86 | 0.09 0.01 to 0.41 |
| METFORMIN | 1.98 1.28 to 3.03 | 8.02 0.26 to 488 | 7.22 2.64 to 21.98 | 4.42 1.45 to 15.16 | 4.04 1.94 to 8.67 | 3.86 2.43 to 6.08 | 3.71 2.05 to 6.79 | 3.63 1.99 to 6.71 | 3.40 1.84 to 6.46 | 3.11 1.78 to 5.60 | 2.89 0.49 to 34.42 | 2.74 1.03 to 7.81 | 2.74 1.23 to 6.04 | 2.61 0.45 to 18.05 | 2.52 1.60 to 3.98 | 2.51 0.99 to 6.73 | 2.48 0.96 to 6.20 | 2.41 0.50 to 9.33 | 2.09 0.60 to 7.21 | 1.97 0.78 to 5.31 | 1.91 1.09 to 3.28 | 1.91 0.60 to 6.56 | 1.87 1.08 to 3.22 | 1.84 0.86 to 4.03 | 1.83 0.14 to 14.26 | 1.73 0.70 to 4.35 | 1.66 0.64 to 4.56 | 1.66 1.05 to 2.64 | 1.58 0.91 to 2.71 | 1.55 0.73 to 3.29 | 1.51 0.96 to 2.41 | 1.38 0.89 to 2.14 | 1.14 0.75 to 1.75 | 1.14 0.69 to 1.83 | 1.09 0.62 to 1.90 | 1.06 0.68 to 1.63 | 1.05 0.49 to 2.26 | METFORMIN | 0.93 0.42 to 2.04 | 0.93 0.58 to 1.44 | 0.93 0.41 to 1.99 | 0.89 0.53 to 1.45 | 0.87 0.40 to 1.85 | 0.86 0.19 to 3.28 | 0.83 0.22 to 2.90 | 0.81 0.20 to 3.66 | 0.71 0.07 to 7.10 | 0.70 0.43 to 1.15 | 0.58 0.13 to 2.01 | 0.52 0.10 to 1.84 | 0.52 0.24 to 1.09 | 0.46 0.20 to 1.04 | 0.46 0.11 to 1.65 | 0.45 0.20 to 0.96 | 0.41 0.04 to 1.96 | 0.30 0.10 to 0.79 | 0.09 0.01 to 0.40 |
| VISEPE_SC | 2.13 1.09 to 4.19 | 8.63 0.26 to 583 | 7.79 2.47 to 26.45 | 4.73 1.37 to 18.80 | 4.38 1.75 to 11.04 | 4.14 2.04 to 8.48 | 3.98 1.80 to 8.94 | 3.89 1.71 to 8.95 | 3.66 1.52 to 8.76 | 3.37 1.55 to 7.47 | 3.15 0.47 to 42.22 | 2.96 0.95 to 9.59 | 2.93 1.13 to 7.58 | 2.79 0.44 to 20.94 | 2.72 1.34 to 5.64 | 2.70 0.91 to 8.54 | 2.67 0.87 to 7.65 | 2.58 0.47 to 11.34 | 2.27 0.54 to 9.15 | 2.11 0.72 to 6.57 | 2.07 0.96 to 4.41 | 2.05 0.57 to 8.10 | 2.00 0.93 to 4.38 | 1.98 0.76 to 5.02 | 1.93 0.15 to 16.66 | 1.86 0.64 to 5.43 | 1.78 0.61 to 5.49 | 1.78 0.88 to 3.62 | 1.70 0.78 to 3.68 | 1.66 0.66 to 4.18 | 1.63 0.79 to 3.34 | 1.49 0.72 to 3.02 | 1.23 0.62 to 2.49 | 1.22 0.60 to 2.51 | 1.17 0.55 to 2.55 | 1.14 0.56 to 2.31 | 1.13 0.44 to 2.87 | 1.07 0.49 to 2.39 | VISEPE_SC | 1.00 0.49 to 2.03 | 0.99 0.39 to 2.53 | 0.95 0.46 to 2.00 | 0.94 0.38 to 2.31 | 0.93 0.18 to 3.94 | 0.88 0.21 to 3.58 | 0.87 0.19 to 4.26 | 0.78 0.07 to 8.04 | 0.75 0.37 to 1.57 | 0.62 0.13 to 2.41 | 0.55 0.10 to 2.18 | 0.56 0.22 to 1.38 | 0.50 0.18 to 1.30 | 0.50 0.11 to 2.00 | 0.48 0.18 to 1.23 | 0.43 0.04 to 2.36 | 0.32 0.10 to 0.98 | 0.10 0.01 to 0.47 |
| SEMA_SC | 2.13 1.73 to 2.65 | 8.52 0.29 to 528 | 7.77 3.13 to 22.52 | 4.79 1.65 to 15.57 | 4.34 2.30 to 8.48 | 4.15 3.20 to 5.48 | 3.98 2.50 to 6.50 | 3.91 2.43 to 6.32 | 3.65 2.07 to 6.59 | 3.38 2.18 to 5.31 | 3.12 0.54 to 37.40 | 2.97 1.18 to 7.91 | 2.93 1.55 to 5.64 | 2.82 0.52 to 18.58 | 2.71 2.06 to 3.68 | 2.69 1.14 to 6.70 | 2.66 1.16 to 6.04 | 2.59 0.56 to 9.59 | 2.29 0.64 to 7.87 | 2.11 0.95 to 5.18 | 2.07 1.36 to 3.13 | 2.04 0.68 to 6.82 | 2.01 1.33 to 3.05 | 1.99 0.97 to 4.03 | 1.98 0.16 to 14.87 | 1.85 0.79 to 4.45 | 1.79 0.74 to 4.61 | 1.79 1.35 to 2.40 | 1.70 1.13 to 2.55 | 1.66 0.92 to 3.04 | 1.63 1.22 to 2.23 | 1.49 1.11 to 2.00 | 1.23 0.97 to 1.59 | 1.23 0.90 to 1.69 | 1.18 0.77 to 1.82 | 1.14 0.89 to 1.47 | 1.14 0.62 to 2.11 | 1.08 0.69 to 1.73 | 1.00 0.49 to 2.04 | SEMA_SC | 1.00 0.49 to 1.96 | 0.95 0.67 to 1.34 | 0.94 0.48 to 1.78 | 0.93 0.21 to 3.40 | 0.88 0.25 to 2.98 | 0.86 0.23 to 3.84 | 0.78 0.07 to 7.37 | 0.76 0.56 to 1.05 | 0.63 0.15 to 2.04 | 0.56 0.12 to 1.84 | 0.56 0.28 to 1.07 | 0.50 0.23 to 1.05 | 0.50 0.12 to 1.72 | 0.48 0.24 to 0.95 | 0.44 0.05 to 2.07 | 0.32 0.12 to 0.81 | 0.10 0.01 to 0.41 |
| EFPE_SC | 2.13 1.13 to 4.25 | 8.58 0.27 to 566 | 7.90 2.48 to 26.91 | 4.89 1.39 to 18.51 | 4.37 1.80 to 11.31 | 4.17 2.09 to 8.67 | 3.99 1.85 to 9.18 | 3.93 1.77 to 9.13 | 3.68 1.56 to 9.05 | 3.41 1.56 to 7.60 | 3.15 0.48 to 40.30 | 3.03 0.96 to 9.96 | 2.96 1.15 to 7.85 | 2.83 0.46 to 20.62 | 2.74 1.36 to 5.81 | 2.71 0.92 to 8.53 | 2.70 0.92 to 7.75 | 2.59 0.50 to 11.56 | 2.29 0.56 to 9.50 | 2.13 0.74 to 6.67 | 2.07 0.98 to 4.47 | 2.08 0.59 to 7.91 | 2.02 0.96 to 4.44 | 1.99 0.77 to 5.23 | 1.98 0.15 to 16.19 | 1.87 0.64 to 5.65 | 1.81 0.62 to 5.74 | 1.79 0.93 to 3.68 | 1.71 0.81 to 3.71 | 1.68 0.68 to 4.28 | 1.64 0.83 to 3.42 | 1.50 0.75 to 3.11 | 1.24 0.63 to 2.55 | 1.23 0.60 to 2.61 | 1.18 0.54 to 2.62 | 1.14 0.58 to 2.35 | 1.15 0.45 to 2.93 | 1.08 0.50 to 2.45 | 1.01 0.39 to 2.58 | 1.00 0.51 to 2.04 | EFPE_SC | 0.96 0.47 to 2.00 | 0.95 0.38 to 2.37 | 0.94 0.19 to 4.13 | 0.88 0.22 to 3.68 | 0.87 0.20 to 4.49 | 0.79 0.07 to 8.08 | 0.76 0.38 to 1.57 | 0.63 0.14 to 2.49 | 0.56 0.11 to 2.25 | 0.56 0.23 to 1.39 | 0.50 0.18 to 1.35 | 0.50 0.10 to 2.00 | 0.48 0.19 to 1.26 | 0.44 0.05 to 2.37 | 0.32 0.10 to 0.98 | 0.10 0.01 to 0.49 |
| ORFO_PO | 2.23 1.71 to 3.02 | 9.00 0.30 to 547 | 8.12 3.14 to 24.13 | 5.01 1.68 to 16.65 | 4.53 2.39 to 9.25 | 4.35 3.08 to 6.27 | 4.18 2.50 to 7.16 | 4.10 2.42 to 6.95 | 3.85 2.09 to 7.18 | 3.55 2.17 to 5.90 | 3.28 0.56 to 39.81 | 3.11 1.19 to 8.55 | 3.08 1.51 to 6.45 | 2.94 0.52 to 19.87 | 2.85 2.01 to 4.10 | 2.81 1.15 to 7.20 | 2.81 1.14 to 6.71 | 2.71 0.58 to 10.29 | 2.38 0.66 to 8.48 | 2.22 0.92 to 5.76 | 2.17 1.37 to 3.41 | 2.15 0.71 to 7.24 | 2.11 1.34 to 3.39 | 2.09 0.99 to 4.34 | 2.08 0.16 to 15.31 | 1.96 0.81 to 4.85 | 1.88 0.76 to 4.86 | 1.88 1.34 to 2.70 | 1.78 1.12 to 2.83 | 1.74 0.88 to 3.46 | 1.72 1.21 to 2.49 | 1.56 1.08 to 2.30 | 1.30 0.94 to 1.80 | 1.29 0.93 to 1.77 | 1.24 0.76 to 1.97 | 1.19 0.87 to 1.67 | 1.19 0.59 to 2.39 | 1.13 0.69 to 1.88 | 1.05 0.50 to 2.17 | 1.05 0.74 to 1.49 | 1.05 0.50 to 2.14 | ORFO_PO | 0.98 0.50 to 1.89 | 0.99 0.23 to 3.63 | 0.92 0.26 to 3.22 | 0.91 0.23 to 4.02 | 0.82 0.08 to 7.98 | 0.79 0.54 to 1.18 | 0.66 0.15 to 2.18 | 0.59 0.12 to 1.95 | 0.59 0.29 to 1.15 | 0.53 0.23 to 1.11 | 0.52 0.12 to 1.81 | 0.51 0.24 to 1.03 | 0.46 0.05 to 2.17 | 0.33 0.12 to 0.86 | 0.10 0.01 to 0.44 |
| LOTI_PO | 2.27 1.25 to 4.32 | 9.11 0.30 to 592 | 8.32 2.75 to 28.22 | 5.13 1.50 to 19.72 | 4.65 1.95 to 11.96 | 4.43 2.29 to 8.81 | 4.23 2.01 to 9.45 | 4.17 1.98 to 9.19 | 3.89 1.71 to 9.16 | 3.60 1.71 to 7.84 | 3.36 0.52 to 42.54 | 3.17 1.06 to 10.42 | 3.14 1.26 to 7.98 | 2.97 0.50 to 22.26 | 2.90 1.54 to 5.69 | 2.90 1.00 to 8.72 | 2.85 0.98 to 8.37 | 2.75 0.52 to 11.75 | 2.41 0.59 to 9.90 | 2.24 0.80 to 7.01 | 2.19 1.08 to 4.64 | 2.19 0.65 to 8.17 | 2.14 1.04 to 4.55 | 2.12 0.83 to 5.41 | 2.10 0.15 to 17.35 | 1.98 0.70 to 5.75 | 1.91 0.67 to 6.01 | 1.90 1.00 to 3.76 | 1.81 0.87 to 3.85 | 1.78 0.73 to 4.41 | 1.73 0.90 to 3.50 | 1.58 0.83 to 3.16 | 1.31 0.69 to 2.57 | 1.31 0.71 to 2.46 | 1.26 0.61 to 2.61 | 1.21 0.65 to 2.37 | 1.20 0.50 to 3.03 | 1.15 0.54 to 2.49 | 1.07 0.43 to 2.64 | 1.06 0.56 to 2.07 | 1.06 0.42 to 2.67 | 1.02 0.53 to 2.02 | LOTI_PO | 1.01 0.20 to 4.22 | 0.94 0.24 to 3.62 | 0.93 0.20 to 4.63 | 0.84 0.08 to 8.59 | 0.80 0.42 to 1.61 | 0.67 0.15 to 2.45 | 0.60 0.11 to 2.27 | 0.60 0.24 to 1.42 | 0.53 0.20 to 1.40 | 0.52 0.11 to 2.12 | 0.51 0.21 to 1.27 | 0.47 0.05 to 2.51 | 0.34 0.11 to 1.03 | 0.10 0.01 to 0.51 |
| EXENIMP_IMPLANT | 2.28 0.64 to 9.84 | 9.63 0.26 to 802 | 8.44 1.65 to 51.32 | 5.23 0.99 to 33.91 | 4.66 1.17 to 21.87 | 4.46 1.24 to 19.72 | 4.29 1.11 to 20.05 | 4.19 1.09 to 18.73 | 3.92 1.01 to 18.72 | 3.63 0.98 to 16.10 | 3.49 0.37 to 61.25 | 3.23 0.65 to 18.74 | 3.16 0.74 to 15.94 | 3.08 0.35 to 31.57 | 2.91 0.81 to 12.60 | 2.89 0.64 to 16.09 | 2.85 0.58 to 15.90 | 2.76 0.38 to 18.97 | 2.47 0.39 to 17.34 | 2.32 0.49 to 12.87 | 2.22 0.59 to 9.99 | 2.23 0.39 to 14.24 | 2.16 0.58 to 9.91 | 2.11 0.49 to 10.58 | 2.07 0.13 to 25.74 | 2.01 0.42 to 10.84 | 1.92 0.43 to 10.64 | 1.92 0.53 to 8.49 | 1.80 0.48 to 8.28 | 1.78 0.42 to 9.09 | 1.77 0.51 to 7.51 | 1.61 0.44 to 7.06 | 1.32 0.37 to 5.73 | 1.31 0.36 to 5.85 | 1.27 0.34 to 5.70 | 1.22 0.34 to 5.31 | 1.22 0.29 to 6.40 | 1.16 0.30 to 5.37 | 1.07 0.25 to 5.47 | 1.07 0.29 to 4.69 | 1.07 0.24 to 5.24 | 1.01 0.28 to 4.43 | 0.99 0.24 to 5.05 | EXENIMP_IMPLANT | 0.96 0.16 to 6.22 | 0.95 0.15 to 7.40 | 0.83 0.06 to 11.69 | 0.80 0.22 to 3.54 | 0.66 0.10 to 4.44 | 0.59 0.08 to 3.96 | 0.60 0.15 to 2.98 | 0.53 0.12 to 2.74 | 0.53 0.08 to 3.43 | 0.51 0.12 to 2.58 | 0.46 0.04 to 3.78 | 0.34 0.07 to 1.84 | 0.10 0.01 to 0.84 |
| DULAMACU_SC | 2.42 0.71 to 8.37 | 9.73 0.28 to 682 | 8.97 1.91 to 45.11 | 5.49 1.08 to 30.22 | 5.01 1.30 to 19.15 | 4.73 1.40 to 16.61 | 4.55 1.27 to 16.72 | 4.46 1.24 to 16.27 | 4.10 1.12 to 15.86 | 3.85 1.06 to 14.23 | 3.72 0.44 to 56.77 | 3.38 0.74 to 16.51 | 3.31 0.84 to 13.95 | 3.24 0.40 to 30.05 | 3.08 0.89 to 10.67 | 3.08 0.71 to 14.20 | 3.04 0.69 to 13.18 | 2.94 0.41 to 17.49 | 2.55 0.45 to 14.67 | 2.41 0.57 to 10.72 | 2.35 0.67 to 8.56 | 2.34 0.46 to 12.88 | 2.28 0.64 to 8.40 | 2.27 0.56 to 9.10 | 2.19 0.14 to 23.60 | 2.12 0.50 to 9.16 | 2.06 0.44 to 9.45 | 2.03 0.59 to 7.13 | 1.93 0.55 to 6.92 | 1.89 0.48 to 7.47 | 1.86 0.54 to 6.57 | 1.69 0.50 to 5.92 | 1.41 0.42 to 4.81 | 1.39 0.40 to 4.97 | 1.33 0.38 to 4.80 | 1.30 0.38 to 4.47 | 1.30 0.33 to 5.21 | 1.21 0.34 to 4.46 | 1.13 0.28 to 4.66 | 1.13 0.34 to 3.96 | 1.14 0.27 to 4.56 | 1.09 0.31 to 3.84 | 1.07 0.28 to 4.18 | 1.04 0.16 to 6.24 | DULAMACU_SC | 0.99 0.27 to 4.15 | 0.88 0.06 to 10.66 | 0.86 0.25 to 3.10 | 0.71 0.11 to 3.91 | 0.62 0.09 to 3.58 | 0.63 0.16 to 2.49 | 0.56 0.14 to 2.37 | 0.56 0.09 to 3.17 | 0.54 0.13 to 2.19 | 0.49 0.04 to 3.53 | 0.36 0.08 to 1.68 | 0.11 0.01 to 0.78 |
| OTHER_ACTIVE_macupatide | 2.45 0.56 to 9.27 | 9.92 0.24 to 713 | 8.96 1.61 to 48.36 | 5.52 0.90 to 32.92 | 5.02 1.06 to 22.04 | 4.78 1.06 to 18.69 | 4.60 0.98 to 19.07 | 4.50 0.98 to 18.60 | 4.21 0.89 to 18.00 | 3.90 0.84 to 15.88 | 3.66 0.36 to 61.47 | 3.43 0.59 to 17.96 | 3.39 0.66 to 15.47 | 3.23 0.35 to 33.26 | 3.18 0.71 to 12.03 | 3.09 0.57 to 15.82 | 3.06 0.57 to 15.05 | 2.91 0.36 to 19.73 | 2.61 0.39 to 16.34 | 2.42 0.46 to 12.40 | 2.35 0.54 to 9.57 | 2.36 0.38 to 13.83 | 2.32 0.50 to 9.62 | 2.29 0.45 to 10.37 | 2.16 0.12 to 25.35 | 2.14 0.41 to 10.44 | 2.03 0.38 to 10.70 | 2.06 0.47 to 8.05 | 1.96 0.44 to 7.84 | 1.93 0.39 to 8.46 | 1.89 0.43 to 7.25 | 1.71 0.39 to 6.75 | 1.42 0.32 to 5.31 | 1.42 0.32 to 5.52 | 1.36 0.30 to 5.42 | 1.32 0.30 to 5.13 | 1.31 0.27 to 5.66 | 1.24 0.27 to 5.00 | 1.15 0.23 to 5.15 | 1.16 0.26 to 4.42 | 1.15 0.22 to 5.09 | 1.09 0.25 to 4.38 | 1.08 0.22 to 4.88 | 1.06 0.14 to 6.79 | 1.01 0.24 to 3.68 | OTHER_ACTIVE_macupatide | 0.90 0.06 to 11.85 | 0.88 0.19 to 3.35 | 0.71 0.09 to 4.29 | 0.63 0.08 to 3.67 | 0.64 0.13 to 2.78 | 0.57 0.11 to 2.64 | 0.57 0.08 to 3.51 | 0.55 0.11 to 2.52 | 0.48 0.04 to 3.91 | 0.36 0.06 to 1.88 | 0.11 0.01 to 0.86 |
| VILDAGLIPTIN | 2.71 0.29 to 28.84 | 11.40 0.19 to 1276 | 10.26 0.93 to 127 | 6.20 0.55 to 84.00 | 5.57 0.57 to 64.76 | 5.35 0.57 to 55.37 | 5.08 0.54 to 55.14 | 4.98 0.53 to 55.00 | 4.72 0.48 to 51.90 | 4.31 0.45 to 47.87 | 4.33 0.23 to 116 | 3.85 0.35 to 44.01 | 3.78 0.38 to 41.62 | 3.63 0.21 to 72.15 | 3.47 0.37 to 36.25 | 3.48 0.33 to 40.52 | 3.43 0.31 to 41.22 | 3.24 0.21 to 48.53 | 2.90 0.22 to 42.38 | 2.71 0.26 to 32.14 | 2.65 0.29 to 28.06 | 2.66 0.23 to 34.50 | 2.58 0.27 to 27.17 | 2.53 0.25 to 29.09 | 2.48 0.09 to 55.13 | 2.42 0.22 to 27.46 | 2.30 0.22 to 27.99 | 2.28 0.24 to 24.40 | 2.17 0.23 to 22.63 | 2.12 0.20 to 24.60 | 2.10 0.22 to 22.83 | 1.92 0.20 to 20.14 | 1.58 0.17 to 17.00 | 1.58 0.17 to 16.40 | 1.50 0.16 to 15.59 | 1.45 0.16 to 15.18 | 1.47 0.14 to 16.22 | 1.40 0.14 to 15.24 | 1.29 0.12 to 14.37 | 1.28 0.14 to 13.40 | 1.27 0.12 to 13.52 | 1.22 0.13 to 12.83 | 1.19 0.12 to 12.94 | 1.20 0.09 to 17.99 | 1.14 0.09 to 15.61 | 1.11 0.08 to 17.63 | VILDAGLIPTIN | 0.97 0.10 to 10.08 | 0.78 0.06 to 10.91 | 0.69 0.05 to 9.47 | 0.72 0.07 to 7.61 | 0.63 0.06 to 7.19 | 0.63 0.04 to 8.92 | 0.62 0.06 to 7.10 | 0.54 0.03 to 9.15 | 0.40 0.04 to 4.99 | 0.12 0.01 to 1.90 |
| TIRZ_SC | 2.82 2.14 to 3.70 | 11.35 0.36 to 702 | 10.20 3.99 to 29.51 | 6.36 2.18 to 20.47 | 5.72 2.98 to 11.41 | 5.51 4.10 to 7.32 | 5.27 3.40 to 8.34 | 5.18 3.24 to 8.11 | 4.84 2.67 to 8.93 | 4.49 2.77 to 7.17 | 4.14 0.71 to 49.10 | 3.97 1.53 to 10.54 | 3.89 1.92 to 7.92 | 3.70 0.67 to 24.71 | 3.60 2.54 to 5.11 | 3.55 1.47 to 9.10 | 3.53 1.44 to 8.38 | 3.44 0.74 to 12.97 | 3.00 0.83 to 10.37 | 2.77 1.20 to 7.17 | 2.73 1.77 to 4.15 | 2.68 0.89 to 8.94 | 2.66 1.72 to 4.12 | 2.63 1.27 to 5.43 | 2.59 0.21 to 19.75 | 2.47 1.03 to 5.97 | 2.37 0.97 to 6.09 | 2.37 1.70 to 3.27 | 2.25 1.47 to 3.40 | 2.20 1.11 to 4.38 | 2.16 1.56 to 3.00 | 1.97 1.37 to 2.79 | 1.63 1.23 to 2.16 | 1.62 1.13 to 2.31 | 1.56 0.97 to 2.43 | 1.51 1.11 to 2.04 | 1.50 0.76 to 3.01 | 1.42 0.87 to 2.30 | 1.33 0.64 to 2.74 | 1.32 0.96 to 1.80 | 1.32 0.64 to 2.62 | 1.26 0.85 to 1.85 | 1.24 0.62 to 2.41 | 1.24 0.28 to 4.46 | 1.17 0.32 to 3.95 | 1.14 0.30 to 5.15 | 1.04 0.10 to 9.59 | TIRZ_SC | 0.83 0.20 to 2.70 | 0.74 0.15 to 2.47 | 0.74 0.36 to 1.42 | 0.66 0.30 to 1.40 | 0.66 0.16 to 2.27 | 0.64 0.31 to 1.28 | 0.58 0.06 to 2.77 | 0.42 0.15 to 1.08 | 0.13 0.02 to 0.55 |
| HRS7535_PO | 3.40 1.06 to 13.71 | 14.34 0.41 to 1006 | 12.67 2.87 to 69.62 | 7.75 1.62 to 46.55 | 6.99 1.80 to 32.38 | 6.66 2.01 to 27.64 | 6.41 1.85 to 27.44 | 6.28 1.75 to 27.84 | 5.82 1.58 to 26.77 | 5.43 1.60 to 22.96 | 5.18 0.60 to 88.81 | 4.83 1.09 to 24.84 | 4.69 1.20 to 22.72 | 4.58 0.58 to 43.40 | 4.34 1.34 to 18.29 | 4.36 1.03 to 23.00 | 4.31 1.03 to 21.62 | 4.16 0.57 to 27.37 | 3.71 0.64 to 22.69 | 3.42 0.78 to 18.02 | 3.30 0.96 to 14.25 | 3.33 0.65 to 19.96 | 3.24 0.95 to 13.76 | 3.20 0.81 to 14.95 | 3.16 0.21 to 35.65 | 3.01 0.70 to 15.28 | 2.90 0.66 to 15.33 | 2.85 0.85 to 11.78 | 2.72 0.80 to 11.49 | 2.68 0.69 to 12.22 | 2.61 0.79 to 10.97 | 2.36 0.73 to 9.87 | 1.97 0.61 to 8.22 | 1.96 0.61 to 8.23 | 1.89 0.56 to 8.25 | 1.82 0.56 to 7.54 | 1.83 0.47 to 8.36 | 1.73 0.50 to 7.49 | 1.60 0.41 to 7.69 | 1.59 0.49 to 6.60 | 1.60 0.40 to 7.37 | 1.52 0.46 to 6.48 | 1.50 0.41 to 6.84 | 1.52 0.23 to 10.19 | 1.41 0.26 to 8.85 | 1.42 0.23 to 10.61 | 1.29 0.09 to 16.95 | 1.21 0.37 to 5.04 | HRS7535_PO | 0.89 0.13 to 5.53 | 0.90 0.24 to 4.15 | 0.80 0.20 to 3.85 | 0.80 0.13 to 5.02 | 0.77 0.20 to 3.50 | 0.68 0.06 to 5.77 | 0.51 0.11 to 2.75 | 0.16 0.02 to 1.20 |
| DANU_PO | 3.79 1.18 to 18.10 | 16.66 0.42 to 1233 | 14.43 3.12 to 89.87 | 8.75 1.75 to 58.82 | 7.79 2.09 to 42.10 | 7.41 2.24 to 35.95 | 7.10 2.01 to 36.45 | 7.03 1.94 to 36.85 | 6.56 1.79 to 33.87 | 6.06 1.75 to 30.57 | 5.96 0.66 to 95.35 | 5.48 1.19 to 32.30 | 5.26 1.36 to 28.90 | 5.21 0.64 to 61.40 | 4.83 1.46 to 23.42 | 4.98 1.07 to 29.67 | 4.77 1.10 to 27.62 | 4.68 0.65 to 34.46 | 4.18 0.70 to 27.78 | 3.82 0.89 to 22.68 | 3.70 1.07 to 18.51 | 3.74 0.76 to 25.79 | 3.61 1.04 to 17.75 | 3.56 0.90 to 19.29 | 3.55 0.23 to 47.86 | 3.42 0.78 to 19.77 | 3.27 0.72 to 19.20 | 3.16 0.96 to 15.73 | 3.03 0.88 to 15.29 | 2.99 0.78 to 16.77 | 2.92 0.89 to 14.37 | 2.66 0.80 to 13.19 | 2.20 0.68 to 10.51 | 2.19 0.65 to 10.67 | 2.10 0.61 to 10.52 | 2.02 0.63 to 9.73 | 2.04 0.53 to 11.13 | 1.92 0.54 to 9.90 | 1.80 0.46 to 10.09 | 1.78 0.54 to 8.51 | 1.80 0.44 to 9.49 | 1.70 0.51 to 8.34 | 1.67 0.44 to 8.81 | 1.69 0.25 to 12.50 | 1.60 0.28 to 11.23 | 1.59 0.27 to 13.00 | 1.44 0.11 to 20.86 | 1.35 0.41 to 6.65 | 1.13 0.18 to 7.58 | DANU_PO | 1.00 0.27 to 5.38 | 0.90 0.22 to 4.88 | 0.88 0.14 to 6.56 | 0.86 0.23 to 4.60 | 0.78 0.07 to 6.65 | 0.57 0.12 to 3.60 | 0.18 0.02 to 1.42 |
| COTA_SC | 3.80 2.06 to 7.32 | 15.43 0.49 to 961 | 13.92 4.65 to 47.88 | 8.59 2.51 to 31.39 | 7.86 3.28 to 19.38 | 7.42 3.91 to 14.97 | 7.15 3.39 to 16.16 | 7.04 3.22 to 15.44 | 6.54 2.93 to 15.11 | 6.07 2.88 to 13.08 | 5.61 0.88 to 70.25 | 5.33 1.76 to 16.99 | 5.28 2.14 to 13.19 | 5.02 0.84 to 37.17 | 4.86 2.55 to 9.72 | 4.81 1.71 to 14.87 | 4.79 1.63 to 13.92 | 4.62 0.88 to 20.37 | 4.08 1.00 to 16.20 | 3.78 1.36 to 11.58 | 3.68 1.81 to 7.80 | 3.67 1.08 to 13.65 | 3.60 1.75 to 7.57 | 3.57 1.43 to 9.03 | 3.53 0.27 to 28.88 | 3.35 1.21 to 9.54 | 3.20 1.12 to 9.70 | 3.19 1.69 to 6.32 | 3.00 1.50 to 6.64 | 2.98 1.23 to 7.41 | 2.93 1.51 to 5.73 | 2.66 1.37 to 5.39 | 2.21 1.16 to 4.36 | 2.20 1.13 to 4.36 | 2.11 1.00 to 4.45 | 2.03 1.11 to 3.93 | 2.05 0.82 to 5.10 | 1.93 0.92 to 4.19 | 1.80 0.72 to 4.51 | 1.78 0.94 to 3.56 | 1.78 0.72 to 4.39 | 1.70 0.87 to 3.44 | 1.66 0.71 to 4.18 | 1.68 0.34 to 6.89 | 1.58 0.40 to 6.24 | 1.56 0.36 to 7.66 | 1.40 0.13 to 14.69 | 1.35 0.70 to 2.79 | 1.11 0.24 to 4.25 | 1.00 0.19 to 3.68 | COTA_SC | 0.89 0.34 to 2.34 | 0.89 0.19 to 3.52 | 0.85 0.35 to 2.15 | 0.78 0.08 to 4.14 | 0.57 0.18 to 1.73 | 0.18 0.02 to 0.85 |
| SAFIGL_PO | 4.28 2.13 to 9.15 | 17.39 0.57 to 1130 | 15.70 5.02 to 54.98 | 9.75 2.68 to 38.83 | 8.79 3.44 to 23.59 | 8.34 4.01 to 18.08 | 8.00 3.46 to 19.17 | 7.85 3.47 to 19.53 | 7.40 3.01 to 18.38 | 6.77 3.01 to 16.03 | 6.33 0.94 to 83.13 | 6.04 1.86 to 20.18 | 5.91 2.20 to 16.58 | 5.76 0.90 to 43.58 | 5.47 2.60 to 12.05 | 5.44 1.81 to 17.56 | 5.40 1.77 to 16.31 | 5.19 0.96 to 23.58 | 4.64 1.12 to 18.08 | 4.24 1.41 to 13.98 | 4.14 1.87 to 9.53 | 4.14 1.12 to 16.30 | 4.03 1.79 to 9.51 | 3.99 2.11 to 7.86 | 3.97 0.29 to 33.67 | 3.75 1.40 to 10.42 | 3.66 1.16 to 11.67 | 3.59 1.71 to 7.89 | 3.42 1.52 to 7.81 | 3.35 1.27 to 9.08 | 3.28 1.55 to 7.20 | 3.00 1.45 to 6.37 | 2.48 1.20 to 5.38 | 2.46 1.16 to 5.39 | 2.36 1.06 to 5.46 | 2.30 1.11 to 4.99 | 2.31 0.88 to 5.97 | 2.17 0.96 to 5.06 | 2.01 0.77 to 5.56 | 2.01 0.95 to 4.36 | 2.00 0.74 to 5.43 | 1.90 0.90 to 4.29 | 1.87 0.72 to 5.12 | 1.88 0.36 to 8.16 | 1.79 0.42 to 7.33 | 1.75 0.38 to 9.11 | 1.58 0.14 to 16.85 | 1.52 0.72 to 3.36 | 1.25 0.26 to 5.09 | 1.11 0.21 to 4.60 | 1.12 0.43 to 2.98 | SAFIGL_PO | 0.99 0.21 to 4.15 | 0.96 0.37 to 2.60 | 0.87 0.09 to 5.03 | 0.65 0.19 to 2.10 | 0.20 0.02 to 1.02 |
| EXENROSI_SC | 4.29 1.28 to 17.60 | 18.17 0.46 to 1389 | 15.83 3.49 to 89.27 | 9.80 1.98 to 61.50 | 8.78 2.32 to 40.68 | 8.37 2.44 to 34.53 | 8.04 2.19 to 34.85 | 7.86 2.18 to 33.06 | 7.33 1.96 to 33.68 | 6.79 1.88 to 29.18 | 6.59 0.72 to 106 | 6.12 1.34 to 34.23 | 5.88 1.51 to 28.23 | 5.63 1.41 to 33.35 | 5.47 1.60 to 22.96 | 5.52 1.18 to 28.11 | 5.41 1.17 to 27.26 | 5.17 0.73 to 35.82 | 4.64 0.74 to 29.60 | 4.30 0.99 to 22.53 | 4.18 1.21 to 17.66 | 4.21 0.82 to 25.63 | 4.05 1.16 to 17.38 | 4.01 1.00 to 18.77 | 3.92 0.23 to 46.61 | 3.79 0.87 to 18.56 | 3.65 0.81 to 18.36 | 3.58 1.09 to 14.95 | 3.41 0.95 to 14.46 | 3.37 0.85 to 15.73 | 3.27 0.98 to 13.66 | 3.00 0.87 to 12.41 | 2.49 0.73 to 10.33 | 2.47 0.70 to 10.22 | 2.37 0.67 to 9.76 | 2.29 0.67 to 9.45 | 2.28 0.57 to 10.96 | 2.18 0.61 to 9.22 | 2.02 0.50 to 9.40 | 2.00 0.58 to 8.49 | 2.00 0.50 to 9.63 | 1.92 0.55 to 8.10 | 1.91 0.47 to 8.90 | 1.89 0.29 to 12.37 | 1.77 0.32 to 10.93 | 1.76 0.28 to 12.89 | 1.60 0.11 to 22.53 | 1.52 0.44 to 6.35 | 1.25 0.20 to 7.67 | 1.13 0.15 to 7.26 | 1.12 0.28 to 5.16 | 1.01 0.24 to 4.80 | EXENROSI_SC | 0.97 0.25 to 4.55 | 0.87 0.07 to 6.85 | 0.64 0.14 to 3.33 | 0.20 0.02 to 1.41 |
| MAZD_SC | 4.41 2.30 to 8.80 | 17.76 0.54 to 1210 | 16.23 5.24 to 56.86 | 10.01 2.92 to 38.26 | 9.10 3.70 to 23.35 | 8.62 4.36 to 17.41 | 8.31 3.75 to 18.66 | 8.16 3.63 to 18.72 | 7.60 3.29 to 18.45 | 7.01 3.31 to 15.29 | 6.58 0.99 to 86.62 | 6.23 2.04 to 20.09 | 6.08 2.41 to 15.81 | 5.88 0.98 to 43.43 | 5.65 2.87 to 11.70 | 5.63 1.89 to 17.26 | 5.56 1.86 to 16.38 | 5.36 1.05 to 23.67 | 4.72 1.13 to 19.65 | 4.43 1.51 to 13.37 | 4.29 2.04 to 9.19 | 4.29 1.23 to 16.24 | 4.18 2.01 to 9.19 | 4.16 1.58 to 10.69 | 4.05 0.32 to 34.68 | 3.88 1.37 to 11.32 | 3.74 1.28 to 11.35 | 3.73 1.89 to 7.44 | 3.53 1.67 to 7.54 | 3.46 1.40 to 8.75 | 3.39 1.71 to 6.99 | 3.10 1.53 to 6.40 | 2.56 1.34 to 5.08 | 2.55 1.26 to 5.25 | 2.44 1.12 to 5.35 | 2.35 1.21 to 4.76 | 2.36 0.93 to 6.19 | 2.24 1.04 to 4.93 | 2.08 0.82 to 5.52 | 2.07 1.05 to 4.19 | 2.07 0.80 to 5.31 | 1.98 0.97 to 4.10 | 1.96 0.78 to 4.72 | 1.95 0.39 to 8.29 | 1.84 0.46 to 7.42 | 1.81 0.40 to 8.74 | 1.61 0.14 to 16.27 | 1.57 0.78 to 3.28 | 1.30 0.29 to 4.97 | 1.16 0.22 to 4.42 | 1.17 0.46 to 2.86 | 1.04 0.38 to 2.73 | 1.03 0.22 to 4.07 | MAZD_SC | 0.90 0.09 to 4.80 | 0.66 0.21 to 2.06 | 0.20 0.03 to 1.03 |
| ECNO_SC | 4.89 1.06 to 43.58 | 21.12 0.50 to 2229 | 18.42 2.96 to 198 | 11.21 1.70 to 125 | 10.05 1.90 to 97.40 | 9.53 2.02 to 86.74 | 9.06 1.87 to 84.12 | 8.97 1.83 to 83.65 | 8.46 1.64 to 79.77 | 7.72 1.61 to 70.41 | 7.85 0.68 to 176 | 7.00 1.18 to 71.47 | 6.78 1.24 to 63.97 | 6.74 0.63 to 107 | 6.23 1.31 to 57.00 | 6.19 1.06 to 65.91 | 6.15 1.03 to 65.39 | 6.08 0.68 to 72.45 | 5.32 0.72 to 61.51 | 4.96 0.84 to 51.47 | 4.77 0.97 to 43.90 | 4.81 0.72 to 52.29 | 4.58 0.96 to 41.94 | 4.55 0.86 to 46.02 | 4.64 0.25 to 81.92 | 4.30 0.74 to 44.55 | 4.17 0.69 to 42.59 | 4.10 0.87 to 37.63 | 3.87 0.80 to 35.64 | 3.82 0.71 to 37.27 | 3.76 0.79 to 33.50 | 3.42 0.72 to 31.07 | 2.82 0.60 to 26.03 | 2.81 0.60 to 25.50 | 2.70 0.56 to 24.96 | 2.62 0.55 to 23.49 | 2.61 0.49 to 26.45 | 2.46 0.51 to 22.88 | 2.34 0.42 to 22.34 | 2.30 0.48 to 21.24 | 2.28 0.42 to 21.63 | 2.18 0.46 to 20.10 | 2.14 0.40 to 21.56 | 2.17 0.26 to 26.00 | 2.04 0.28 to 24.21 | 2.06 0.26 to 24.67 | 1.86 0.11 to 39.10 | 1.73 0.36 to 15.87 | 1.47 0.17 to 16.14 | 1.29 0.15 to 14.95 | 1.28 0.24 to 11.91 | 1.15 0.20 to 11.31 | 1.15 0.15 to 13.79 | 1.11 0.21 to 10.58 | ECNO_SC | 0.74 0.12 to 7.33 | 0.23 0.02 to 3.16 |
| EFSUBA_SC | 6.68 2.71 to 17.87 | 27.53 0.87 to 1987 | 24.55 6.69 to 100 | 15.19 3.66 to 69.13 | 13.66 4.61 to 44.33 | 13.04 5.13 to 36.68 | 12.44 4.65 to 36.87 | 12.31 4.45 to 36.42 | 11.36 4.09 to 35.67 | 10.63 3.91 to 30.09 | 9.86 1.30 to 146 | 9.49 2.51 to 37.12 | 9.25 3.00 to 29.78 | 8.96 1.29 to 72.50 | 8.51 3.35 to 23.50 | 8.52 2.41 to 32.12 | 8.37 2.36 to 30.41 | 8.06 1.34 to 42.85 | 7.14 1.57 to 32.50 | 6.61 1.93 to 25.29 | 6.47 2.41 to 18.51 | 6.44 1.62 to 29.94 | 6.29 2.39 to 18.31 | 6.23 1.93 to 21.22 | 6.09 0.42 to 62.22 | 5.86 1.68 to 21.98 | 5.65 1.64 to 20.73 | 5.58 2.26 to 15.62 | 5.32 2.01 to 15.56 | 5.20 1.73 to 16.54 | 5.13 2.01 to 14.25 | 4.65 1.85 to 12.98 | 3.86 1.55 to 10.59 | 3.83 1.50 to 10.56 | 3.69 1.37 to 10.73 | 3.56 1.42 to 9.72 | 3.62 1.16 to 11.62 | 3.37 1.26 to 9.94 | 3.16 1.02 to 10.19 | 3.13 1.24 to 8.59 | 3.12 1.02 to 10.08 | 2.99 1.17 to 8.34 | 2.96 0.97 to 9.15 | 2.92 0.54 to 14.06 | 2.77 0.59 to 12.81 | 2.80 0.53 to 15.48 | 2.49 0.20 to 28.26 | 2.37 0.92 to 6.60 | 1.96 0.36 to 9.04 | 1.74 0.28 to 8.19 | 1.76 0.58 to 5.62 | 1.54 0.48 to 5.26 | 1.56 0.30 to 7.31 | 1.51 0.49 to 4.86 | 1.36 0.14 to 8.43 | EFSUBA_SC | 0.31 0.03 to 1.73 |
| BGM050_SC | 21.49 5.17 to 163 | 93.94 2.15 to 8606 | 80.31 14.65 to 702 | 50.47 7.88 to 466 | 44.82 9.26 to 359 | 41.98 9.98 to 322 | 40.08 9.20 to 311 | 39.95 8.91 to 312 | 36.98 8.18 to 294 | 34.66 7.55 to 259 | 33.65 3.11 to 738 | 30.55 5.40 to 257 | 29.78 6.37 to 240 | 29.34 3.01 to 427 | 27.58 6.55 to 211 | 28.20 5.11 to 249 | 27.22 5.19 to 231 | 26.33 3.19 to 285 | 23.64 3.41 to 226 | 21.98 4.06 to 180 | 20.86 4.76 to 162 | 21.46 3.39 to 197 | 20.40 4.67 to 155 | 20.28 4.10 to 167 | 20.45 1.17 to 340 | 19.30 3.54 to 166 | 18.65 3.29 to 164 | 18.11 4.35 to 135 | 17.27 4.01 to 125 | 16.94 3.57 to 142 | 16.71 3.94 to 125 | 15.10 3.57 to 114 | 12.53 2.98 to 93.18 | 12.45 2.94 to 94.46 | 12.05 2.73 to 89.43 | 11.57 2.76 to 86.42 | 11.49 2.46 to 93.64 | 10.91 2.50 to 86.01 | 10.24 2.12 to 81.78 | 10.16 2.44 to 76.51 | 10.11 2.04 to 84.21 | 9.62 2.28 to 73.06 | 9.55 1.96 to 75.94 | 9.64 1.18 to 98.44 | 9.17 1.29 to 87.70 | 9.13 1.17 to 95.86 | 8.03 0.53 to 151 | 7.67 1.83 to 57.88 | 6.42 0.83 to 63.40 | 5.70 0.70 to 55.33 | 5.69 1.18 to 44.96 | 5.07 0.98 to 41.89 | 5.07 0.71 to 50.16 | 4.92 0.98 to 38.30 | 4.42 0.32 to 54.21 | 3.23 0.58 to 29.41 | BGM050_SC |
Heterogeneity, fit and convergence
Bayesian random effects (primary)
Inconsistency
Do trials comparing two treatments directly agree with the indirect evidence through other treatments?
No comparison here has both direct and indirect evidence, so inconsistency cannot be checked by node splitting.
Small study effects
A comparison adjusted funnel plot: each point is one trial comparison, centered on its own network estimate. Asymmetry can signal that small trials with unfavorable results are missing.
Fewer than ten trial comparisons, too few to judge funnel plot asymmetry.
Comparability of the trials
Checked across designs (the set of treatments each trial compares) for eligibility, outcome definition and assessment, and the baseline factors above. Flags point to possible intransitivity; notes describe variation that is not tied to design.
- FlagEligibility, hba1c entry range: a design requires hba1c 1000 or more while another admits only 8 or less
- FlagEligibility, bmi entry range: a design requires bmi 50 or more while another admits only 35 or less
- NoteRisk of bias, blinding: mixed: double_blind 105, not_reported 1, open_label 68, single_blind 6
- NoteRisk of bias, funding: mixed: industry 167, mixed 4, non_industry 8, not_reported 1
- NoteOutcome assessment, time point: selected time points span 0.43 to 365.26 weeks
- NoteOutcome assessment, analysis set: mixed: completers 2, full_analysis 8, modified_itt 11, other 4, randomized 11, safety 144
- NoteOutcome assessment, definition: mixed: ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms 1, ADA 2018 level 2, glucose below 3.0 mmol/L; level 3 printed as zero in all arms 1, adverse event term hypoglycemia, threshold not stated 1, all hypoglycemia, PG 70 mg/dL or less and/or symptoms, treatment period 1, any hypoglycemia, blood glucose below 70 mg/dL 1, Any hypoglycemia, including mild symptomatic 1, Any signs or symptoms of hypoglycemia regardless of glucose 1, confirmed: severe or plasma glucose below 3.1 mmol/L 1, documented plasma glucose below 3.0 mmol/L regardless of symptoms 1, Documented symptomatic, plasma glucose 3.9 mmol/L or lower 1, EAC confirmed MACE; components not defined 1, glucose below 3.0 mmol/L; no severe events in any arm 1, Grade 1 or 2 hypoglycemia below 3.9 mmol/L 1, Hypoglycaemia reported as treatment emergent adverse event 1, Hypoglycemia adverse event of special interest 1, Hypoglycemia adverse event term 1, hypoglycemia adverse event term, any severity 1, hypoglycemia adverse event, definition not stated 1, hypoglycemia adverse reaction, undefined 1, hypoglycemia below 3.0 mmol/L or requiring assistance 1, hypoglycemia glucose 3.9 mmol/L or lower; both events mild 1, Hypoglycemia preferred term, mostly mild by investigator 1, hypoglycemia reported as serious adverse event; level not stated 1, hypoglycemia requiring medical assistance 1, hypoglycemia requiring third party assistance 1, hypoglycemia, definition not stated 1, investigator reported symptomatic hypoglycemia 1, level 2 hypoglycemia, glucose below 54 mg/dL 1, level 3 severe hypoglycemia 2, minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia 1, minor: symptomatic, glucose below 3.0 mmol/L, not major 1, minor: symptoms with glucose below 3 mmol/L, self treated or resolved 1, not stated 126, participants with serious adverse events 1, plasma glucose 54 mg/dL or lower 1, serious adverse event term hypoglycaemia 1, serious adverse events 1, Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptoms 1, severe (ADA) or symptomatic with plasma glucose below 3.1 mmol/L 1, severe hypoglycemia needing assistance of another person 1, Severe hypoglycemia needing medical treatment 1, severe hypoglycemia needing third party assistance 1, Severe hypoglycemia requiring assistance of another person 1, severe hypoglycemia with severe cognitive impairment needing medical treatment 1, severe or blood glucose confirmed below 3.1 mmol/L with or without symptoms 1, severe symptomatic hypoglycemia needing assistance 1, severe, requiring assistance of another person 1, severe: third party assistance with glucose below 2.8 mmol/L or prompt recovery 1, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery 1, symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery with carbohydrate 1, Symptomatic hypoglycemia with glucose below 60 mg/dL or symptoms without measurement 1, TEAE leading to death 1, TEAE preferred term hypoglycemia, not necessarily protocol defined 1, Zero implied by no hypoglycemia of any kind 1
- NoteOutcome assessment, adjudicated: mixed: not stated 177, yes 3
- NoteOutcome assessment, proportion method: mixed: not stated 177, observed 3
- NoteOutcome assessment, intercurrent events (discontinuation): mixed: not stated 173, treatment_policy 1, while_on_treatment 6
- NoteOutcome assessment, intercurrent events (rescue): mixed: hypothetical 1, not stated 175, treatment_policy 4
- NoteData handling, input conversions: arms_combined 82, count_from_percent 7, nonserious_only 148, printed_denominator 23
| Trial | time weeks | analysis set | definition | instrument | adjudicated | proportion method | intercurrent events (discontinuation) | blinding | intercurrent events (rescue) | funding | start year | Eligibility |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03131687 | 30 | safety | severe hypoglycemia needing assistance of another person | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2017 | age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 50; diet and exercise or metformin |
| NCT00754988 | 156 | safety | hypoglycemia adverse event, definition not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 25 (23 Asian) to 45; metformin at least 1500 mg |
| NCT05407961 | 12 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2022 | Age 18 to 70; BMI 23 to 45; HbA1c 7.0 to 10.0 on metformin or diet, 6.0 to 9.5 on DPP-4 or SGLT2 inhibitor (washed out) |
| NCT00518115 | 24 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2007 | age 18 to 75; BMI 20 to 40; HbA1c 7 to 10 percent; drug naive or metformin |
| NCT01296412 | 26 | safety | investigator reported symptomatic hypoglycemia | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2011 | age 18 to 79; HbA1c 7.0 to 11.0 percent on metformin 1500 mg or more; eGFR 60 or more |
| DUAL™ I China | 27 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2017 | Chinese adults 18 y or older; HbA1c 7.0 to 10.0; BMI 40 or less; metformin with or without one OAD |
| NCT00838916 | 164 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2009 | age 18 or older, HbA1c 7.0 to 10.0 percent, BMI 20 to 45, creatinine clearance above 60 |
| SURPASS-6 | 56 | safety | not stated | not stated | yes | not stated | while_on_treatment | open_label | not stated | industry | 2020 | adults 18 or older; HbA1c 7.5 to 11 percent; BMI 23 to 45; basal insulin at least 30 U/day with or without up to 2 oral drugs |
| PIONEER 4 | 57 | safety | not stated | not stated | not stated | not stated | while_on_treatment | double_blind | treatment_policy | industry | 2016 | Age 18 or older; T2D on metformin with or without SGLT2i; HbA1c 7.0 to 9.5 percent; eGFR 60 or more |
| NCT04965506 | 24 | safety | glucose below 3.0 mmol/L; no severe events in any arm | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2021 | age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 20 to under 40; diet or metformin |
| REWIND | 365.26 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2011 | age 50 or older with T2D; HbA1c 9.5 percent or less; BMI 23 or more; CV disease or risk factors |
| COMBINE 2 | 57 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2022 | adults T2D on GLP-1 RA with or without oral drugs; HbA1c 7.0 to 10.0 percent |
| SCALE™ Insulin | 58 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2017 | age 18 or older; BMI 27 or higher; HbA1c 6.0 to 10 percent; basal insulin plus up to 2 oral drugs |
| Lixilan-O-AP | 24.43 | safety | documented plasma glucose below 3.0 mmol/L regardless of symptoms | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2019 | adults with T2D on metformin with or without a second OAD; HbA1c 7.5 to 11 percent, or 7 to 10 percent with a non SGLT2i second OAD |
| NCT01476475 | 24 | safety | Documented symptomatic, plasma glucose 3.9 mmol/L or lower | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2011 | Adults with T2D; HbA1c 7 to 10 percent on metformin at least 1.5 g/day; insulin naive |
| OUTSTAND-1 | 32 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2024 | age 18 to 75; HbA1c 7.0 to 10.0 percent; BMI 19.0 to 40.0; diet and exercise only |
| PB119 | 24 | safety | Severe hypoglycemia needing medical treatment | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2020 | age 18 to 75; HbA1c 7.5 to 11.0 at screening and 7.0 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or more; drug naive |
| NCT01001104 | 12 | safety | all hypoglycemia, PG 70 mg/dL or less and/or symptoms, treatment period | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2009 | Japanese T2D age 20 to 74; BMI 18.5 to 40; HbA1c 7.0 to 9.5 percent after lead in |
| PIONEER 10 | 57 | safety | not stated | not stated | yes | not stated | while_on_treatment | single_blind | treatment_policy | industry | 2017 | Japanese adults 20 or older; T2D; HbA1c 7.0 to 10.5 percent on one oral glucose lowering drug |
| NCT02846233 | 16 | randomized | any hypoglycemia, blood glucose below 70 mg/dL | not stated | not stated | not stated | not stated | open_label | not stated | non_industry | 2016 | age over 21; BMI 30 or more; HbA1c above 8 percent; eGFR above 45; basal plus prandial or premixed insulin |
| AWARD-7 | 52 | safety | Hypoglycaemia reported as treatment emergent adverse event | not stated | not stated | not stated | treatment_policy | single_blind | treatment_policy | industry | 2012 | adults with T2D and CKD stage 3 to 4 (eGFR 15 to below 60); HbA1c 7.5 to 10.5 percent on insulin; maximal ACEI or ARB; BMI 23 to 45 |
| NCT01584232 | 26 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2012 | Japanese adults 20 years or older; BMI 18.5 to less than 35 kg/m2; HbA1c 7.0 to 10.0 percent; on sulfonylurea and/or biguanide |
| NCT03235050 | 58 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2017 | age 18 or older; BMI 25 or higher; HbA1c 7.0 to 10.5 percent; on metformin |
| NCT04235959 | 28 | safety | hypoglycemia glucose 3.9 mmol/L or lower; both events mild | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2020 | Chinese adults 20 to 70 years, HbA1c 7.0 to 10.5 diet only or 6.5 to 10.0 on one OAM, BMI 23 or more |
| AWARD-10 | 24 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2015 | T2D; HbA1c 7.0 to 9.5 percent; BMI 45 or lower; SGLT2i with or without metformin |
| SUSTAIN™ 3 | 62 | safety | not stated | not stated | not stated | not stated | while_on_treatment | open_label | not stated | industry | 2013 | age 18 or older; T2D on stable 1 to 2 oral drugs; HbA1c 7.0 to 10.5 percent; eGFR 60 or more |
| NCT00393718 | 52 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2006 | age 20 or older; HbA1c 7.4 to 10.4 percent NGSP; with or without prior oral agents |
| EGO | 16 | safety | serious adverse events | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | overweight or obese adults with type 2 diabetes |
| NCT00765817 | 30 | full_analysis | minor: symptoms with glucose below 3 mmol/L, self treated or resolved | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | adults 18 or older; insulin glargine 20 U/d or more alone or with metformin or pioglitazone; HbA1c 7.1 to 10.5 percent; BMI 45 or less |
| NCT01029886 | 26 | modified_itt | not stated | not stated | not stated | not stated | while_on_treatment | open_label | not stated | industry | 2010 | adults 18 or older with type 2 diabetes on oral agents, HbA1c 7.1 to 11.0 percent, BMI 45 or less |
| LIXILAN JP-L | 26.43 | randomized | not stated | not stated | not stated | not stated | while_on_treatment | open_label | treatment_policy | industry | 2016 | Japanese adults; T2D over 1 year; HbA1c 7.5 to 9.5 on basal insulin plus 1 or 2 oral drugs |
| SUSTAIN 11 | 52 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2018 | adults; HbA1c above 7.5 to 10.0 percent on insulin glargine plus metformin |
| SUSTAIN 7 | 45 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2016 | age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin background |
| NCT00791479 | 12 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | adults with type 2 diabetes on no background glucose lowering drug |
| NCT00637273 | 26 | modified_itt | not stated | not stated | not stated | observed | not stated | double_blind | not stated | industry | 2008 | age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45; stable metformin |
| SURPASS-1 | 44 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2019 | adults; HbA1c 7.0 to 9.5 percent; BMI 23 or higher; no glucose lowering drug in prior 90 days |
| NCT00717457 | 104 | safety | adverse event term hypoglycemia, threshold not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2008 | age 18 to 75; HbA1c 7 to 10 percent; BMI 25 to 45 (above 23 for Asians); metformin with or without TZD |
| NCT00976937 | 24 | safety | severe symptomatic hypoglycemia needing assistance | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2009 | age 18 to under 50; BMI 30 or more; HbA1c 7.0 to 10 percent; metformin at least 1.5 g/day |
| ACHIEVE-3 | 57 | safety | hypoglycemia reported as serious adverse event; level not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2023 | adults T2D on metformin; HbA1c 7.0 to 10.5 percent |
| NCT00082407 | 52 | modified_itt | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2003 | Age 30 to 75; HbA1c 7.0 to 11.0 on metformin plus sulfonylurea; BMI 25 to 40 |
| AWARD-9 | 28 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2014 | adults with T2D on basal insulin glargine with or without metformin |
| NCT05579977 | 28 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2022 | age 18 to 75; T2D cohort on metformin, HbA1c 7.0 to 10.0, BMI 23 or more; obesity cohort BMI 30 or more without diabetes |
| COMBINE 1 | 57 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2022 | adults 18+; HbA1c 7.0-10.0%; BMI 40 or less; basal insulin 20-80 U/day; eGFR 30 or more |
| SUSTAIN 9 | 36 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2017 | adults 18 or older (20 in Japan); HbA1c 7.0 to 10.5 percent; stable SGLT2i with or without metformin or SU |
| GETGOAL-L-ASIA | 24 | safety | symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2009 | age 25 to 81; type 2 diabetes at least 1 year; stable basal insulin at least 10 U/day with or without sulfonylurea; HbA1c 7 to 10 percent |
| GETGOAL-S | 120 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | adults on sulfonylurea with or without metformin; HbA1c 7 to 10 percent |
| PIONEER 12 | 31 | safety | ADA 2018 level 2, glucose below 3.0 mmol/L; level 3 printed as zero in all arms | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2019 | adults with type 2 diabetes on metformin, HbA1c 7.0 to 10.5 percent |
| NCT06589765 | 52 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2024 | age 18 to 75; HbA1c 7.5 to 11.0 percent; BMI 19 to 40; metformin monotherapy; eGFR 45 or more |
| SUSTAIN 10 | 35 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2017 | adults with T2D, HbA1c 7.0 to 11.0 percent on 1 to 3 oral drugs |
| NCT01175473 | 4.43 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2010 | age 37 to 74; HbA1c 6.5 to 9.0 percent; BMI above 20 and below 37; metformin 1.5 g/day or more |
| NCT03951753 | 32 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2019 | age 20 to 74; BMI 25 to 45; metformin with or without one other oral agent |
| NCT00960661 | 30 | other | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2009 | age 18 or older; T2D on insulin glargine and metformin with or without sulfonylurea; HbA1c 7.0 to 10.0; BMI 25.0 (23.0 in South Korea) to 45.0; HbA1c above 7.0 after optimization |
| NCT00935532 | 26 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2009 | type 2 diabetes on biguanide with or without thiazolidinedione |
| NCT02008682 | 26 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2013 | Chinese adults 18 to 80; HbA1c 7.0 to 10.0 on metformin; BMI 45 or lower |
| NCT03555994 | 9 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2018 | adults; BMI 27 to 40; HbA1c 8.0 or lower on metformin alone |
| NCT02229383 | 38 | safety | minor: symptomatic, glucose below 3.0 mmol/L, not major | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2014 | adults; insulin glargine 20 U/d or more with or without metformin; HbA1c 7.0 to 10.5 percent at randomization |
| NCT02081118 | 22 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2014 | age 18 to under 75; metformin; HbA1c 7.0 to 10 percent; BMI under 40 |
| NCT00577824 | 24 | full_analysis | Any signs or symptoms of hypoglycemia regardless of glucose | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | age 20 to 75; HbA1c 7.0 to 10.0 percent JDS; weight 50 kg or more; sulfonylurea based oral therapy |
| ATTAIN-2 | 74 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2023 | adults with type 2 diabetes; BMI 27 or higher; HbA1c 7.0 to 10.0 percent |
| NCT02973321 | 26.4 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2016 | adults with type 2 diabetes and overweight or obesity |
| NCT01149421 | 26 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2010 | adults 18 or older; HbA1c 7 to 9.5 percent; stable oral agents |
| NCT00434954 | 26 | full_analysis | not stated | not stated | not stated | observed | not stated | open_label | not stated | industry | 2007 | adults with T2D on metformin, HbA1c 6.5 to 10.0 percent |
| NCT02229396 | 104 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2014 | age 18 or older; HbA1c 8.0 to 12.0 percent on metformin 1500 mg/d or more |
| GetGoal-Duo1 | 24.43 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2009 | T2D on metformin 1.5 g or more with or without SU, glinide or TZD, HbA1c 7 to 10, BMI over 20; HbA1c 7 to 9 after run in |
| NCT01558271 | 52 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2012 | Japanese; age 20 or more; BMI 18.5 to 35; HbA1c 7.0 to 10.0 percent; OAM naive or OAM stopped |
| NCT00849017 | 164 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2009 | age 18 or older; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; diet and exercise only |
| NCT00395746 | 52 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2006 | age 20 or older; HbA1c 7.4 to 10.4 on one sulfonylurea |
| NCT01147627 | 48 | randomized | not stated | not stated | not stated | not stated | not stated | open_label | not stated | mixed | 2010 | newly diagnosed drug naive T2D; age 30 to 70; HbA1c 7 to 10 percent; BMI 20 to 35 |
| NCT05759897 | 16 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2023 | age 18 to 75; BMI 19.0 to 40.0; HbA1c 7.5 to 11.0 on stable metformin |
| SUSTAIN™1 | 35 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2014 | age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; drug naive on diet and exercise; eGFR 30 or more |
| GetGoal-O | 24.43 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2013 | age 70 or older; type 2 diabetes uncontrolled on basal insulin and/or oral drugs; eGFR 30 or higher |
| NCT04093752 | 44 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2019 | adults with T2D on metformin with or without sulfonylurea |
| NCT01617434 | 27 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2012 | age 18 to 80; HbA1c 7.0 to 10.0 percent; BMI 20 to 45; basal insulin analogue 20 U or more with or without metformin |
| NCT00135330 | 20 | randomized | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2005 | age 18 to 75; BMI 25 to 40; HbA1c 6.8 to 10.0 percent; stable metformin only |
| LIRA-Ramadan™ | 30 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2014 | age 18 to 80; HbA1c 7 to 10 percent; BMI 20 or more; metformin plus sulfonylurea; intent to fast in Ramadan |
| NCT02200991 | 4.43 | safety | severe hypoglycemia needing third party assistance | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2014 | age 20 to 75; T2D 5 years or more; HbA1c 7.0 to 10.0; FBG 180 mg/dL or less; stable glargine |
| NCT00097500 | 64 | safety | Hypoglycemia adverse event term | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2004 | age 30 to 75; HbA1c 6.5 to 9.5 percent; BMI 25 to 40; on metformin |
| ACHIEVE-5 | 42 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2023 | adults with T2D on insulin glargine with or without metformin or SGLT2 inhibitor |
| NCT00894322 | 12 | safety | not stated | not stated | not stated | not stated | not stated | single_blind | not stated | industry | 2009 | adults with T2D on diet and exercise, metformin, TZD or both |
| AWARD-CHN1 | 26 | safety | severe, requiring assistance of another person | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2012 | age 18 or older; BMI 19 to 35 kg/m2; HbA1c 7.0 to 10.5 percent OAM naive or 6.5 to 10.0 percent on OAM monotherapy |
| AWARD-8 | 24 | modified_itt | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2013 | age 18 or older; BMI up to 45; HbA1c 7.5 to 9.5 percent on sulfonylurea at least half maximal dose |
| NCT01733758 | 52 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2013 | Japanese adults; diet and exercise with or without one oral drug; HbA1c 7 to 10 percent after washout |
| NCT00359762 | 234.81 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2006 | age 18 to 85; BMI 25 to below 40; HbA1c 6.5 to below 9.0 percent on maximum tolerated metformin |
| LIRA-SWITCH™ | 27 | safety | confirmed: severe or plasma glucose below 3.1 mmol/L | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2013 | age 18 or more; HbA1c 7.5 to 9.5 percent; BMI 20 or more; on sitagliptin 100 mg and metformin for 90 days or more |
| LixiLan-G | 26 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2016 | T2D 1 year or more; HbA1c 7 to 9 percent; BMI over 20 to 40; maximum tolerated GLP-1 RA plus metformin |
| AWARD-2 | 78 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2010 | type 2 diabetes on metformin and glimepiride |
| DUAL™ VIII | 108.29 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2016 | adults with type 2 diabetes uncontrolled on oral drugs, insulin naive |
| DURATION-NEO-2 | 28 | safety | minor (symptomatic, glucose below 54 mg/dL) or major hypoglycemia | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2013 | age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 45 or lower; metformin 1500 mg or more |
| NCT05514535 | 45 | safety | level 3 severe hypoglycemia | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2022 | adults with T2D, BMI 25 or more, HbA1c 7 to 10 percent, basal insulin up to 40 U/day plus metformin with or without SGLT2i |
| AWARD-6 | 30 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2012 | adults; HbA1c 7 to 10 percent; metformin 1500 mg/day or more |
| NCT03985293 | 20 | safety | TEAE preferred term hypoglycemia, not necessarily protocol defined | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2019 | age 18 to 75; HbA1c 7 to 10.5 percent; BMI 22.5 (Asia) or 24.5 to 45.4; metformin or diet and exercise |
| NCT00701935 | 26.07 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | adults with T2D on metformin |
| NCT01191268 | 56 | safety | participants with serious adverse events | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2010 | adults with type 2 diabetes on conventional insulin with or without metformin |
| LixiLan-O | 30.29 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2014 | adults; HbA1c 7.5 to 10% on metformin or 7 to 9% on metformin plus second OAD; 7 to 10% after run in |
| NCT06974825 | 20 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2023 | age 18 to 65; HbA1c 7.0 to 10.0 percent; BMI 19.5 to 35.0; no glucose lowering drug for 8 weeks |
| GETGOAL-P | 132 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | type 2 diabetes on pioglitazone 30 mg or more with or without metformin; HbA1c 7 percent or more |
| SUSTAIN™ 4 | 35 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2014 | adults with T2D, insulin naive, on metformin with or without SU; HbA1c 7.0 to 10.0 percent |
| NCT00375492 | 24 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2006 | type 2 diabetes; weight loss trial |
| NCT04504396 | 24 | safety | severe hypoglycemia with severe cognitive impairment needing medical treatment | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2020 | age 18 to 75; HbA1c 7.0 to 10.5 percent; BMI 40 or lower; eGFR 60 or higher; metformin monotherapy at least 1000 mg |
| SURPASS-4 | 108 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2018 | age 18 or older; HbA1c 7.5 to 10.5 percent; BMI 25 or more; increased cardiovascular risk; 1 to 3 oral agents |
| NCT00877890 | 24 | modified_itt | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2009 | age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45 |
| SUSTAIN | 35 | safety | Severe (ADA) or glucose confirmed below 3.1 mmol/L with symptoms | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2017 | Adults 18 or older, HbA1c 7.0 to 10.5 percent on metformin monotherapy, eGFR 60 or more |
| NCT00360334 | 26 | full_analysis | severe: third party assistance with glucose below 2.8 mmol/L or prompt recovery | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2006 | BMI above 27; HbA1c 7.5 to 10.0 percent; 2 or 3 oral drugs; at least one CV risk factor |
| DUAL™ V | 27 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2013 | T2D uncontrolled on insulin glargine 20 to 50 U plus metformin |
| NCT04552470 | 12 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2020 | Japanese adults 20 to 70, diet and exercise only, HbA1c 7 to 10.5 percent, BMI 22.5 to 45.4 |
| NCT01003184 | 26 | modified_itt | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2009 | age 18 or older; HbA1c 7.1 to 10.0 percent; BMI 25 to 45; metformin with or without SU |
| SOLID-DKD | 18 | safety | level 3 severe hypoglycemia | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2024 | age 18 to 75; T2D with UACR 300 to below 3000 mg/g; eGFR 30 or more; HbA1c 6.5 to 10; BMI 20 to 40 |
| NCT00917267 | 36 | modified_itt | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2009 | Asian adults 20 or older; HbA1c 7 to 11; BMI 21 to 35; on oral drugs |
| GETGOAL-X | 116 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2008 | age 21 to 84; HbA1c 7 to 10 percent; metformin at least 1.5 g/day |
| NCT00299871 | 13.43 | safety | symptomatic hypoglycemia with glucose below 3.3 mmol/L or prompt recovery with carbohydrate | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2006 | age 30 to 75; HbA1c 7.0 to below 9.0 percent on metformin at least 1000 mg/day |
| NCT02212067 | 17 | randomized | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2014 | age 18 to 64; HbA1c 6.5 to 9.0 percent; BMI 20 to 35; diet and exercise or metformin |
| SUSTAIN™ | 62 | safety | severe (ADA) or symptomatic with plasma glucose below 3.1 mmol/L | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2014 | Japanese adults 20 or older; HbA1c 7.0 to 10.5 percent; diet and exercise or OAD monotherapy; eGFR 30 or more |
| LEAD-2 | 104.28 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2006 | age 18 to 80; HbA1c 7 to 11 percent on one OAD or 7 to 10 on combination; BMI 40 or less; no recent insulin |
| NCT01620489 | 27 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2012 | type 2 diabetes; eGFR 30 to 59 mL/min/1.73m2 (MDRD); oral drugs and/or insulin |
| NCT05486065 | 49 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2022 | age 18 to 64; HbA1c 7.0 to 10.5; BMI 27 or more; on metformin |
| DUAL™ II China | 30 | safety | EAC confirmed MACE; components not defined | not stated | yes | not stated | not stated | double_blind | not stated | industry | 2017 | age 18 or older; BMI 24 or higher; HbA1c 7.5 or higher; basal insulin 20 to 50 U plus metformin |
| GETGOAL-F1 | 112 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | adults with T2D on metformin |
| SURPASS-3 | 56 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2019 | insulin naive; HbA1c 7.0 to 10.5 percent; BMI at least 25; metformin with or without SGLT2i; eGFR above 45 |
| NCT00460941 | 8 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2007 | age 18 to 75; HbA1c 7.0 to 9.5 percent on metformin; BMI above 25 to 45 |
| SURPASS-5 | 44 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2019 | HbA1c 7.0 to 10.5 percent; BMI 23 or higher; insulin glargine above 0.25 U/kg or 20 U daily with or without metformin |
| NCT03322631 | 12 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2017 | Japanese adults 20 to 70; T2D 1 year or more on diet or metformin or DPP-4 inhibitor (washed out); BMI 20 to 35 |
| NCT00744926 | 24 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | age 18 to 80; drug naive; HbA1c 6.5 to 10 percent; BMI 25 to 45 |
| PIONEER 1 | 31 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2016 | adults with type 2 diabetes on diet and exercise only; HbA1c 7.0 to 9.5 percent |
| NCT02420262 | 27 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2015 | age 18 or older; HbA1c 7.0 to 10.0; BMI up to 40; glargine 20 to 50 U plus metformin |
| NCT00641056 | 84 | modified_itt | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2008 | age 18 or older; HbA1c 7.1 to 11.0 percent; BMI 25 to 45; metformin with or without sulfonylurea |
| ELEGANT | 26 | randomized | Grade 1 or 2 hypoglycemia below 3.9 mmol/L | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2012 | age 18 to 75; BMI 25 or more; HbA1c 6.5 to 8.5 percent; insulin 3 to 16 months with 4 percent weight gain |
| NCT01126580 | 52 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2010 | type 2 diabetes on diet and exercise or one oral drug; registry gives no ranges |
| PIONEER 11 | 31 | safety | ADA 2018 level 2 (below 3.0 mmol/L); level 3 row zero in all arms | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2019 | age 18 or older; HbA1c 7.0 to 10.0 percent at screening, 7.0 to 9.5 at randomization; no glucose lowering drugs; eGFR 60 or more |
| NCT01272232 | 68 | safety | hypoglycemia adverse event term, any severity | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2011 | adults with T2D, BMI 27 or more, HbA1c 7.0 to 10.0 percent, diet alone or up to 3 oral drugs |
| NCT00943917 | 12 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2009 | age 18 to 70; HbA1c 7 to 10 percent; BMI 40 or less; stable metformin 3 months |
| SUSTAIN 8 | 57 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2017 | age 18 or older; HbA1c 7.0 to 10.5 percent; eGFR 60 or higher; metformin 1500 mg or maximum tolerated |
| SUSTAIN™ 5 | 35 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2014 | age 18 or older (20 in Japan); HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin; eGFR 30 or more |
| NCT02229227 | 26 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2014 | age 18 to 75; HbA1c 7.0 to 9.5 percent at screening; BMI 40 or less; basal plus prandial insulin |
| NCT00382239 | 12 | full_analysis | Hypoglycemia preferred term, mostly mild by investigator | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2006 | age 20 to 75; HbA1c 7 to 10 percent on sulfonylurea based therapy; weight 50 kg or more |
| SUSTAIN™ 6 | 109 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2013 | T2D HbA1c 7.0 or more; age 50 or more with CVD, CHF or CKD stage 3 or more, or age 60 or more with CV risk factor |
| SURPASS-SWITCH | 44 | modified_itt | level 2 hypoglycemia, glucose below 54 mg/dL | not stated | not stated | observed | not stated | open_label | not stated | industry | 2022 | age 18 or older; HbA1c 7.0 to 9.5 percent; BMI 25 or more; stable dulaglutide 0.75 or 1.5 mg |
| PIONEER 9 | 57 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2017 | Japanese adults 20 y or older; HbA1c 6.5 to 9.5 on one oral drug washed out, or 7.0 to 10.0 on diet and exercise |
| AGAC2 | 0.43 | randomized | not stated | not stated | not stated | not stated | not stated | open_label | not stated | non_industry | 2011 | age over 20, T2DM over 2 years, A1C 8 to 12 percent, premixed insulin twice daily over 0.6 U/kg/day |
| ACHIEVE-1 | 42 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2023 | adults with type 2 diabetes on diet and exercise alone; HbA1c 7.0 to 9.5 percent |
| DUAL™ I Japan | 53 | safety | severe or blood glucose confirmed below 3.1 mmol/L with or without symptoms | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2015 | Japanese adults 20 or older; HbA1c 7.0 to 11.0 percent; BMI at least 20; insulin naive on one oral drug |
| NCT00676338 | 26 | full_analysis | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | adults, HbA1c 7.1 to 11.0 percent, BMI 23 to 45 kg/m2, drug naive |
| NCT05086445 | 14 | safety | Hypoglycemia adverse event of special interest | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2021 | Japanese; age 20 to 70; BMI 20 to 35; HbA1c 7.0 to 10.0 diet only or 6.5 to 9.0 on one OAM, withdrawn 28 days |
| NCT00423501 | 12 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2007 | age 18 to 75; metformin 1500 mg or more; HbA1c 7 to 9.5 percent; BMI 25 to 45 |
| LIXILAN JP-O1 | 52.43 | safety | TEAE leading to death | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2016 | insulin naive Japanese adults; HbA1c 7.5 to 10%; FPG 13.8 mmol/L or less; one or two OADs |
| GETGOAL-L | 125 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | adults; HbA1c 7.0 to 10.0 percent; stable basal insulin with or without metformin |
| PIONEER 5 | 31 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2016 | type 2 diabetes; HbA1c 7.0 to 9.5 percent; moderate renal impairment |
| DUAL™ II Japan | 27 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2016 | Japanese adults; BMI 23 kg/m2 or more; HbA1c 7.5 to 11.0 percent; basal or premix insulin 20 to 50 U with metformin |
| NCT03550378 | 8.43 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2018 | age 18 to 84; BMI 25 to 45; eGFR 30 to 59; HbA1c 6.5 to 10.5 percent |
| AMPLITUDE-M | 56 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2017 | type 2 diabetes on diet and exercise, HbA1c 7 to 10 percent, no glucose lowering drug in prior 3 months |
| SUSTAIN™ | 35 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2014 | Japanese; age 20 or older; HbA1c 6.5 to 9.5 percent on one OAD or 7.0 to 10.5 percent on diet and exercise |
| NCT02288273 | 14 | modified_itt | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2014 | age 18 to 75; T2D on metformin 1500 mg or more; HbA1c 7.0 to 10.0 percent; BMI 45 or less |
| LEAD-5 | 27 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2006 | age 18 to 80; HbA1c 7.5 to 10 on monotherapy or 7 to 10 on combination; BMI 45 or lower |
| Lixilan-L-CN | 30.43 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2019 | Chinese adults; HbA1c 7.0 to 10.5 percent; basal insulin 10 to 25 U/day with up to 2 oral drugs; FPG at most 8.9 mmol/L |
| NCT04998032 | 24 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2021 | age 18 to 75; metformin monotherapy; HbA1c 7.5 to 10.5 at randomization; BMI 18.5 to 40; eGFR 60 or higher |
| AWARD-1 | 56 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2010 | adults with type 2 diabetes on metformin and pioglitazone |
| GETGOAL-M | 76.43 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2008 | type 2 diabetes on metformin 1.5 g/day or more for 3 months; HbA1c 7 to 10 percent; FPG 13.9 mmol/L or less |
| NCT01425580 | 18 | other | not stated | not stated | not stated | not stated | not stated | single_blind | not stated | mixed | 2012 | type 2 diabetes; HbA1c 45 to 97 mmol/mol; subclinical LV dysfunction on echocardiography; BMI 40 or less |
| NCT03311724 | 16 | modified_itt | plasma glucose 54 mg/dL or lower | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2017 | age 18 to 75; T2D at least 6 months; HbA1c 7.0 to 10.5%; BMI 23 to 45; diet or stable metformin |
| NCT05048719 | 28 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2021 | adults with type 2 diabetes, HbA1c 7.0 to 10.5 percent, BMI 23 or more, diet or metformin |
| PIONEER 3 | 83 | safety | serious adverse event term hypoglycaemia | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2016 | adults with T2D; HbA1c 7.0 to 10.5 percent; metformin with or without sulfonylurea |
| DUAL™ II | 27 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2011 | HbA1c 7.5 to 10 percent; BMI 27 or higher; basal insulin 20 to 40 U plus metformin with or without SU or glinides |
| NCT04466904 | 20 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2020 | age 18 to 75; T2D on diet and exercise or stable metformin; HbA1c 7.5 to 11.0 percent; BMI 20 to 35 |
| NCT02113332 | 24 | full_analysis | Severe hypoglycemia requiring assistance of another person | not stated | not stated | not stated | not stated | double_blind | hypothetical | industry | 2013 | T2D on multiple daily insulin injections; HbA1c 7.5 to 11.5 percent; BMI 27.5 to 45 kg/m2 |
| NCT00700817 | 52 | other | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2008 | age 18 to 80; HbA1c 7.5 to 10%; BMI 45 or less; metformin 1500 mg/day or more for 3 months |
| PIONEER 8 | 57 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2017 | adults with type 2 diabetes on basal, premixed or basal bolus insulin with or without metformin |
| NCT06256523 | 29 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2022 | age 18 to 65; HbA1c 7.0 to 10.0 percent; BMI 18.5 to 35; eGFR 60 or more |
| S002858 | 24 | randomized | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | T2D age over 35; clinical CKD; eGFR above 30 mL/min; stable ACE inhibitor or ARB | |
| S002904 | 12 | full_analysis | hypoglycemia, definition not stated | not stated | not stated | not stated | not stated | open_label | not stated | mixed | 2014 | age 20 or older; HbA1c 8.0 percent or more; diet or oral drugs; no insulin or GLP-1 RA |
| S002928 | 24 | safety | hypoglycemia below 3.0 mmol/L or requiring assistance | not stated | not stated | not stated | not stated | single_blind | not stated | non_industry | 2022 | age 18 to 65; BMI 50 or more; type 2 diabetes |
| S002946 | 26 | randomized | Zero implied by no hypoglycemia of any kind | not stated | not stated | not stated | not stated | open_label | not stated | not_reported | 2020 | age over 20; T2D on liraglutide 0.6 or 0.9 mg; no new diabetes drug for 3 months |
| S002947 | 25 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2021 | age 18 to 65; HbA1c 7.0 to 10.5 percent; BMI 20 to 35; diet or one oral agent washed out |
| S002951 | 16 | safety | not stated | not stated | not stated | not stated | not stated | open_label | not stated | non_industry | 2022 | age 18 to 65; BMI 25 or more; HbA1c 7.0 to 10.0 percent; lifestyle or one OAD |
| NCT05654831 | 4.86 | safety | not stated | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2022 | MAD: age 18 to 70; BMI 24 to 40; HbA1c 7.0 to 10.5 percent; T2DM on metformin or lifestyle |
| S003009 | 24 | completers | not stated | not stated | not stated | not stated | not stated | open_label | not stated | industry | 2023 | age 18 or more; HbA1c 7.0 to 10.0 percent; eGFR 30 to 90; UACR above 30 to 5000 mg/g |
| S003047 | 6.57 | safety | Symptomatic hypoglycemia with glucose below 60 mg/dL or symptoms without measurement | not stated | not stated | not stated | not stated | double_blind | not stated | industry | 2006 | age 20 to 75; HbA1c 7.0 to 10.0 percent; BMI 35 or less; sulfonylurea with or without metformin |
| S003071 | 24 | randomized | hypoglycemia requiring third party assistance | not stated | not stated | not stated | not stated | open_label | not stated | non_industry | 2010 | age 18 to under 80; HbA1c 6.9 to 9.4 percent NGSP; BMI 35 or less; on sulfonylurea |
| S003072 | 14 | completers | not stated | not stated | not stated | not stated | not stated | open_label | not stated | mixed | 2011 | age 20 to 80; HbA1c above 6.9 percent on sitagliptin 50 mg for 3 months or more |
| S003079 | 5 | safety | hypoglycemia requiring medical assistance | not stated | not stated | not stated | not stated | open_label | not stated | non_industry | 2010 | age 18 to 80, HbA1c 7.5 to 12 percent, BMI 21 to 35, T2D at least 6 months |
| S003108 | 24 | randomized | Any hypoglycemia, including mild symptomatic | not stated | not stated | not stated | not stated | single_blind | not stated | non_industry | 2012 | T2D with coronary artery disease; no severe heart failure; creatinine up to 150 umol/L |
| S003427 | 52.14 | other | hypoglycemia adverse reaction, undefined | not stated | not stated | not stated | not stated | not_reported | not stated | non_industry | 2019 | adults with type 2 diabetes, stable treatment, measurable CIMT; no prior CVD events |
Trial data
What each trial contributes. Arm rows give the arm value with its standard error, or events over participants; contrast rows give the hazard ratio (from event counts) on the analysis scale (log) against the trial's first row. Flags mark converted, combined or approximated inputs.
| Trial | Arm | Treatment | Week | Data | Value | SE | Events / N | Flags | Source |
|---|---|---|---|---|---|---|---|---|---|
| NCT03131687 | A1 | PLACEBO | 30 | arm, events | 2 / 51 | R0016215:Table 3 | |||
| NCT03131687 | A2+A3+A4+A5 | TIRZ_SC | 30 | arm, events | 49 / 213 | arms_combined | R0016215:Table 3 | ||
| NCT03131687 | A6 | DULA_SC | 30 | arm, events | 9 / 54 | R0016215:Table 3 | |||
| NCT00754988 | A2+A3 | TASP_SC | 156 | arm, events | 61 / 388 | arms_combined | R0022521:Table 2 | ||
| NCT00754988 | A4 | SITAGLIPTIN | 156 | arm, events | 10 / 185 | R0022521:Table 2 | |||
| NCT05407961 | A1 | OTHER_ACTIVE_macupatide | 12 | arm, events | 4 / 15 | R0015193:Table 2 | |||
| NCT05407961 | A2 | DULA_SC | 12 | arm, events | 5 / 29 | R0015193:Table 2 | |||
| NCT05407961 | A3 | DULAMACU_SC | 12 | arm, events | 7 / 28 | R0015193:Table 2 | |||
| NCT00518115 | A1 | PLACEBO | 24 | arm, events | 2 / 52 | nonserious_only | registry:adverse_events | ||
| NCT00518115 | A10+A3+A4+A5+A6+A7+A8+A9 | ALBI_SC | 24 | arm, events | 42 / 274 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT00518115 | A2 | EXEN_SC | 24 | arm, events | 8 / 35 | nonserious_only | registry:adverse_events | ||
| NCT01296412 | A1 | SITAGLIPTIN | 26 | arm, events | 7 / 326 | R0026295:Table 3 | |||
| NCT01296412 | A2 | LIRA_SC | 26 | arm, events | 35 / 327 | R0026295:Table 3 | |||
| DUAL™ I China | A1 | IDEGLIRA_SC | 27 | arm, events | 23 / 361 | R0012560:Table 3 | |||
| DUAL™ I China | A2 | INS_DEGLUDEC | 27 | arm, events | 3 / 179 | R0012560:Table 3 | |||
| DUAL™ I China | A3 | LIRA_SC | 27 | arm, events | 26 / 180 | R0012560:Table 3 | |||
| NCT00838916 | A1 | ALBI_SC | 164 | arm, events | 55 / 516 | nonserious_only | registry:adverse_events | ||
| NCT00838916 | A2 | INS_GLARGINE | 164 | arm, events | 19 / 263 | nonserious_only | registry:adverse_events | ||
| SURPASS-6 | A1+A2+A3 | TIRZ_SC | 56 | arm, events | 91 / 717 | arms_combined | R0009666:Table 3 | ||
| SURPASS-6 | A4 | INS_LISPRO | 56 | arm, events | 17 / 711 | R0009666:Table 3 | |||
| PIONEER 4 | A1 | SEMA_PO | 57 | arm, events | 43 / 285 | R0015836:Table 3 | |||
| PIONEER 4 | A2 | LIRA_SC | 57 | arm, events | 31 / 284 | R0015836:Table 3 | |||
| PIONEER 4 | A3 | PLACEBO | 57 | arm, events | 11 / 142 | R0015836:Table 3 | |||
| NCT04965506 | A1+A2+A3 | MAZD_SC | 24 | arm, events | 53 / 149 | arms_combined | R0012443:Table 2 | ||
| NCT04965506 | A4 | DULA_SC | 24 | arm, events | 8 / 50 | R0012443:Table 2 | |||
| NCT04965506 | A5 | PLACEBO | 24 | arm, events | 4 / 51 | R0012443:Table 2 | |||
| REWIND | A1 | PLACEBO | 365.26 | arm, events | 436 / 4,952 | nonserious_only | registry:adverse_events | ||
| REWIND | A2 | DULA_SC | 365.26 | arm, events | 665 / 4,949 | nonserious_only | registry:adverse_events | ||
| COMBINE 2 | A1 | ICOSEMA_SC | 57 | arm, events | 38 / 342 | R0005851:Table 4 | |||
| COMBINE 2 | A2 | SEMA_SC | 57 | arm, events | 42 / 341 | R0005851:Table 4 | |||
| SCALE™ Insulin | A1 | LIRA_SC | 58 | arm, events | 45 / 198 | R0024063:Table 3 | |||
| SCALE™ Insulin | A2 | PLACEBO | 58 | arm, events | 30 / 198 | R0024063:Table 3 | |||
| Lixilan-O-AP | A1 | IGLARLIXI_SC | 24.43 | arm, events | 22 / 351 | R0013321:Table 3 | |||
| Lixilan-O-AP | A2 | INS_GLARGINE | 24.43 | arm, events | 8 / 350 | R0013321:Table 3 | |||
| Lixilan-O-AP | A3 | LIXI_SC | 24.43 | arm, events | 12 / 177 | R0013321:Table 3 | |||
| NCT01476475 | A1 | IGLARLIXI_SC | 24 | arm, events | 5 / 161 | R0021236:Table 2 | |||
| NCT01476475 | A2 | INS_GLARGINE | 24 | arm, events | 6 / 162 | R0021236:Table 2 | |||
| OUTSTAND-1 | A1+A2+A3 | SAFIGL_PO | 32 | arm, events | 50 / 212 | arms_combined | R0011607:Table 3 | ||
| OUTSTAND-1 | A4 | PLACEBO | 32 | arm, events | 3 / 72 | R0011607:Table 3 | |||
| PB119 | A1 | VISEPE_SC | 24 | arm, events | 11 / 137 | R0011471:Table 4 | |||
| PB119 | A2 | PLACEBO | 24 | arm, events | 2 / 136 | R0011471:Table 4 | |||
| NCT01001104 | A1 | PLACEBO | 12 | arm, events | 2 / 37 | R0015000:Table 3 | |||
| NCT01001104 | A2+A3+A4 | DULA_SC | 12 | arm, events | 3 / 108 | arms_combined | R0015000:Table 3 | ||
| PIONEER 10 | A1+A2+A3 | SEMA_PO | 57 | arm, events | 14 / 393 | arms_combined | R0018421:Table 2 | ||
| PIONEER 10 | A4 | DULA_SC | 57 | arm, events | 4 / 65 | R0018421:Table 2 | |||
| NCT02846233 | A1 | DULA_SC | 16 | arm, events | 1 / 12 | R0028441:Table 5 | |||
| NCT02846233 | A2 | OTHER_ACTIVE_basal_bolus_insulin | 16 | arm, events | 0 / 10 | R0028441:Table 5 | |||
| AWARD-7 | A1 | INS_GLARGINE | 52 | arm, events | 14 / 194 | R0017387:Table 2 | |||
| AWARD-7 | A2+A3 | DULA_SC | 52 | arm, events | 63 / 383 | arms_combined | R0017387:Table 2 | ||
| NCT01584232 | A1 | DULA_SC | 26 | arm, events | 22 / 181 | R0016159:Table 3 | |||
| NCT01584232 | A2 | INS_GLARGINE | 26 | arm, events | 4 / 180 | R0016159:Table 3 | |||
| NCT03235050 | A1 | PLACEBO | 58 | arm, events | 10 / 112 | nonserious_only | registry:adverse_events | ||
| NCT03235050 | A2 | LIRA_SC | 58 | arm, events | 4 / 110 | nonserious_only | registry:adverse_events | ||
| NCT03235050 | A3+A4+A5 | COTA_SC | 58 | arm, events | 90 / 612 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT04235959 | A1 | PLACEBO | 28 | arm, events | 0 / 4 | R0019570:Table 2 | |||
| NCT04235959 | A3 | TIRZ_SC | 28 | arm, events | 4 / 10 | R0019570:Table 2 | |||
| AWARD-10 | A1+A2 | DULA_SC | 24 | arm, events | 22 / 284 | arms_combined | R0020348:p1 | ||
| AWARD-10 | A3 | PLACEBO | 24 | arm, events | 4 / 140 | R0020348:p1 | |||
| SUSTAIN™ 3 | A1 | SEMA_SC | 62 | arm, events | 46 / 406 | nonserious_only | registry:adverse_events | ||
| SUSTAIN™ 3 | A2 | EXENER_SC | 62 | arm, events | 34 / 407 | nonserious_only | registry:adverse_events | ||
| NCT00393718 | A1 | LIRA_SC | 52 | arm, events | 26 / 272 | R0022766:Table 4 | |||
| NCT00393718 | A2 | GLIBENCLAMIDE | 52 | arm, events | 9 / 139 | R0022766:Table 4 | |||
| EGO | A1+A2+A3 | DULA_SC | 16 | arm, events | 18 / 196 | nonserious_only;arms_combined | registry:adverse_events | ||
| EGO | A4 | PLACEBO | 16 | arm, events | 5 / 66 | nonserious_only | registry:adverse_events | ||
| NCT00765817 | A1 | EXEN_SC | 30 | arm, events | 25 / 138 | R0027069:Table 3 | |||
| NCT00765817 | A2 | PLACEBO | 30 | arm, events | 10 / 123 | R0027069:Table 3 | |||
| NCT01029886 | A1 | EXENER_SC | 26 | arm, events | 28 / 461 | R0016299:Table 3 | |||
| NCT01029886 | A2 | LIRA_SC | 26 | arm, events | 59 / 451 | R0016299:Table 3 | |||
| LIXILAN JP-L | A1 | IGLARLIXI_SC | 26.43 | arm, events | 13 / 255 | R0008233:Supplement Table S1 | |||
| LIXILAN JP-L | A2 | INS_GLARGINE | 26.43 | arm, events | 3 / 257 | R0008233:Supplement Table S1 | |||
| SUSTAIN 11 | A1 | SEMA_SC | 52 | arm, events | 65 / 874 | R0022346:Table 3 | |||
| SUSTAIN 11 | A2 | INS_ASPART | 52 | arm, events | 23 / 874 | R0022346:Table 3 | |||
| SUSTAIN 7 | A1+A2 | SEMA_SC | 45 | arm, events | 84 / 601 | nonserious_only;arms_combined | registry:adverse_events | ||
| SUSTAIN 7 | A3+A4 | DULA_SC | 45 | arm, events | 76 / 600 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT00791479 | A1+A2+A3+A4+A5 | DULA_SC | 12 | arm, events | 9 / 135 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT00791479 | A6 | PLACEBO | 12 | arm, events | 1 / 32 | nonserious_only | registry:adverse_events | ||
| NCT00637273 | A1 | EXENER_SC | 26 | arm, events | 29 / 170 | count_from_percent | R0024240:Table 4 | ||
| NCT00637273 | A2 | SITAGLIPTIN | 26 | arm, events | 17 / 172 | count_from_percent | R0024240:Table 4 | ||
| NCT00637273 | A3 | PIOGLITAZONE | 26 | arm, events | 12 / 172 | count_from_percent | R0024240:Table 4 | ||
| SURPASS-1 | A1+A2+A3 | TIRZ_SC | 44 | arm, events | 45 / 363 | arms_combined | R0007531:Supplement Table S2 | ||
| SURPASS-1 | A4 | PLACEBO | 44 | arm, events | 9 / 115 | R0007531:Supplement Table S2 | |||
| NCT00717457 | A1+A2 | TASP_SC | 104 | arm, events | 119 / 797 | arms_combined | R0013639:Table 2 | ||
| NCT00717457 | A3 | EXEN_SC | 104 | arm, events | 53 / 392 | R0013639:Table 2 | |||
| NCT00976937 | A1 | LIXI_SC | 24 | arm, events | 14 / 158 | R0012687:Table 2 | |||
| NCT00976937 | A2 | SITAGLIPTIN | 24 | arm, events | 12 / 161 | R0012687:Table 2 | |||
| ACHIEVE-3 | A1+A2 | ORFO_PO | 57 | arm, events | 191 / 847 | nonserious_only;arms_combined | registry:adverse_events | ||
| ACHIEVE-3 | A3+A4 | SEMA_PO | 57 | arm, events | 133 / 851 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT00082407 | A1 | EXEN_SC | 52 | arm, events | 24 / 255 | R0025791:Table 3 | |||
| NCT00082407 | A2 | INS_PREMIX | 52 | arm, events | 5 / 250 | R0025791:Table 3 | |||
| AWARD-9 | A1 | DULA_SC | 28 | arm, events | 17 / 150 | nonserious_only | registry:adverse_events | ||
| AWARD-9 | A2 | PLACEBO | 28 | arm, events | 6 / 150 | nonserious_only | registry:adverse_events | ||
| NCT05579977 | A1+A8 | PLACEBO | 28 | arm, events | 13 / 139 | arms_combined | R0004106:Table 2 | ||
| NCT05579977 | A10+A11+A12+A13+A2+A3+A4+A5+A6+A9 | LOTI_PO | 28 | arm, events | 107 / 690 | arms_combined | R0004106:Table 2 | ||
| NCT05579977 | A7 | SEMA_PO | 28 | arm, events | 6 / 73 | R0004106:Table 2 | |||
| COMBINE 1 | A1 | ICOSEMA_SC | 57 | arm, events | 102 / 646 | nonserious_only | registry:adverse_events | ||
| COMBINE 1 | A2 | INS_ICODEC | 57 | arm, events | 46 / 645 | nonserious_only | registry:adverse_events | ||
| SUSTAIN 9 | A1 | SEMA_SC | 36 | arm, events | 17 / 151 | nonserious_only | registry:adverse_events | ||
| SUSTAIN 9 | A2 | PLACEBO | 36 | arm, events | 9 / 151 | nonserious_only | registry:adverse_events | ||
| GETGOAL-L-ASIA | A1 | LIXI_SC | 24 | arm, events | 10 / 154 | R0022626:Table 2 | |||
| GETGOAL-L-ASIA | A2 | PLACEBO | 24 | arm, events | 4 / 157 | R0022626:Table 2 | |||
| GETGOAL-S | A1 | PLACEBO | 120 | arm, events | 27 / 286 | nonserious_only | registry:adverse_events | ||
| GETGOAL-S | A2 | LIXI_SC | 120 | arm, events | 71 / 573 | nonserious_only | registry:adverse_events | ||
| PIONEER 12 | A1+A2+A3 | SEMA_PO | 31 | arm, events | 110 / 1,082 | arms_combined | R0019776:Table 3 | ||
| PIONEER 12 | A4 | SITAGLIPTIN | 31 | arm, events | 16 / 359 | R0019776:Table 3 | |||
| NCT06589765 | A1+A2+A3 | SAFIGL_PO | 52 | arm, events | 113 / 608 | arms_combined | R0029347:Table 3 | ||
| NCT06589765 | A4 | DAPAGLIFLOZIN | 52 | arm, events | 13 / 202 | R0029347:Table 3 | |||
| SUSTAIN 10 | A1 | SEMA_SC | 35 | arm, events | 45 / 290 | nonserious_only | registry:adverse_events | ||
| SUSTAIN 10 | A2 | LIRA_SC | 35 | arm, events | 35 / 287 | nonserious_only | registry:adverse_events | ||
| NCT01175473 | A1 | LIXI_SC | 4.43 | arm, events | 2 / 77 | R0022723:Table 3 | |||
| NCT01175473 | A2 | LIRA_SC | 4.43 | arm, events | 11 / 71 | R0022723:Table 3 | |||
| NCT03951753 | A1 | TIRZ_SC | 32 | arm, events | 9 / 45 | nonserious_only | registry:adverse_events | ||
| NCT03951753 | A2 | SEMA_SC | 32 | arm, events | 13 / 44 | nonserious_only | registry:adverse_events | ||
| NCT03951753 | A3 | PLACEBO | 32 | arm, events | 6 / 28 | nonserious_only | registry:adverse_events | ||
| NCT00960661 | A1 | EXEN_SC | 30 | arm, events | 34 / 316 | R0016788:Supplement Table 4 | |||
| NCT00960661 | A2 | INS_LISPRO | 30 | arm, events | 16 / 321 | R0016788:Supplement Table 4 | |||
| NCT00935532 | A1 | EXENER_SC | 26 | arm, events | 19 / 215 | nonserious_only | registry:adverse_events | ||
| NCT00935532 | A2 | INS_GLARGINE | 26 | arm, events | 5 / 212 | nonserious_only | registry:adverse_events | ||
| NCT02008682 | A1 | LIRA_SC | 26 | arm, events | 15 / 184 | R0025836:Table 2 | |||
| NCT02008682 | A2 | SITAGLIPTIN | 26 | arm, events | 4 / 184 | R0025836:Table 2 | |||
| NCT03555994 | A1 | PLACEBO | 9 | arm, events | 1 / 11 | nonserious_only | registry:adverse_events | ||
| NCT03555994 | A2 | LIRA_SC | 9 | arm, events | 0 / 10 | nonserious_only | registry:adverse_events | ||
| NCT03555994 | A3 | COTA_SC | 9 | arm, events | 1 / 9 | nonserious_only | registry:adverse_events | ||
| NCT02229383 | A1 | EXENER_SC | 38 | arm, events | 11 / 233 | R0014763:Table 3 | |||
| NCT02229383 | A2 | PLACEBO | 38 | arm, events | 8 / 231 | R0014763:Table 3 | |||
| NCT02081118 | A1 | PLACEBO | 22 | arm, events | 4 / 51 | R0009733:Table 3 | |||
| NCT02081118 | A2+A3+A4 | EFPE_SC | 22 | arm, events | 28 / 157 | printed_denominator;arms_combined | R0009733:Table 3 | ||
| NCT00577824 | A1 | PLACEBO | 24 | arm, events | 2 / 36 | R0018881:Table 2 | |||
| NCT00577824 | A2+A3 | EXEN_SC | 24 | arm, events | 12 / 145 | arms_combined | R0018881:Table 2 | ||
| ATTAIN-2 | A1 | PLACEBO | 74 | arm, events | 94 / 630 | nonserious_only | registry:adverse_events | ||
| ATTAIN-2 | A2+A3+A4 | ORFO_PO | 74 | arm, events | 240 / 983 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT02973321 | A1 | PLACEBO | 26.4 | arm, events | 2 / 33 | nonserious_only | registry:adverse_events | ||
| NCT02973321 | A5 | LIRA_SC | 26.4 | arm, events | 8 / 67 | nonserious_only | registry:adverse_events | ||
| NCT01149421 | A1+A2 | DULA_SC | 26 | arm, events | 55 / 505 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT01149421 | A3 | PLACEBO | 26 | arm, events | 20 / 250 | nonserious_only | registry:adverse_events | ||
| NCT00434954 | A1 | EXEN_SC | 26 | arm, events | 19 / 248 | count_from_percent | R0027127:Results | ||
| NCT00434954 | A2 | INS_PREMIX | 26 | arm, events | 14 / 246 | count_from_percent | R0027127:Results | ||
| NCT02229396 | A1 | DAPAEXEN_SC | 104 | arm, events | 13 / 231 | nonserious_only | registry:adverse_events | ||
| NCT02229396 | A2 | EXENER_SC | 104 | arm, events | 17 / 231 | nonserious_only | registry:adverse_events | ||
| NCT02229396 | A3 | DAPAGLIFLOZIN | 104 | arm, events | 11 / 233 | nonserious_only | registry:adverse_events | ||
| GetGoal-Duo1 | A1 | PLACEBO | 24.43 | arm, events | 7 / 223 | nonserious_only | registry:adverse_events | ||
| GetGoal-Duo1 | A2 | LIXI_SC | 24.43 | arm, events | 15 / 223 | nonserious_only | registry:adverse_events | ||
| NCT01558271 | A1 | DULA_SC | 52 | arm, events | 20 / 281 | R0011754:Table 2 | |||
| NCT01558271 | A2 | LIRA_SC | 52 | arm, events | 6 / 141 | R0011754:Table 2 | |||
| NCT00849017 | A1 | PLACEBO | 164 | arm, events | 15 / 105 | nonserious_only | registry:adverse_events | ||
| NCT00849017 | A2+A3 | ALBI_SC | 164 | arm, events | 29 / 204 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT00395746 | A1+A2 | LIRA_SC | 52 | arm, events | 21 / 178 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT00395746 | A3 | PLACEBO | 52 | arm, events | 7 / 89 | nonserious_only | registry:adverse_events | ||
| NCT01147627 | A1 | EXEN_SC | 48 | arm, events | 6 / 142 | nonserious_only | registry:adverse_events | ||
| NCT01147627 | A2 | INS_PREMIX | 48 | arm, events | 1 / 138 | nonserious_only | registry:adverse_events | ||
| NCT01147627 | A3 | PIOGLITAZONE | 48 | arm, events | 4 / 136 | nonserious_only | registry:adverse_events | ||
| NCT05759897 | A1 | PLACEBO | 16 | arm, events | 0 / 39 | printed_denominator | R0002101:Table 3 | ||
| NCT05759897 | A2+A3+A4+A5 | SAFIGL_PO | 16 | arm, events | 14 / 155 | printed_denominator;arms_combined | R0002101:Table 3 | ||
| SUSTAIN™1 | A1+A2 | SEMA_SC | 35 | arm, events | 30 / 259 | nonserious_only;arms_combined | registry:adverse_events | ||
| SUSTAIN™1 | A3 | PLACEBO | 35 | arm, events | 3 / 129 | nonserious_only | registry:adverse_events | ||
| GetGoal-O | A1 | LIXI_SC | 24.43 | arm, events | 19 / 176 | nonserious_only | registry:adverse_events | ||
| GetGoal-O | A2 | PLACEBO | 24.43 | arm, events | 13 / 174 | nonserious_only | registry:adverse_events | ||
| NCT04093752 | A1+A2+A3 | TIRZ_SC | 44 | arm, events | 281 / 687 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT04093752 | A4 | INS_GLARGINE | 44 | arm, events | 3 / 230 | nonserious_only | registry:adverse_events | ||
| NCT01617434 | A1 | LIRA_SC | 27 | arm, events | 24 / 226 | R0026247:Table 3 | |||
| NCT01617434 | A2 | PLACEBO | 27 | arm, events | 11 / 225 | R0026247:Table 3 | |||
| NCT00135330 | A1 | EXEN_SC | 20 | arm, events | 3 / 45 | nonserious_only | registry:adverse_events | ||
| NCT00135330 | A2 | EXENROSI_SC | 20 | arm, events | 10 / 47 | nonserious_only | registry:adverse_events | ||
| NCT00135330 | A3 | ROSIGLITAZONE | 20 | arm, events | 2 / 45 | nonserious_only | registry:adverse_events | ||
| LIRA-Ramadan™ | A1 | LIRA_SC | 30 | arm, events | 37 / 172 | R0025756:Supplement Table S2 | |||
| LIRA-Ramadan™ | A2 | OTHER_ACTIVE_sulfonylurea | 30 | arm, events | 6 / 171 | R0025756:Supplement Table S2 | |||
| NCT02200991 | A1 | LIXI_SC | 4.43 | arm, events | 3 / 69 | R0024589:Table 3 | |||
| NCT02200991 | A2 | SITAGLIPTIN | 4.43 | arm, events | 0 / 67 | R0024589:Table 3 | |||
| NCT00097500 | A1 | EXEN_SC | 64 | arm, events | 3 / 36 | nonserious_only | registry:adverse_events | ||
| NCT00097500 | A2 | INS_GLARGINE | 64 | arm, events | 1 / 33 | nonserious_only | registry:adverse_events | ||
| ACHIEVE-5 | A1 | PLACEBO | 42 | arm, events | 10 / 141 | nonserious_only | registry:adverse_events | ||
| ACHIEVE-5 | A2+A3+A4 | ORFO_PO | 42 | arm, events | 66 / 405 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT00894322 | A1 | EXENER_SC | 12 | arm, events | 4 / 23 | nonserious_only | registry:adverse_events | ||
| NCT00894322 | A2 | PLACEBO | 12 | arm, events | 2 / 12 | nonserious_only | registry:adverse_events | ||
| AWARD-CHN1 | A1+A2 | DULA_SC | 26 | arm, events | 60 / 492 | arms_combined | R0014229:Table 2 | ||
| AWARD-CHN1 | A3 | GLIMEPIRIDE | 26 | arm, events | 7 / 245 | R0014229:Table 2 | |||
| AWARD-8 | A1 | DULA_SC | 24 | arm, events | 20 / 240 | R0016038:Table 2 | |||
| AWARD-8 | A2 | PLACEBO | 24 | arm, events | 0 / 60 | R0016038:Table 2 | |||
| NCT01733758 | A2+A3 | ALBI_SC | 52 | arm, events | 10 / 310 | printed_denominator;arms_combined | R0010997:Table 3 | ||
| NCT01733758 | A4 | LIRA_SC | 52 | arm, events | 5 / 103 | printed_denominator | R0010997:Table 3 | ||
| NCT00359762 | A1 | EXEN_SC | 234.81 | arm, events | 62 / 515 | nonserious_only | registry:adverse_events | ||
| NCT00359762 | A2 | GLIMEPIRIDE | 234.81 | arm, events | 33 / 514 | nonserious_only | registry:adverse_events | ||
| LIRA-SWITCH™ | A1 | LIRA_SC | 27 | arm, events | 33 / 203 | R0025720:Table 1 | |||
| LIRA-SWITCH™ | A2 | SITAGLIPTIN | 27 | arm, events | 19 / 204 | R0025720:Table 1 | |||
| LixiLan-G | A1 | IGLARLIXI_SC | 26 | arm, events | 14 / 257 | nonserious_only | registry:adverse_events | ||
| LixiLan-G | A2 | GLP1RE_SC | 26 | arm, events | 6 / 257 | nonserious_only | registry:adverse_events | ||
| AWARD-2 | A1+A2 | DULA_SC | 78 | arm, events | 55 / 545 | nonserious_only;arms_combined | registry:adverse_events | ||
| AWARD-2 | A3 | INS_GLARGINE | 78 | arm, events | 15 / 265 | nonserious_only | registry:adverse_events | ||
| DUAL™ VIII | A1 | IDEGLIRA_SC | 108.29 | arm, events | 39 / 506 | nonserious_only | registry:adverse_events | ||
| DUAL™ VIII | A2 | INS_GLARGINE | 108.29 | arm, events | 12 / 506 | nonserious_only | registry:adverse_events | ||
| DURATION-NEO-2 | A1 | EXENER_SC | 28 | arm, events | 5 / 182 | R0010641:Table 3 | |||
| DURATION-NEO-2 | A2 | SITAGLIPTIN | 28 | arm, events | 2 / 122 | R0010641:Table 3 | |||
| DURATION-NEO-2 | A3 | PLACEBO | 28 | arm, events | 1 / 61 | R0010641:Table 3 | |||
| NCT05514535 | A1 | SEMA_SC | 45 | arm, events | 39 / 288 | R0015842:Table 2 | |||
| NCT05514535 | A2 | INS_GLARGINE | 45 | arm, events | 12 / 285 | R0015842:Table 2 | |||
| AWARD-6 | A1 | DULA_SC | 30 | arm, events | 36 / 299 | nonserious_only | registry:adverse_events | ||
| AWARD-6 | A2 | LIRA_SC | 30 | arm, events | 36 / 300 | nonserious_only | registry:adverse_events | ||
| NCT03985293 | A1 | PLACEBO | 20 | arm, events | 2 / 66 | R0006095:Table 3 | |||
| NCT03985293 | A2+A3+A4+A5+A6 | DANU_PO | 20 | arm, events | 34 / 346 | arms_combined | R0006095:Table 3 | ||
| NCT00701935 | A1 | EXEN_SC | 26.07 | arm, events | 7 / 43 | nonserious_only | registry:adverse_events | ||
| NCT00701935 | A2 | PLACEBO | 26.07 | arm, events | 1 / 37 | nonserious_only | registry:adverse_events | ||
| NCT01191268 | A1+A2 | DULA_SC | 56 | arm, events | 78 / 588 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT01191268 | A3 | INS_GLARGINE | 56 | arm, events | 15 / 296 | nonserious_only | registry:adverse_events | ||
| LixiLan-O | A1 | IGLARLIXI_SC | 30.29 | arm, events | 42 / 469 | R0015993:Table 1 | |||
| LixiLan-O | A2 | INS_GLARGINE | 30.29 | arm, events | 20 / 467 | R0015993:Table 1 | |||
| LixiLan-O | A3 | LIXI_SC | 30.29 | arm, events | 21 / 234 | R0015993:Table 1 | |||
| NCT06974825 | A1+A2+A3 | BGM050_SC | 20 | arm, events | 18 / 38 | arms_combined | R0015161:Results | ||
| NCT06974825 | A4 | SEMA_SC | 20 | arm, events | 1 / 16 | R0015161:Results | |||
| NCT06974825 | A5 | PLACEBO | 20 | arm, events | 0 / 13 | R0015161:Results | |||
| GETGOAL-P | A1 | PLACEBO | 132 | arm, events | 23 / 161 | nonserious_only | registry:adverse_events | ||
| GETGOAL-P | A2 | LIXI_SC | 132 | arm, events | 35 / 323 | nonserious_only | registry:adverse_events | ||
| SUSTAIN™ 4 | A1+A2 | SEMA_SC | 35 | arm, events | 128 / 722 | nonserious_only;printed_denominator;arms_combined | registry:adverse_events | ||
| SUSTAIN™ 4 | A3 | INS_GLARGINE | 35 | arm, events | 16 / 360 | nonserious_only;printed_denominator | registry:adverse_events | ||
| NCT00375492 | A1 | EXEN_SC | 24 | arm, events | 18 / 96 | nonserious_only | registry:adverse_events | ||
| NCT00375492 | A2 | PLACEBO | 24 | arm, events | 21 / 98 | nonserious_only | registry:adverse_events | ||
| NCT04504396 | A1 | VISEPE_SC | 24 | arm, events | 23 / 310 | R0009432:Table 3 | |||
| NCT04504396 | A2 | PLACEBO | 24 | arm, events | 15 / 310 | R0009432:Table 3 | |||
| SURPASS-4 | A1+A2+A3 | TIRZ_SC | 108 | arm, events | 180 / 997 | arms_combined | R0007531:Supplement Table S2 | ||
| SURPASS-4 | A4 | INS_GLARGINE | 108 | arm, events | 44 / 1,005 | R0007531:Supplement Table S2 | |||
| NCT00877890 | A1 | EXENER_SC | 24 | arm, events | 12 / 129 | nonserious_only | registry:adverse_events | ||
| NCT00877890 | A2 | EXEN_SC | 24 | arm, events | 5 / 125 | nonserious_only | registry:adverse_events | ||
| SUSTAIN | A1+A2 | SEMA_SC | 35 | arm, events | 107 / 578 | arms_combined | R0014802:Table 3 | ||
| SUSTAIN | A3 | SITAGLIPTIN | 35 | arm, events | 20 / 290 | R0014802:Table 3 | |||
| NCT00360334 | A1 | EXEN_SC | 26 | arm, events | 22 / 118 | R0024925:Table 3 | |||
| NCT00360334 | A2 | INS_GLARGINE | 26 | arm, events | 14 / 117 | R0024925:Table 3 | |||
| DUAL™ V | A1 | IDEGLIRA_SC | 27 | arm, events | 20 / 278 | nonserious_only | registry:adverse_events | ||
| DUAL™ V | A2 | INS_GLARGINE | 27 | arm, events | 7 / 279 | nonserious_only | registry:adverse_events | ||
| NCT04552470 | A1 | PLACEBO | 12 | arm, events | 0 / 9 | R0004540:Table 2 | |||
| NCT04552470 | A2+A3+A4 | DANU_PO | 12 | arm, events | 4 / 28 | arms_combined | R0004540:Table 2 | ||
| NCT01003184 | A1 | EXENER_SC | 26 | arm, events | 19 / 111 | R0027663:Table 2 | |||
| NCT01003184 | A2 | INS_DETEMIR | 26 | arm, events | 11 / 111 | R0027663:Table 2 | |||
| SOLID-DKD | A1+A2 | HRS7535_PO | 18 | arm, events | 20 / 187 | arms_combined | R0004355:Table 2 | ||
| SOLID-DKD | A3 | PLACEBO | 18 | arm, events | 3 / 94 | R0004355:Table 2 | |||
| NCT00917267 | A1 | EXENER_SC | 36 | arm, events | 32 / 340 | nonserious_only;printed_denominator | registry:adverse_events | ||
| NCT00917267 | A2 | EXEN_SC | 36 | arm, events | 27 / 338 | nonserious_only;printed_denominator | registry:adverse_events | ||
| GETGOAL-X | A1 | LIXI_SC | 116 | arm, events | 48 / 320 | nonserious_only | registry:adverse_events | ||
| GETGOAL-X | A2 | EXEN_SC | 116 | arm, events | 54 / 319 | nonserious_only | registry:adverse_events | ||
| NCT00299871 | A1 | PLACEBO | 13.43 | arm, events | 8 / 109 | R0021613:Table 3 | |||
| NCT00299871 | A2+A3+A4+A5+A6+A7+A8+A9 | LIXI_SC | 13.43 | arm, events | 43 / 433 | arms_combined | R0021613:Table 3 | ||
| NCT02212067 | A1 | SEMA_SC | 17 | arm, events | 4 / 37 | R0021892:Results | |||
| NCT02212067 | A2 | PLACEBO | 17 | arm, events | 3 / 38 | R0021892:Results | |||
| SUSTAIN™ | A1+A2 | SEMA_SC | 62 | arm, events | 62 / 480 | arms_combined | R0025024:Table 2 | ||
| SUSTAIN™ | A3 | OTHER_ACTIVE_additional_OAD | 62 | arm, events | 8 / 121 | R0025024:Table 2 | |||
| LEAD-2 | A1+A2+A3 | LIRA_SC | 104.28 | arm, events | 98 / 725 | nonserious_only;arms_combined | registry:adverse_events | ||
| LEAD-2 | A4 | GLIMEPIRIDE | 104.28 | arm, events | 14 / 244 | nonserious_only | registry:adverse_events | ||
| LEAD-2 | A5 | PLACEBO | 104.28 | arm, events | 5 / 122 | nonserious_only | registry:adverse_events | ||
| NCT01620489 | A1 | LIRA_SC | 27 | arm, events | 10 / 140 | nonserious_only | registry:adverse_events | ||
| NCT01620489 | A2 | PLACEBO | 27 | arm, events | 4 / 139 | nonserious_only | registry:adverse_events | ||
| NCT05486065 | A1+A2+A3 | SEMA_SC | 49 | arm, events | 42 / 185 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT05486065 | A4 | PLACEBO | 49 | arm, events | 7 / 60 | nonserious_only | registry:adverse_events | ||
| DUAL™ II China | A1 | IDEGLIRA_SC | 30 | arm, events | 22 / 302 | R0012135:Table 3 | |||
| DUAL™ II China | A2 | INS_DEGLUDEC | 30 | arm, events | 2 / 151 | R0012135:Table 3 | |||
| GETGOAL-F1 | A1 | PLACEBO | 112 | arm, events | 21 / 160 | nonserious_only;printed_denominator | registry:adverse_events | ||
| GETGOAL-F1 | A2+A3 | LIXI_SC | 112 | arm, events | 40 / 322 | nonserious_only;arms_combined | registry:adverse_events | ||
| SURPASS-3 | A1+A2+A3 | TIRZ_SC | 56 | arm, events | 171 / 1,079 | arms_combined | R0015264:Table 2 | ||
| SURPASS-3 | A4 | INS_DEGLUDEC | 56 | arm, events | 14 / 365 | R0007531:Supplement Table S2 | |||
| NCT00460941 | A1 | PLACEBO | 8 | arm, events | 3 / 32 | printed_denominator | R0021258:Table 2 | ||
| NCT00460941 | A2+A3+A4 | TASP_SC | 8 | arm, events | 14 / 97 | printed_denominator;arms_combined | R0021258:Table 2 | ||
| SURPASS-5 | A1+A2+A3 | TIRZ_SC | 44 | arm, events | 54 / 355 | arms_combined | R0007531:Supplement Table S2 | ||
| SURPASS-5 | A4 | PLACEBO | 44 | arm, events | 12 / 120 | R0007531:Supplement Table S2 | |||
| NCT03322631 | A1 | PLACEBO | 12 | arm, events | 0 / 9 | R0021917:Table 2 | |||
| NCT03322631 | A2+A3+A4 | TIRZ_SC | 12 | arm, events | 8 / 39 | arms_combined | R0021917:Table 2 | ||
| NCT00744926 | A1 | PLACEBO | 24 | arm, events | 5 / 123 | printed_denominator | R0025346:Table 1 | ||
| NCT00744926 | A2+A3 | TASP_SC | 24 | arm, events | 28 / 245 | printed_denominator;arms_combined | R0025346:Table 1 | ||
| PIONEER 1 | A1+A2+A3 | SEMA_PO | 31 | arm, events | 33 / 525 | nonserious_only;arms_combined | registry:adverse_events | ||
| PIONEER 1 | A4 | PLACEBO | 31 | arm, events | 4 / 178 | nonserious_only | registry:adverse_events | ||
| NCT02420262 | A1 | IDEGLIRA_SC | 27 | arm, events | 16 / 252 | nonserious_only | registry:adverse_events | ||
| NCT02420262 | A2 | OTHER_ACTIVE_basal_bolus_insulin | 27 | arm, events | 10 / 254 | nonserious_only | registry:adverse_events | ||
| NCT00641056 | A1 | EXENER_SC | 84 | arm, events | 28 / 233 | R0027747:Table 1 | |||
| NCT00641056 | A2 | INS_GLARGINE | 84 | arm, events | 13 / 234 | R0027747:Table 1 | |||
| ELEGANT | A1 | LIRA_SC | 26 | arm, events | 10 / 26 | R0025175:Table 3 | |||
| ELEGANT | A2 | STANDARD_CARE | 26 | arm, events | 6 / 24 | R0025175:Table 3 | |||
| NCT01126580 | A1+A2 | DULA_SC | 52 | arm, events | 57 / 539 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT01126580 | A3 | METFORMIN | 52 | arm, events | 39 / 268 | nonserious_only | registry:adverse_events | ||
| PIONEER 11 | A1+A2+A3 | SEMA_PO | 31 | arm, events | 28 / 390 | arms_combined | R0019663:Table 3 | ||
| PIONEER 11 | A4 | PLACEBO | 31 | arm, events | 2 / 131 | R0019663:Table 3 | |||
| NCT01272232 | A1+A2 | LIRA_SC | 68 | arm, events | 145 / 634 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT01272232 | A3 | PLACEBO | 68 | arm, events | 27 / 212 | nonserious_only | registry:adverse_events | ||
| NCT00943917 | A1+A2 | EXENIMP_IMPLANT | 12 | arm, events | 10 / 102 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT00943917 | A3 | EXEN_SC | 12 | arm, events | 3 / 53 | nonserious_only | registry:adverse_events | ||
| SUSTAIN 8 | A1 | SEMA_SC | 57 | arm, events | 59 / 394 | nonserious_only | registry:adverse_events | ||
| SUSTAIN 8 | A2 | CANAGLIFLOZIN | 57 | arm, events | 37 / 394 | nonserious_only | registry:adverse_events | ||
| SUSTAIN™ 5 | A1+A2 | SEMA_SC | 35 | arm, events | 15 / 264 | arms_combined | R0012671:Table 2 | ||
| SUSTAIN™ 5 | A3 | PLACEBO | 35 | arm, events | 2 / 133 | R0012671:Table 2 | |||
| NCT02229227 | A1 | ALBI_SC | 26 | arm, events | 31 / 402 | nonserious_only | registry:adverse_events | ||
| NCT02229227 | A2 | INS_LISPRO | 26 | arm, events | 18 / 412 | nonserious_only | registry:adverse_events | ||
| NCT00382239 | A1 | PLACEBO | 12 | arm, events | 0 / 40 | R0027621:Table 3 | |||
| NCT00382239 | A2+A3+A4 | EXEN_SC | 12 | arm, events | 8 / 113 | arms_combined | R0027621:Table 3 | ||
| SUSTAIN™ 6 | A1+A2 | SEMA_SC | 109 | arm, events | 296 / 1,648 | nonserious_only;arms_combined | registry:adverse_events | ||
| SUSTAIN™ 6 | A3+A4 | PLACEBO | 109 | arm, events | 184 / 1,649 | nonserious_only;arms_combined | registry:adverse_events | ||
| SURPASS-SWITCH | A1 | TIRZ_SC | 44 | arm, events | 31 / 139 | count_from_percent | R0008264:Results | ||
| SURPASS-SWITCH | A2 | DULA_SC | 44 | arm, events | 19 / 143 | count_from_percent | R0008264:Results | ||
| PIONEER 9 | A1+A2+A3 | SEMA_PO | 57 | arm, events | 8 / 146 | nonserious_only;arms_combined | registry:adverse_events | ||
| PIONEER 9 | A4 | LIRA_SC | 57 | arm, events | 2 / 48 | nonserious_only | registry:adverse_events | ||
| PIONEER 9 | A5 | PLACEBO | 57 | arm, events | 1 / 49 | nonserious_only | registry:adverse_events | ||
| AGAC2 | A1 | PLACEBO | 0.43 | arm, events | 0 / 21 | R0020827:Supplement Table 2 | |||
| AGAC2 | A2 | EXEN_SC | 0.43 | arm, events | 1 / 30 | R0020827:Supplement Table 2 | |||
| ACHIEVE-1 | A1 | PLACEBO | 42 | arm, events | 13 / 138 | nonserious_only | registry:adverse_events | ||
| ACHIEVE-1 | A2+A3+A4 | ORFO_PO | 42 | arm, events | 92 / 421 | nonserious_only;arms_combined | registry:adverse_events | ||
| DUAL™ I Japan | A1 | IDEGLIRA_SC | 53 | arm, events | 15 / 275 | R0014857:Table 2 | |||
| DUAL™ I Japan | A2 | INS_DEGLUDEC | 53 | arm, events | 12 / 271 | R0014857:Table 2 | |||
| DUAL™ I Japan | A3 | LIRA_SC | 53 | arm, events | 24 / 273 | R0014857:Table 2 | |||
| NCT00676338 | A1 | EXENER_SC | 26 | arm, events | 27 / 248 | R0027761:Table 1 | |||
| NCT00676338 | A2 | METFORMIN | 26 | arm, events | 31 / 246 | R0027761:Table 1 | |||
| NCT00676338 | A3 | PIOGLITAZONE | 26 | arm, events | 6 / 163 | R0027761:Table 1 | |||
| NCT00676338 | A4 | SITAGLIPTIN | 26 | arm, events | 9 / 163 | R0027761:Table 1 | |||
| NCT05086445 | A1 | PLACEBO | 14 | arm, events | 2 / 11 | R0003844:Table 2 | |||
| NCT05086445 | A2+A3+A4 | ORFO_PO | 14 | arm, events | 3 / 49 | arms_combined | R0003844:Table 2 | ||
| NCT00423501 | A1 | PLACEBO | 12 | arm, events | 4 / 49 | printed_denominator | R0022337:Table 2 | ||
| NCT00423501 | A2+A3+A4+A5+A6 | TASP_SC | 12 | arm, events | 31 / 248 | printed_denominator;arms_combined | R0022337:Table 2 | ||
| LIXILAN JP-O1 | A1 | IGLARLIXI_SC | 52.43 | arm, events | 13 / 161 | R0015751:Table 3 | |||
| LIXILAN JP-O1 | A2 | LIXI_SC | 52.43 | arm, events | 11 / 160 | R0015751:Table 3 | |||
| GETGOAL-L | A1 | PLACEBO | 125 | arm, events | 10 / 167 | nonserious_only | registry:adverse_events | ||
| GETGOAL-L | A2 | LIXI_SC | 125 | arm, events | 37 / 329 | nonserious_only | registry:adverse_events | ||
| PIONEER 5 | A1 | SEMA_PO | 31 | arm, events | 17 / 163 | nonserious_only | registry:adverse_events | ||
| PIONEER 5 | A2 | PLACEBO | 31 | arm, events | 6 / 161 | nonserious_only | registry:adverse_events | ||
| DUAL™ II Japan | A1 | IDEGLIRA_SC | 27 | arm, events | 15 / 105 | R0015589:Table 2 | |||
| DUAL™ II Japan | A2 | INS_DEGLUDEC | 27 | arm, events | 5 / 105 | R0015589:Table 2 | |||
| NCT03550378 | A1 | COTA_SC | 8.43 | arm, events | 5 / 21 | R0019218:Table 2 | |||
| NCT03550378 | A2 | PLACEBO | 8.43 | arm, events | 0 / 20 | R0019218:Table 2 | |||
| AMPLITUDE-M | A1+A2+A3 | EFPE_SC | 56 | arm, events | 51 / 304 | arms_combined | R0007136:Table 2 | ||
| AMPLITUDE-M | A4 | PLACEBO | 56 | arm, events | 9 / 102 | R0007136:Table 2 | |||
| SUSTAIN™ | A1+A2 | SEMA_SC | 35 | arm, events | 16 / 205 | arms_combined | R0014736:Supplement Table S4 | ||
| SUSTAIN™ | A3 | SITAGLIPTIN | 35 | arm, events | 2 / 103 | R0014736:Supplement Table S4 | |||
| NCT02288273 | A1 | EXENER_SC | 14 | arm, events | 3 / 61 | R0025397:Table 2 | |||
| NCT02288273 | A2 | PLACEBO | 14 | arm, events | 2 / 56 | R0025397:Table 2 | |||
| LEAD-5 | A1 | LIRA_SC | 27 | arm, events | 23 / 232 | R0027336:Supplement Table 2 | |||
| LEAD-5 | A2 | PLACEBO | 27 | arm, events | 6 / 115 | R0027336:Supplement Table 2 | |||
| LEAD-5 | A3 | INS_GLARGINE | 27 | arm, events | 3 / 234 | R0027336:Supplement Table 2 | |||
| Lixilan-L-CN | A1 | IGLARLIXI_SC | 30.43 | arm, events | 9 / 212 | R0014540:Table 3 | |||
| Lixilan-L-CN | A2 | INS_GLARGINE | 30.43 | arm, events | 10 / 214 | R0014540:Table 3 | |||
| NCT04998032 | A1 | EFSUBA_SC | 24 | arm, events | 37 / 171 | R0006975:Table 3 | |||
| NCT04998032 | A2 | PLACEBO | 24 | arm, events | 6 / 173 | R0006975:Table 3 | |||
| AWARD-1 | A1+A2 | DULA_SC | 56 | arm, events | 63 / 559 | nonserious_only;arms_combined | registry:adverse_events | ||
| AWARD-1 | A3 | EXEN_SC | 56 | arm, events | 22 / 278 | nonserious_only | registry:adverse_events | ||
| GETGOAL-M | A1+A2 | LIXI_SC | 76.43 | arm, events | 75 / 510 | nonserious_only;arms_combined | registry:adverse_events | ||
| GETGOAL-M | A3 | PLACEBO | 76.43 | arm, events | 20 / 170 | nonserious_only;printed_denominator | registry:adverse_events | ||
| NCT01425580 | A1 | LIRA_SC | 18 | arm, events | 3 / 33 | nonserious_only | R0025885:Results | ||
| NCT01425580 | A2 | GLIMEPIRIDE | 18 | arm, events | 1 / 29 | nonserious_only | R0025885:Results | ||
| NCT03311724 | A1 | PLACEBO | 16 | arm, events | 2 / 26 | R0010282:Table 2 | |||
| NCT03311724 | A2+A3+A4 | TIRZ_SC | 16 | arm, events | 28 / 85 | arms_combined | R0010282:Table 2 | ||
| NCT05048719 | A1 | PLACEBO | 28 | arm, events | 4 / 55 | nonserious_only | registry:adverse_events | ||
| NCT05048719 | A2+A3+A4+A5+A6+A7+A8 | ORFO_PO | 28 | arm, events | 54 / 278 | nonserious_only;arms_combined | registry:adverse_events | ||
| NCT05048719 | A9 | DULA_SC | 28 | arm, events | 6 / 50 | nonserious_only | registry:adverse_events | ||
| PIONEER 3 | A1+A2+A3 | SEMA_PO | 83 | arm, events | 153 / 1,397 | nonserious_only;arms_combined | registry:adverse_events | ||
| PIONEER 3 | A4 | SITAGLIPTIN | 83 | arm, events | 37 / 467 | nonserious_only | registry:adverse_events | ||
| DUAL™ II | A1 | IDEGLIRA_SC | 27 | arm, events | 13 / 207 | nonserious_only | registry:adverse_events | ||
| DUAL™ II | A2 | INS_DEGLUDEC | 27 | arm, events | 7 / 206 | nonserious_only | registry:adverse_events | ||
| NCT04466904 | A1+A2+A3 | MAZD_SC | 20 | arm, events | 7 / 24 | arms_combined | R0009340:Table 2 | ||
| NCT04466904 | A4 | DULA_SC | 20 | arm, events | 2 / 6 | printed_denominator | R0009340:Table 2 | ||
| NCT04466904 | A5 | PLACEBO | 20 | arm, events | 0 / 12 | printed_denominator | R0009340:Table 2 | ||
| NCT02113332 | A1 | LIRA_SC | 24 | arm, events | 5 / 64 | R0026157:Results | |||
| NCT02113332 | A2 | PLACEBO | 24 | arm, events | 3 / 60 | R0026157:Results | |||
| NCT00700817 | A1+A2 | LIRA_SC | 52 | arm, events | 47 / 446 | arms_combined | R0024199:Table 2 | ||
| NCT00700817 | A3 | SITAGLIPTIN | 52 | arm, events | 14 / 219 | R0024199:Table 2 | |||
| PIONEER 8 | A1+A2+A3 | SEMA_PO | 57 | arm, events | 64 / 547 | nonserious_only;arms_combined | registry:adverse_events | ||
| PIONEER 8 | A4 | PLACEBO | 57 | arm, events | 11 / 184 | nonserious_only | registry:adverse_events | ||
| NCT06256523 | A1 | BOFANG_SC | 29 | arm, events | 3 / 27 | printed_denominator | R0002476:Table 2 | ||
| NCT06256523 | A2 | PLACEBO | 29 | arm, events | 1 / 9 | printed_denominator | R0002476:Table 2 | ||
| S002858 | A1 | LIXI_SC | 24 | arm, events | 4 / 51 | R0001573:Supplement Table S1 | |||
| S002858 | A2 | PLACEBO | 24 | arm, events | 3 / 50 | R0001573:Supplement Table S1 | |||
| S002904 | A1 | LIRAGL_SC | 12 | arm, events | 0 / 60 | R0003210:Table 3 | |||
| S002904 | A2 | LIRA_SC | 12 | arm, events | 1 / 60 | R0003210:Table 3 | |||
| S002928 | A1 | PLACEBO | 24 | arm, events | 2 / 41 | R0007034:Table 4 | |||
| S002928 | A2+A3 | PEGLOX_SC | 24 | arm, events | 1 / 82 | arms_combined | R0007034:Table 4 | ||
| S002946 | A1 | SEMA_SC | 26 | arm, events | 4 / 16 | R0006360:Supplement Table S2 | |||
| S002946 | A2 | DULA_SC | 26 | arm, events | 1 / 16 | R0006360:Supplement Table S2 | |||
| S002947 | A1+A2+A3 | ECNO_SC | 25 | arm, events | 16 / 109 | arms_combined | R0006482:Table 3 | ||
| S002947 | A4 | PLACEBO | 25 | arm, events | 1 / 36 | R0006482:Table 3 | |||
| S002951 | A1 | PEGLOX_SC | 16 | arm, events | 3 / 104 | R0007588:Table 3 | |||
| S002951 | A2 | METFORMIN | 16 | arm, events | 2 / 52 | R0007588:Table 3 | |||
| NCT05654831 | A1+A2+A3+A4 | ECC500_PO | 4.86 | arm, events | 7 / 39 | arms_combined | R0007796:Table 2 | ||
| NCT05654831 | A5 | PLACEBO | 4.86 | arm, events | 3 / 13 | R0007796:Table 2 | |||
| S003009 | A1 | PEGLOX_SC | 24 | arm, events | 2 / 44 | R0011381:Table 4 | |||
| S003009 | A2 | DAPAGLIFLOZIN | 24 | arm, events | 1 / 44 | R0011381:Table 4 | |||
| S003047 | A1+A2 | LIXI_SC | 6.57 | arm, events | 12 / 80 | printed_denominator;arms_combined | R0016337:Table 3 | ||
| S003047 | A3 | PLACEBO | 6.57 | arm, events | 5 / 40 | printed_denominator | R0016337:Table 3 | ||
| S003071 | A1 | LIRA_SC | 24 | arm, events | 1 / 50 | R0023696:Results | |||
| S003071 | A2 | SITAGLIPTIN | 24 | arm, events | 0 / 49 | R0023696:Results | |||
| S003072 | A1 | VILDAGLIPTIN | 14 | arm, events | 2 / 62 | R0023470:Table 4 | |||
| S003072 | A2 | LIRA_SC | 14 | arm, events | 1 / 60 | R0023470:Table 4 | |||
| S003079 | A1 | EXEN_SC | 5 | arm, events | 0 / 18 | R0025923:Results | |||
| S003079 | A2 | STANDARD_CARE | 5 | arm, events | 0 / 18 | R0025923:Results | |||
| S003108 | A1+A3 | LIRA_SC | 24 | arm, events | 5 / 60 | arms_combined | R0025278:Table 4 | ||
| S003108 | A2 | METFORMIN | 24 | arm, events | 2 / 30 | R0025278:Table 4 | |||
| S003108 | A4 | LIRAMETF_SC | 24 | arm, events | 1 / 30 | R0025278:Table 4 | |||
| S003427 | A1 | LIRA_SC | 52.14 | arm, events | 2 / 74 | R0044046:Table IV | |||
| S003427 | A2 | SEMA_SC | 52.14 | arm, events | 3 / 74 | R0044046:Table IV |
Rerun this analysis yourself
Remove treatments or trials and refit the frequentist and Bayesian models in your browser, with the same methods as the published analysis.